<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antioxidants for male subfertility - de Ligny, W - 2022 | Cochrane Library</title> <meta content="Antioxidants for male subfertility - de Ligny, W - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007411.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antioxidants for male subfertility - de Ligny, W - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007411.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007411.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Antioxidants for male subfertility" name="citation_title"/> <meta content="Wiep de Ligny" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="wiep.deligny@radboudumc.nl" name="citation_author_email"/> <meta content="Roos M Smits" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Rebecca Mackenzie-Proctor" name="citation_author"/> <meta content="Auckland City Hospital" name="citation_author_institution"/> <meta content="Vanessa Jordan" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Kathrin Fleischer" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Jan Peter de Bruin" name="citation_author"/> <meta content="Jeroen Bosch Hospital" name="citation_author_institution"/> <meta content="Marian G Showell" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007411.pub5" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007411.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007411.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007411.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Abortion, Spontaneous [epidemiology]; Antioxidants [adverse effects]; *Infertility, Female [drug therapy]; *Infertility, Male [drug therapy, etiology]; Live Birth [epidemiology]; Pregnancy Rate" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007411.pub5&amp;doi=10.1002/14651858.CD007411.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007411\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007411\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","th","ms","ja","hr","id","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007411.pub5",title:"Antioxidants for male subfertility",firstPublishedDate:"May 4, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007411.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007411.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007411.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007411.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007411.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007411.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007411.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007411.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007411.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007411.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7283 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007411.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/appendices#CD007411-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/supinfo/CD007411StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/supinfo/CD007411StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antioxidants for male subfertility</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Wiep de Ligny</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0005">Roos M Smits</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0006">Rebecca Mackenzie-Proctor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0007">Vanessa Jordan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0008">Kathrin Fleischer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0009">Jan Peter de Bruin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information#CD007411-cr-0010">Marian G Showell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information/en#CD007411-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007411.pub5">https://doi.org/10.1002/14651858.CD007411.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007411-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007411-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007411-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007411-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007411-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD007411-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007411-abs-0001" lang="en"> <section id="CD007411-sec-0001"> <h3 class="title" id="CD007411-sec-0001">Background</h3> <p>The inability to have children affects 10% to 15% of couples worldwide. A male factor is estimated to account for up to half of the infertility cases with between 25% to 87% of male subfertility considered to be due to the effect of oxidative stress. Oral supplementation with antioxidants is thought to improve sperm quality by reducing oxidative damage. Antioxidants are widely available and inexpensive when compared to other fertility treatments, however most antioxidants are uncontrolled by regulation and the evidence for their effectiveness is uncertain. We compared the benefits and risks of different antioxidants used for male subfertility. </p> </section> <section id="CD007411-sec-0002"> <h3 class="title" id="CD007411-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of supplementary oral antioxidants in subfertile men. </p> </section> <section id="CD007411-sec-0003"> <h3 class="title" id="CD007411-sec-0003">Search methods</h3> <p>The Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, AMED, and two trial registers were searched on 15 February 2021, together with reference checking and contact with experts in the field to identify additional trials. </p> </section> <section id="CD007411-sec-0004"> <h3 class="title" id="CD007411-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared any type, dose or combination of oral antioxidant supplement with placebo, no treatment, or treatment with another antioxidant, among subfertile men of a couple attending a reproductive clinic. We excluded studies comparing antioxidants with fertility drugs alone and studies that included men with idiopathic infertility and normal semen parameters or fertile men attending a fertility clinic because of female partner infertility. </p> </section> <section id="CD007411-sec-0005"> <h3 class="title" id="CD007411-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane. The primary review outcome was live birth. Clinical pregnancy, adverse events and sperm parameters were secondary outcomes. </p> </section> <section id="CD007411-sec-0006"> <h3 class="title" id="CD007411-sec-0006">Main results</h3> <p>We included 90 studies with a total population of 10,303 subfertile men, aged between 18 and 65 years, part of a couple who had been referred to a fertility clinic and some of whom were undergoing medically assisted reproduction (MAR). Investigators compared and combined 20 different oral antioxidants. The evidence was of 'low' to 'very low' certainty: the main limitation was that out of the 67 included studies in the meta‐analysis only 20 studies reported clinical pregnancy, and of those 12 reported on live birth. The evidence is current up to February 2021. </p> <p>Live birth: antioxidants may lead to increased live birth rates (odds ratio (OR) 1.43, 95% confidence interval (CI) 1.07 to 1.91, P = 0.02, 12 RCTs, 1283 men, I<sup>2</sup> = 44%, very low‐certainty evidence). Results in the studies contributing to the analysis of live birth rate suggest that if the baseline chance of live birth following placebo or no treatment is assumed to be 16%, the chance following the use of antioxidants is estimated to be between 17% and 27%. However, this result was based on only 246 live births from 1283 couples in 12 small or medium‐sized studies. When studies at high risk of bias were removed from the analysis, there was no evidence of increased live birth (Peto OR 1.22, 95% CI 0.85 to 1.75, 827 men, 8 RCTs, P = 0.27, I<sup>2</sup> = 32%). </p> <p>Clinical pregnancy rate: antioxidants may lead to increased clinical pregnancy rates (OR 1.89, 95% CI 1.45 to 2.47, P &lt; 0.00001, 20 RCTs, 1706 men, I<sup>2</sup> = 3%, low‐certainty evidence) compared with placebo or no treatment. This suggests that, in the studies contributing to the analysis of clinical pregnancy, if the baseline chance of clinical pregnancy following placebo or no treatment is assumed to be 15%, the chance following the use of antioxidants is estimated to be between 20% and 30%. This result was based on 327 clinical pregnancies from 1706 couples in 20 small studies. </p> <p>Adverse events<br/>Miscarriage: only six studies reported on this outcome and the event rate was very low. No evidence of a difference in miscarriage rate was found between the antioxidant and placebo or no treatment group (OR 1.46, 95% CI 0.75 to 2.83, P = 0.27, 6 RCTs, 664 men, I<sup>2</sup> = 35%, very low‐certainty evidence). The findings suggest that in a population of subfertile couples, with male factor infertility, with an expected miscarriage rate of 5%, the risk of miscarriage following the use of an antioxidant would be between 4% and 13%. </p> <p>Gastrointestinal: antioxidants may lead to an increase in mild gastrointestinal discomfort when compared with placebo or no treatment (OR 2.70, 95% CI 1.46 to 4.99, P = 0.002, 16 RCTs, 1355 men, I<sup>2</sup> = 40%, low‐certainty evidence). This suggests that if the chance of gastrointestinal discomfort following placebo or no treatment is assumed to be 2%, the chance following the use of antioxidants is estimated to be between 2% and 7%. However, this result was based on a low event rate of 46 out of 1355 men in 16 small or medium‐sized studies, and the certainty of the evidence was rated low and heterogeneity was high. </p> <p>We were unable to draw conclusions from the antioxidant versus antioxidant comparison as insufficient studies compared the same interventions. </p> </section> <section id="CD007411-sec-0007"> <h3 class="title" id="CD007411-sec-0007">Authors' conclusions</h3> <p>In this review, there is very low‐certainty evidence from 12 small or medium‐sized randomised controlled trials suggesting that antioxidant supplementation in subfertile males may improve live birth rates for couples attending fertility clinics. Low‐certainty evidence suggests that clinical pregnancy rates may increase. There is no evidence of increased risk of miscarriage, however antioxidants may give more mild gastrointestinal discomfort, based on very low‐certainty evidence. Subfertile couples should be advised that overall, the current evidence is inconclusive based on serious risk of bias due to poor reporting of methods of randomisation, failure to report on the clinical outcomes live birth rate and clinical pregnancy, often unclear or even high attrition, and also imprecision due to often low event rates and small overall sample sizes. Further large well‐designed randomised placebo‐controlled trials studying infertile men and reporting on pregnancy and live births are still required to clarify the exact role of antioxidants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007411-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007411-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007411-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007411-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007411-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007411-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007411-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD007411-abs-0010">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007411-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007411-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007411-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD007411-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007411-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007411-abs-0002" lang="en"> <h3>Antioxidants for male subfertility</h3> <p><b>Review question</b><br/>Do supplementary oral antioxidants compared with placebo, no treatment or another antioxidant improve fertility outcomes for subfertile men? </p> <p><b>Background</b><br/>A couple may be considered to have fertility problems if they have been trying to conceive for over a year with no success. Many subfertile men undergoing fertility treatment also take dietary supplements in the hope of improving their fertility. Fertility treatment can be a very stressful time for men and their partners. It is important that these couples have access to high‐certainty evidence that will allow them to make informed decisions on whether to take a supplemental antioxidant. This is especially important as most antioxidant supplements are uncontrolled by regulation. This review aimed to assess whether supplements with oral antioxidants, taken by subfertile men, would increase the chances of a couple to achieve a (clinical) pregnancy confirmed by ultrasound and ultimately the birth of a baby (live birth). This review did not examine the use of antioxidants in men with normal sperm. </p> <p><b>Study characteristics</b> </p> <p>Cochrane authors conducted a review including 90 randomised controlled trials comparing 18 different antioxidants with placebo, no treatment or another antioxidant in a total population of 10,303 subfertile men. The age range of the participants was 18 to 65 years; they were part of a couple who had been referred to a fertility clinic and some were undergoing fertility treatment. The evidence is current to February 2021. </p> <p><b>Main results</b><br/>Antioxidants may be associated with an increased live birth and clinical pregnancy rate. Based on the studied population for live birth, we would expect that out of 100 subfertile men not taking antioxidants, 16 couples would have a baby. In subfertile men taking antioxidants, between 17 and 27 per 100 couples would have a baby. If studies with high risk of bias were removed from the analysis, there was no evidence of increased live birth in the population taking antioxidants. In the people who were studied for clinical pregnancy, we would expect that out of 100 subfertile men not taking antioxidants, 15 couples would have a clinical pregnancy. In subfertile men taking antioxidants, between 20 and 30 per 100 couples would have a clinical pregnancy. Adverse events were poorly reported. Only six studies reported miscarriage. In these studies, miscarriage did not occur more often in the group using antioxidants when compared with the group with placebo or no treatment. However, there is insufficient evidence to draw conclusions about antioxidant use and the risk of miscarriage. The use of antioxidants may be associated with more mild stomach discomfort, with a frequency of 2% in subfertile men not taking antioxidants, and between 2% and 7% in men taking antioxidants. The oral supplements may cause discomforts such as nausea or stomach ache. </p> <p><b>Authors' conclusion and certainty of the evidence </b><br/>Antioxidant supplementation taken by subfertile males of a couple attending a fertility clinic may increase the chance of a live birth, however the overall certainty of evidence was very low from only 12 small to medium‐sized randomised controlled trials. Low‐certainty evidence suggests that clinical pregnancy rates may increase. Overall, there is no evidence of increased risk of miscarriage. Evidence of low certainty suggests that antioxidants may be associated with more gastrointestinal discomfort. Subfertile couples should be advised that overall the current evidence is inconclusive due to the poor reporting of methods, failure to report on live birth and clinical pregnancy rate, imprecision due to low event rates, high number of dropouts and small study group sizes. Large well‐designed randomised placebo‐controlled trials studying infertile men and reporting on pregnancy and live births are still required to clarify the exact role of antioxidants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007411-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007411-sec-0116"></div> <h3 class="title" id="CD007411-sec-0117">Implications for practice</h3> <section id="CD007411-sec-0117"> <p>In this review, there is very low‐certainty evidence suggesting that antioxidant supplementation in subfertile males may improve live birth rates for couples attending fertility clinics. Low‐certainty evidence suggests that clinical pregnancy rates may increase as well. Overall, there is no evidence of increased risk of miscarriage. Based on low‐certainty evidence, antioxidants may be associated with more gastrointestinal discomfort. Subfertile couples should be advised that the current evidence is inconclusive based on serious risk of bias. </p> </section> <h3 class="title" id="CD007411-sec-0118">Implications for research</h3> <section id="CD007411-sec-0118"> <p>As opposed to previous updates of this review, we have now included several recently published clinical trials with live birth as an outcome. This shows that investigators acknowledge the need for more trials with clinical outcomes in this field. However, the proportion of well‐powered trials with low risk of bias remains small. Hence, large well‐designed placebo‐controlled randomised trials, focusing on male factor infertility and with live birth as primary outcome, are urgently needed. Researchers should make an effort to register and report important confounding factors including the use of other supplements, lifestyle factors (e.g. diet, physical activity, smoking habits, and alcohol consumption), and living environment. </p> <p>There is insufficient evidence supporting one type or dose of antioxidants versus another, or a single antioxidant versus a combination of antioxidants. </p> <p>The side‐effect profile of antioxidant supplements appears to be low and mild. However, conclusions cannot be drawn based on the limited research reporting this outcome. Future trials should include predefined adverse events of antioxidants, with a focus on clinical outcomes such as miscarriage, stillbirth and ectopic pregnancy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007411-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007411-sec-0008"></div> <div class="table" id="CD007411-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants compared to placebo or no treatment for patients with male subfertility</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antioxidants compared to placebo or no treatment for patients with male subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with male subfertility<br/><b>Setting: clinic</b> <br/><b>Intervention:</b> antioxidants<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antioxidants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate per couple randomised</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(171 to 269)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.43</p> <p>(1.07 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1283</p> <p>(12 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate per couple randomised</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1000</p> <p>(199 to 297)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.89</p> <p>(1.45 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1706</p> <p>(20 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events ‐ Miscarriage</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 1000</p> <p>(36 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.46</p> <p>(0.75 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>664</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Gastrointestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> <p>(22 to 71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.70</p> <p>(1.46 to 4.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1355</p> <p>(16 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Peto Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias: lack of blinding and incomplete accounting of patients and outcome events </p> <p><sup>2</sup> Downgraded one level for suspected publication bias based on the funnel plot </p> <p><sup>3</sup> Downgraded one level for serious imprecision: less than 400 events </p> <p><sup>4</sup> Downgraded one level for serious imprecision: crossing the line of no effect </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007411-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007411-sec-0009"></div> <section id="CD007411-sec-0010"> <h3 class="title" id="CD007411-sec-0010">Description of the condition</h3> <p>It is believed that 48.5 to 186 million people worldwide are affected by the inability to have children (<a href="./references#CD007411-bbs2-0197" title="BoivinJ , BuntingL , CollinsJA , NygrenKG .International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Human Reproduction2007;22(6):1506-12. [0268-1161]">Boivin 2007</a>; <a href="./references#CD007411-bbs2-0238" title="InhornMC , PatrizioP .Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Human Reproduction Update2015;21(4):411-26. [1460-2369: (Electronic)]">Inhorn 2015</a>; <a href="./references#CD007411-bbs2-0257" title="MascarenhasMN , FlaxmanSR , BoermaT , VanderpoelS , StevensGA .National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLOS Medicine2012;9(12):e1001356. [1549-1676: (Electronic)]">Mascarenhas 2012</a>), with delayed conception affecting 10% to 15% of couples trying to conceive (<a href="./references#CD007411-bbs2-0222" title="EversJL .Female subfertility. Lancet2002;360(9327):151-9. [0140-6736: (Print)]">Evers 2002</a>). The International Glossary on Infertility and Fertility Care (<a href="./references#CD007411-bbs2-0292" title="Zegers-HochschildF , AdamsonGD , DyerS , RacowskyC , deMouzonJ , SokolR , et al.The International Glossary on Infertility and Fertility Care, 2017. Human Reproduction2017;32(9):1786-801. [DOI: 10.1093/humrep/dex234]">Zegers‐Hochschild 2017</a>) defines <i>infertility</i> as a disease characterised by the failure to establish a clinical pregnancy after 12 months of regular, unprotected intercourse and is used interchangeably with the term <i>subfertility</i> (<a href="./references#CD007411-bbs2-0292" title="Zegers-HochschildF , AdamsonGD , DyerS , RacowskyC , deMouzonJ , SokolR , et al.The International Glossary on Infertility and Fertility Care, 2017. Human Reproduction2017;32(9):1786-801. [DOI: 10.1093/humrep/dex234]">Zegers‐Hochschild 2017</a>). Subfertility generally describes any form or grade of reduced fertility in couples trying to conceive (<a href="./references#CD007411-bbs2-0226" title="GnothC , GodehardtE , Frank-HerrmannP , FriolK , TiggesJ , FreundlG .Definition and prevalence of subfertility and infertility. Human Reproduction2005;20(5):1144-7.">Gnoth 2005</a>). </p> <p>In 2010, it was stated in a World Health Organization (WHO) report, based on data from 190 countries (<a href="./references#CD007411-bbs2-0257" title="MascarenhasMN , FlaxmanSR , BoermaT , VanderpoelS , StevensGA .National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLOS Medicine2012;9(12):e1001356. [1549-1676: (Electronic)]">Mascarenhas 2012</a>), that worldwide 1.9% of women trying to conceive were unable to have a first live birth (primary infertility) and 10.5% with a prior live birth were unable to have an additional live birth (secondary infertility). However, the distribution of male and female causes of infertility has not been well‐defined. Based on a WHO multicentre study from the 1980s, it is suggested that 20% of cases are solely attributed to the male, 38% to the female, 27% to both, and 15% not clearly to either (<a href="./references#CD007411-bbs2-0209" title="ComhaireFH .Towards more objectivity in diagnosis and management of male infertility. International Journal of Andrology. Supplement1987;7.">Comhaire 1987</a>). </p> <p>In the literature, it is suggested that a male factor is indeed involved in up to 50% of infertility cases (<a href="./references#CD007411-bbs2-0242" title="IrvineDS .Epidemiology and aetiology of male infertility. Human Reproduction1998;13 Suppl 1:33-44. [0268-1161: (Print)]">Irvine 1998</a>; <a href="./references#CD007411-bbs2-0289" title="WintersBR , WalshTJ .The epidemiology of male infertility. Urologic Clinics of North America2014;41(1):195-204. [1558-318X: (Electronic)]">Winters 2014</a>). An epidemiological study in the USA showed a mean prevalence of 17.1% of isolated male factor infertility (infertility exclusively caused by a male factor) and 34.6% of total male factor infertility (infertility exclusively or partially caused by a male factor) (<a href="./references#CD007411-bbs2-0263" title="OdishoAY , NangiaAK , KatzPP , SmithJF .Temporal and geospatial trends in male factor infertility with assisted reproductive technology in the United States from 1999-2010. Fertility and Sterility2014;102(2):469-75.">Odisho 2014</a>). The true extent of male infertility is likely to be underestimated due to the lack of male evaluation in infertile couples and the heterogeneity of studies (<a href="./references#CD007411-bbs2-0191" title="BarrattCLR , BjorndahlL , De JongeCJ , LambDJ , Osorio MartiniF , McLachlanR , et al.The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. Human Reproduction Update2017;23(6):660-80. [1460-2369: (Electronic)]">Barratt 2017</a>; <a href="./references#CD007411-bbs2-0218" title="EisenbergML , LathiRB , Baker VL , Westphal LM , MilkiAA , NangiaAK .Frequency of the male infertility evaluation: data from the national survey of family growth. Journal of Urology2013;189(3):1030-4.">Eisenberg 2013</a>). Oxidative stress (OS) has been commonly investigated and found to play a role in 25% to 87% of male factor subfertility (<a href="./references#CD007411-bbs2-0181" title="AitkenRJ , ClarksonJS .Cellular basis of defective sperm function and its association with the genesis of reactive oxygen species by human spermatozoa. Journal of Reproduction and Fertility1987;81(2):459-69. [0022-4251: (Print)]">Aitken 1987</a>; <a href="./references#CD007411-bbs2-0182" title="AitkenRJ , ClarksonJS , HargreaveTB , IrvineDS , WuFC .Analysis of the relationship between defective sperm function and the generation of reactive oxygen species in cases of oligozoospermia. Journal of Andrology1989;10(3):214-20. [0196-3635: (Print)]">Aitken 1989</a>; <a href="./references#CD007411-bbs2-0183" title="AitkenRJ , BuckinghamD , WestK , WuFC , ZikopoulosK , RichardsonDW .Differential contribution of leucocytes and spermatozoa to the generation of reactive oxygen species in the ejaculates of oligozoospermic patients and fertile donors. Journal of Reproduction and Fertility1992;94(2):451-62. [0022-4251: (Print)]">Aitken 1992</a>; <a href="./references#CD007411-bbs2-0243" title="IwasakiA , GagnonC .Formation of reactive oxygen species in spermatozoa of infertile patients. Fertility and Sterility1992;57(2):409-16. [0015-0282: (Print)]">Iwasaki 1992</a>; <a href="./references#CD007411-bbs2-0258" title="MazzilliF , RossiT , MarchesiniM , RonconiC , DonderoF .Superoxide anion in human semen related to seminal parameters and clinical aspects. Fertility and Sterility1994;62(4):862-8. [0015-0282: (Print)]">Mazzilli 1994</a>; <a href="./references#CD007411-bbs2-0277" title="ShekarrizM , Thomas AJ Jr, AgarwalA .Incidence and level of seminal reactive oxygen species in normal men. Urology1995;45(1):103-7. [0090-4295: (Print)]">Shekarriz 1995</a>; <a href="./references#CD007411-bbs2-0298" title="ZiniA , deLamirandeE , GagnonC .Reactive oxygen species in semen of infertile patients: levels of superoxide dismutase- and catalase-like activities in seminal plasma and spermatozoa. International Journal of Andrology1993;16(3):183-8. [0105-6263: (Print)]">Zini 1993</a>). </p> <p>In all cells using oxygen to survive, toxins are produced as a consequence. These toxic end‐products are better known as free radicals. Some free radicals are characterised by having higher reactive activity than molecular oxygen, and are therefore called reactive oxygen species (ROS). Excessive production of ROS can lead to cell damage. Therefore, the human body has developed a defence system in which antioxidants play an important role. Antioxidants are capable of reducing the production of free radicals, slowing or preventing the oxidation, and repairing the damage (<a href="./references#CD007411-bbs2-0261" title="Mirończuk-ChodakowskaI , WitkowskaAM , ZujkoME .Endogenous non-enzymatic antioxidants in the human body. Advances in Medical Sciences2018;63(1):68-78.">Mirończuk‐Chodakowska 2018</a>). </p> <p>The increased levels of ROS are thought to be due to either exogenous or endogenous factors. Exogenous factors could be environmental such as high temperatures, pesticides and pollution, or related to lifestyle such as alcohol consumption, smoking, poor nutrition, and obesity. Endogenous factors are infections, chronic disease, autoimmune disease, and in the male reproductive tract the occurrence of leukocytes (white blood cells) and immature spermatozoa, and varicocele (<a href="./references#CD007411-bbs2-0187" title="Alvarez 2003.Nuture vs nature: how can we optimise sperm quality?Journal of Andrology2003;24(5):640-8.">Alvarez 2003</a>; <a href="./references#CD007411-bbs2-0282" title="TremellenK .Oxidative stress and male infertility - a clinical perspective. Human Reproduction Update2008;14(3):243-58.">Tremellen 2008</a>). </p> <p>Spermatozoa are especially vulnerable to ROS due to the lack of cytoplasm containing antioxidants (<a href="./references#CD007411-bbs2-0184" title="AitkenJ , FisherH .Reactive oxygen species generation and human spermatozoa: the balance of benefit and risk. Bioessays1994;16(4):259-67. [0265-9247: (Print)]">Aitken 1994</a>; <a href="./references#CD007411-bbs2-0217" title="EbischIM , Thomas CM PetersWH , BraatDD , Steegers-TheunissenRP .The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Human Reproduction Update2007;13(2):163-74.">Ebisch 2007</a>). Also, spermatozoal membranes are rich in polyunsaturated fatty acids (PUFAs) which makes them susceptible for lipid peroxidation by ROS, resulting in decreased flexibility of the sperm membrane and reduction of tail motion (<a href="./references#CD007411-bbs2-0244" title="JonesR , MannT .Lipid peroxidation in spermatozoa. Proceedings of the Royal Society Series B-Biological Sciences1973;184(1074):103-7. [0080-4649]">Jones 1973</a>). </p> <p>This means that OS can lead to impaired male fertility firstly by damaging the sperm membrane, thus affecting the sperm motility and ability to break down the oocyte membrane, and secondly by apoptosis and direct alteration of the sperm DNA (<a href="./references#CD007411-bbs2-0246" title="KodamaH , YamaguchiR , FukudaJ , KasaiH , TanakaT .Increased oxidative deoxyribonucleic acid damage in the spermatozoa of infertile male patients. Fertilty and Sterility1997;68(3):519-24. [0015-0282: (Print)]">Kodama 1997</a>; <a href="./references#CD007411-bbs2-0251" title="LewisSE , AitkenRJ , ConnerSJ , IuliisGD , EvensonDP , HenkelR , et al.The impact of sperm DNA damage in assisted conception and beyond: recent advances in diagnosis and treatment. Reproductive BioMedicine Online2013;27(4):325-37.">Lewis 2013</a>). Deceivingly, men with sperm DNA damage can still have normal seminal parameters but have a poor chance of natural conception (<a href="./references#CD007411-bbs2-0186" title="AktanG , Dogru-AbbasogluS , KucukgerginC , KadiogluA , Ozdemirler-ErataG , Kocak-TokerN .Mystery of idiopathic male infertility: is oxidative stress an actual risk?Fertility and Sterility2013;99(5):1211-5.">Aktan 2013</a>; <a href="./references#CD007411-bbs2-0240" title="IntasquiP , AntoniassiM , CamargoM , NichiM , CarvalhoVM , CardozoKH , et al.Differences in the seminal plasma proteome are associated with oxidative stress levels in men with normal semen parameters. Fertility and Sterility2015;104(2):292-301.">Intasqui 2015</a>). Sperm DNA damage or integrity can be measured in several ways, either direct or indirect (<a href="./references#CD007411-bbs2-0179" title="AgarwalA , MajzoubA .Laboratory tests for oxidative stress. Indian Journal of Urology2017;33(3):199-206. [0970-1591: (Print)]">Agarwal 2017</a>). Direct tests measure the actual DNA strand breaks, and indirect tests measure the susceptibility of the damaged DNA to denaturation or fragmentation. </p> <p>The most current sperm DNA fragmentation (SDF) tests used are the terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling (TUNEL) test, the comet assay, and the sperm chromatin structure assay (SCSA). Other options are measurement of 8‐hydroxydeoxyguanosine (8‐OHdG), a by‐product of DNA oxidation, or chemoluminescence assays. </p> <p>Multiple studies and meta‐analyses show an association between low SDF and clinical pregnancy and live birth rate after intrauterine insemination (IUI), in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment (<a href="./references#CD007411-bbs2-0200" title="BungumM , HumaidanP , SpanoM , JepsonK , BungumL , GiwercmanA .The predictive value of sperm chromatin structure assay (SCSA) parameters for the outcome of intrauterine insemination, IVF and ICSI. Human Reproduction2004;19(6):1401-8.">Bungum 2004</a>; <a href="./references#CD007411-bbs2-0280" title="SugiharaA , Van AvermaeteF , RoelantE , PunjabiU , De NeubourgD .The role of sperm DNA fragmentation testing in predicting intra-uterine insemination outcome: a systematic review and meta-analysis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2020;244:8-15.">Sugihara 2020</a>; <a href="./references#CD007411-bbs2-0206" title="CollinsJA , BarnhartKT , SchlegelPN .Do sperm DNA integrity tests predict pregnancy with in vitro fertilization?Fertility and Sterility2008;89(4):823-31.">Collins 2008</a>; <a href="./references#CD007411-bbs2-0221" title="EvensonD , WixonR .Meta-analysis of sperm DNA fragmentation using the sperm chromatin structure assay. Reproductive Biomedicine Online2006;12(4):466-72.">Evenson 2006</a>; <a href="./references#CD007411-bbs2-0252" title="LiZ , WangL , CaiJ , HuangH .Correlation of sperm DNA damage with IVF and ICSI outcomes: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics2006;23(9-10):367-76.">Li 2006</a>; <a href="./references#CD007411-bbs2-0265" title="OsmanA , AlsomaitH , SeshadriS , El-ToukhyT , KhalafY .The effect of sperm DNA fragmentation on live birth rate after IVF or ICSI: a systematic review and meta-analysis. Reproductive Biomedicine Online2015;30(2):120-7.">Osman 2015</a>; <a href="./references#CD007411-bbs2-0293" title="ZhangZ , ZhuL , JiangH , ChenH , ChenY , DaiY .Sperm DNA fragmentation index and pregnancy outcome after IVF or ICSI: a meta-analysis. Journal of Assisted Reproduction and Genetics2015;32(1):17-26.">Zhang 2015</a>; <a href="./references#CD007411-bbs2-0295" title="ZhaoJ , HuangX , XuB , YanY , ZhangQ , LiY .Whether vitamin D was associated with clinical outcome after IVF/ICSI: a systematic review and meta-analysis. Reproductive Biology and Endocrinology2018;16(1):13.">Zhao 2018</a>). However, Cissen and colleagues found that this association does not imply that SDF tests have a predictive value (<a href="./references#CD007411-bbs2-0203" title="CissenM , WelyM , ScholtenI , MansellS , BruinJP , MolBW , et al.Measuring sperm DNA fragmentation and clinical outcomes of medically assisted reproduction: a systematic review and meta-analysis. PLOS One2016;11(11):e0165125.">Cissen 2016</a>). The test used in these studies are heterogenic and most of them are expensive, complex and lack standardisation and validation (<a href="./references#CD007411-bbs2-0198" title="BoriniA , TarozziN , NadaliniM .Sperm DNA fragmentation testing in male infertility work-up: are we ready?Translational Andrology and Urology2017;6(Suppl 4):S580-2.">Borini 2017</a>; <a href="./references#CD007411-bbs2-0203" title="CissenM , WelyM , ScholtenI , MansellS , BruinJP , MolBW , et al.Measuring sperm DNA fragmentation and clinical outcomes of medically assisted reproduction: a systematic review and meta-analysis. PLOS One2016;11(11):e0165125.">Cissen 2016</a>). </p> <p>All the above suggests a leading role of OS in the evaluation and management of male factor infertility. Agarwal and colleagues have even proposed the introduction of a novel condition that comprises subfertile men with abnormal semen characteristics and seminal OS: Male Oxidative Stress Infertility (MOSI) (<a href="./references#CD007411-bbs2-0180" title="AgarwalA , ParekhN , Panner SelvamMK , HenkelR , ShahR , HomaST , et al.Male Oxidative Stress Infertility (MOSI): proposed terminology and clinical practice guidelines for management of idiopathic male infertility. World Journal of Men's Health2019;37(3):296-312.">Agarwal 2019</a>). There are also studies suggesting that sperm DNA damage and OS do not exist in male idiopathic infertility (<a href="./references#CD007411-bbs2-0237" title="HughesCM , LewisSE , McKelvey-MartinVJ , ThompsonW .A comparison of baseline and induced DNA damage in human spermatozoa from fertile and infertile men, using a modified comet assay. Molecular Human Reproduction1996;2(8):613-9. [1360-9947: (Print)]">Hughes 1996</a>; <a href="./references#CD007411-bbs2-0285" title="VeritFF , VeritA , KocyigitA , CiftciH , CelikH , KoksalM .No increase in sperm DNA damage and seminal oxidative stress in patients with idiopathic infertility. Archives of Gynecology and Obstetrics2006;274(6):339-44.">Verit 2006</a>). </p> </section> <section id="CD007411-sec-0011"> <h3 class="title" id="CD007411-sec-0011">Description of the intervention</h3> <p>Antioxidants are substances that inhibit or delay the oxidation of biologically‐relevant molecules, either by directly scavenging free radicals or by chelation of redox metals (<a href="./references#CD007411-bbs2-0283" title="ValkoM , RhodesCJ , MoncolJ , IzakovicM , MazurM .Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions2006;160(1):1-40.">Valko 2006</a>). However, the definition is very general and does not specify how a compound may act as an antioxidant (<a href="./references#CD007411-bbs2-0236" title="HuangD , TocmoR .Assays based on competitive measurement of the scavenging ability of reactive oxygen/nitrogen species. In: ApakR , CapanogluE , ShahidiF , editors(s). Measurement of Antioxidant Activity and Capacity: Recent Trends and Applications. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2018.">Huang 2018</a>). Antioxidants can be categorised as enzymatic and non‐enzymatic. Enzymatic antioxidants prevent the reaction of ROS with bodily substances and repair cellular damage. Non‐enzymatic antioxidants, which include exogenous or dietary antioxidants, act to modify or deactivate ROS (<a href="./references#CD007411-bbs2-0261" title="Mirończuk-ChodakowskaI , WitkowskaAM , ZujkoME .Endogenous non-enzymatic antioxidants in the human body. Advances in Medical Sciences2018;63(1):68-78.">Mirończuk‐Chodakowska 2018</a>). </p> <p>The predominant supplementary antioxidants that are studied in male subfertility clinical trials are carnitines, carotenoids, coenzyme Q10 (ubiquinol), cysteine, the micronutrients folate, selenium and zinc, vitamin C, and vitamin E (<a href="./references#CD007411-bbs2-0220" title="EskanaziB , KiddSA , MarksAR , SloterE , BlockG , WyrobeckAJ .Antioxidant intake is associated with semen quality in healthy men. Human Reproduction2005;20(4):1006-12.">Eskenazi 2005</a>; <a href="./references#CD007411-bbs2-0255" title="MajzoubA , AgarwalA .Antioxidant therapy in idiopathic oligoasthenoteratozoospermia. Indian Journal of Urology2017;33(3):207-14.">Majzoub 2017</a>). Antioxidants can be administered orally as a single or combined supplement. They are widely available and inexpensive when compared to other fertility treatments. However, cost‐benefit analysis is beyond the scope of this review. </p> <p><b>Substances with direct antioxidant action </b> </p> <p><b>Arginine</b><br/>Arginine, or L‐arginine, is an amino acid that is required for normal spermatogenesis. It plays a role in the inflammatory response and directly protects against oxidative damage by being a free radical scavenger. Arginine can be derived from meat products, dairy, nuts and seeds. Significant adverse events have not been observed, however arginine is contraindicated for people with a history of genital or oral herpes, asthma or cancer (<a href="./references#CD007411-bbs2-0189" title="AppletonJ .Arginine: clinical potential of a semi-essential amino acid. Alternative Medicine Review2002;7(6):512-22. [10895159]">Appleton 2002</a>). </p> <p><b>Carnitines</b><br/>Carnitine is an antioxidant, with the two most important isomers being called l‐carnitine (LC) and its active form l‐acetylcarnitine (LAC). In the male genital tract carnitines are found in the epididymis, seminal plasma and in spermatozoa (<a href="./references#CD007411-bbs2-0202" title="BøhmerT , HoelP , PurvisK , HanssonV .Carnitine levels in human accessory sex organs. Archives of Andrology1978;1(1):53-9.">Bøhmer 1978</a>). Carnitines assist sperm metabolism by positively affecting sperm motility and maturation. There might be an association between the concentration of LAC and male fertility (<a href="./references#CD007411-bbs2-0178" title="AgarwalA , SaidTM .Carnitines and male infertility. Reproductive BioMedicine Online (Reproductive Healthcare Limited)2004;8(4):376-84.">Agarwal 2004a</a>). Animal products like meat, fish, poultry and dairy are the best sources for carnitines. Doses above 3 g/day can give gastrointestinal side effects and malodorous effects (<a href="./references#CD007411-bbs2-0188" title="Annals of the New York Academy of Science.Preface: carnitine: lessons from one hundred years of research. Annals of the New York Academy of Science2004;1033(1):ix-xi.">Annals of the New York Academy of Science 2004</a>). </p> <p><b>Carotenoids</b><br/>Carotenoids are pigments found in plants. One of the most important carotenoids is β‐carotene (<a href="./references#CD007411-bbs2-0274" title="RossAC .Modern Nutrition in Health and Disease. Vol. 10th edition. Lippincott Williams &amp; Wilkins, 2006.">Ross 2006</a>), a provitamin A, which can directly scavenge ROS. Other carotenoids found in food are lycopene, lutein, and zeaxanthin, however these are not converted into vitamin A. Both in vivo and in vitro, β‐carotene has been shown to protect isolated lipid membranes from peroxidation (<a href="./references#CD007411-bbs2-0192" title="BendichA , OlsonJA .Biological actions of carotenoids. FASEB Journal1989;3(8):1927-32.">Bendich 1989</a>). Healthy young men with a higher carotenoid intake have higher sperm motility, and higher lycopene intake is associated with better sperm morphology (<a href="./references#CD007411-bbs2-0291" title="ZarebaP , ColaciDS , AfeicheM , GaskinsAJ , JorgensenN , MendiolaJ , et al.Semen quality in relation to antioxidant intake in a healthy male population. Fertility and Sterility2013;100(6):1572-9.">Zareba 2013</a>). However, a review by Grune and colleagues (<a href="./references#CD007411-bbs2-0229" title="GruneT , LietzG , PalouA , RossAC , StahlW , TangG , et al.β-Carotene Is an Important Vitamin A Source for Humans1–3. Journal of Nutrition2010;140(12):2268S-85S.">Grune 2010</a>) stated that there are conflicting results whether β‐carotene has antioxidant properties. Carotenoids come from leafy green vegetables, fruits, and some vegetable oils (<a href="./references#CD007411-bbs2-0274" title="RossAC .Modern Nutrition in Health and Disease. Vol. 10th edition. Lippincott Williams &amp; Wilkins, 2006.">Ross 2006</a>). Excess intake of preformed vitamin A can lead to toxicity (hypervitaminosis A). However, excessive ingestion of provitamins such as carotenoids are not associated with vitamin A toxicity, the only side effect is carotenaemia (yellow‐tinged skin). </p> <p><b>Coenzyme Q10</b><br/>Coenzyme Q10 (CoQ10) is a fat‐soluble antioxidant synthesised endogenously and an essential component of the mitochondrial energy metabolism. In its reduced form, CoQH2, ubiquinol, it inhibits protein and DNA oxidation and lipid peroxidation (<a href="./references#CD007411-bbs2-0253" title="LittarruGP , TianoL .Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Molecular Biotechnology2007;37(1):31-7.">Littarru 2007</a>). CoQ10 seminal fluid levels are significantly correlated to sperm count and motility, except in men with varicocele (<a href="http://onlinelibrary.wiley.com.ezproxy.auckland.ac.nz/doi/10.2164/jandrol.111.013730/full#b68" target="_blank">Mancini 1994</a>). Meat, fish, nuts and some oils are the most important dietary sources of CoQ10 due to their relatively high level of fats and mitochondria (<a href="./references#CD007411-bbs2-0270" title="PravstI , ŽmitekK , ŽmitekJ .Coenzyme Q10 contents in foods and fortification strategies. Critical Reviews in Food Science and Nutrition2010;50(4):269-80.">Pravst 2010</a>). Reported side effects are mild gastrointestinal symptoms (<a href="./references#CD007411-bbs2-0195" title="BhagavanHN , ChopraRK .Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radical Research2006;40(5):445-53.">Bhagavan 2006</a>). </p> <p><b>Cysteine</b><br/>Cysteine plays an important role in glutathione synthesis. N‐acetylcysteine (NAC) is a precursor of the amino acid cysteine and a direct scavenger of ROS. Glutathione becomes depleted when there is OS, and this can be reversed by NAC supplementation (<a href="./references#CD007411-bbs2-0190" title="AtkuriKR , MantovaniJJ , HerzenbergLA , HerzenbergLA .N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Cancer/Immunomodulation2007;7(4):355-9.">Atkuri 2007</a>). NAC is less toxic and less susceptible to oxidation compared to cysteine itself. Oral administration of NAC up to 8000 mg/day is not known to cause significant adverse events (<a href="./references#CD007411-bbs2-0190" title="AtkuriKR , MantovaniJJ , HerzenbergLA , HerzenbergLA .N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Cancer/Immunomodulation2007;7(4):355-9.">Atkuri 2007</a>). Less is known about ethylcysteine, however in vivo and animal studies have shown anti‐oxidative effects (<a href="./references#CD007411-bbs2-0235" title="HsiaT , YinM .Post-intake of S-Ethyl Cysteine and S-Methyl Cysteine improved LPS-induced acute lung injury in mice. Nutrients2016;8(8):507.">Hsia 2016</a>). </p> <p><b>Micronutrients (folate, selenium, zinc)</b><br/>Folate, also known as vitamin B9, is a micronutrient important for the synthesis of DNA, transfer RNA and the amino acids cysteine and methionine. Folic acid, the synthetic form, can scavenge oxidising free radicals, and it inhibits lipid peroxidation (<a href="./references#CD007411-bbs2-0245" title="JoshiR , AdhikariS , PatroBS , ChattopadhyayS , MukherjeeT .Free radical scavenging behavior of folic acid: evidence for possible antioxidant activity. Free Radical Biology &amp; Medicine2001;30(12):1390-9.">Joshi 2001</a>). Folate is present in green‐leafy vegetables, liver, bread, yeast and fruits (<a href="./references#CD007411-bbs2-0217" title="EbischIM , Thomas CM PetersWH , BraatDD , Steegers-TheunissenRP .The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Human Reproduction Update2007;13(2):163-74.">Ebisch 2007</a>). Folic acid doses of 5 mg/day and over can cause abdominal cramps, diarrhoea and rash. Higher doses can even cause altered sleep patterns, irritability, confusion, exacerbation of seizures and nausea (<a href="./references#CD007411-bbs2-0273" title="RogovikAL , VohraS , GoldmanRD .Safety considerations and potential interactions of vitamins: should vitamins be considered drugs?Annals of Pharmacotherapy2009;44(2):311-24.">Rogovik 2009</a>). </p> <p>Zinc is involved as a cofactor in DNA transcription and protein synthesis and has extensive antioxidants properties (<a href="./references#CD007411-bbs2-0217" title="EbischIM , Thomas CM PetersWH , BraatDD , Steegers-TheunissenRP .The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Human Reproduction Update2007;13(2):163-74.">Ebisch 2007</a>). Zinc has an important role in testes development, sperm physiological functions and decrease of zinc in seminal plasma is associated with sperm quality (<a href="./references#CD007411-bbs2-0205" title="ColagarAH , MarzonyET , ChaichiMJ .Zinc levels in seminal plasma are associated with sperm quality in fertile and infertile men. Nutrition Research2009;29(2):82-8.">Colagar 2009a</a>). Zinc, like selenium, is absorbed from the soil into plants. Dietary sources rich of zinc are meat products, wheat and seeds. </p> <p>Magnesium and selenium are different from other antioxidant nutrients because they are involved in the mechanisms of cellular antioxidant defence by increasing the activity of the antioxidant enzyme glutathione peroxidase, and not by directly reacting with oxidant molecules (<a href="./references#CD007411-bbs2-0201" title="BurkRF .Selenium, an antioxidant nutrient. Nutrition in Clinical Care2002;5(2):75-9.">Burk 2002</a>; <a href="./references#CD007411-bbs2-0290" title="YavuzY , MollaogluH , YurumezY , UcokK , DuranL , TunayK , et al.Therapeutic effect of magnesium sulphate on carbon monoxide toxicity-mediated brain lipid peroxidation. European Review for Medical and Pharmacological Sciences2013;17 Suppl 1:28-33. [1128-3602: (Print)]">Yavuz 2013</a>). It is suggested that both magnesium and selenium deficiency would make humans more susceptible to oxidative injury. Selenium is furthermore essential for normal spermatogenesis (<a href="./references#CD007411-bbs2-0196" title="BoitaniC , PuglisiR .Selenium, a key element in spermatogenesis and male fertility. In: Molecular Mechanisms in Spermatogenesis. New York, NY: Springer New York, 2008:65-73.">Boitani 2008</a>). Selenium is derived from fish, meat products, dairy, and soil absorption by plants (<a href="./references#CD007411-bbs2-0262" title="Navarro-AlarconM , Cabrera-ViqueC .Selenium in food and the human body: a review. Science of The total environment2008;400(1):115-41.">Navarro‐Alarcon 2008</a>). Early indicators of excess intake are a garlic odour in the breath and a metallic taste in the mouth. The most common clinical signs of chronically high selenium intakes are gastrointestinal symptoms, fatigue, hair loss, joint pain, and nail problems (<a href="./references#CD007411-bbs2-0254" title="MacFarquharJK , BroussardDL , MelstromP , HutchinsonR , WolkinA , MartinC , et al.Acute selenium toxicity associated with a dietary supplement. Archives of Internal Medicine2010;170(3):256-61.">MacFarquhar 2010</a>). Magnesium is derived from green leafy vegetables, nuts, beans, and cereals (<a href="./references#CD007411-bbs2-0259" title="McNeillDA , AliPS , SongYS .Mineral analyses of vegetarian, health, and conventional foods: magnesium, zinc, copper, and manganese content. Journal of the American Dietetic Association1985;85(5):569-72. [0002-8223: (Print)]">McNeill 1985</a>). </p> <p><b>Vitamin E</b><br/>Vitamin E, also known as the bioactive form α‐tocopherol, has a principal role by being the first defence against oxidant‐induced membrane injury (<a href="./references#CD007411-bbs2-0281" title="TraberMG , AtkinsonJ .Vitamin E, antioxidant and nothing more. Free Radical Biology and Medicine2007;43(1):4-15.">Traber 2007</a>). Vitamin E is found in vegetable oils and there is a given upper daily limit based on the possible increased bleeding risk (<a href="./references#CD007411-bbs2-0239" title="Institute of Medicine.Vitamin E. In: Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: The National Academies Press, 2000.">Institute of Medicine 2000</a>). </p> <p><b>Vitamin C</b><br/>Vitamin C, also known as ascorbic acid, is able to diminish DNA damage directly by scavenging free radicals and decreasing formation of lipid hydroperoxides (<a href="./references#CD007411-bbs2-0267" title="PadayattySJ , KatzA , WangY , EckP , KwonO , LeeJ , et al.Vitamin C as an antioxidant: evaluation of Its role in disease prevention. Journal of the American College of Nutrition2003;22(1):18-35.">Padayatty 2003</a>). Ascorbic acid concentrations are 10‐fold higher in seminal plasma compared to blood plasma. Low levels of seminal plasma ascorbic acid are directly related to decreased number of spermatozoa with normal morphology and increased sperm DNA damage (<a href="./references#CD007411-bbs2-0204" title="ColagarAH , MarzonyET .Ascorbic acid in human seminal plasma: determination and its relationship to sperm quality. Journal of Clinical Biochemistry and Nutrition2009;45(2):144-9.">Colagar 2009</a>). Vitamin C is mainly found in fruits and vegetables. </p> <p><b>Substances with antioxidant properties </b> </p> <p><b>Myo‐inositol</b><br/>Inositol is a polyalcohol, naturally occurring as nine stereoisomers including myo‐inositol. Myo‐inositol, a "pseudovitamin" and previously known as vitamin B8, plays an important role in cell membrane formation and lipid synthesis. The highest concentration in the genital tract is within the seminiferous tubules. Myo‐inositol is produced by Sertoli cells in response to follicle‐stimulating hormone (FSH) (<a href="./references#CD007411-bbs2-0249" title="LewinLM , YannaiY , SulimoviciS , KraicerPF .Studies on the metabolic role of myo-inositol. Distribution of radioactive myo-inositol in the male rat. Biochemical Journal1976;156(2):375-80.">Lewin 1976</a>). Myo‐inositol is a precursor for the phosphatidyl‐inositol signalling pathway and directly involved in regulation of sperm motility, capacitation and acrosome reaction (<a href="./references#CD007411-bbs2-0194" title="BevilacquaA , CarlomagnoG , GerliS , Montanino OlivaM , DevroeyP , LanzoneA , et al.Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology – assisted reproduction technology. Gynecological Endocrinology2015;31(6):441-6.">Bevilacqua 2015</a>). Myo‐inositol has a role as a possible antioxidant agent by increasing endogenous antioxidant enzymes and directly affecting the mitochondria leading to an increase of the membrane potential (<a href="./references#CD007411-bbs2-0208" title="ColoneM , MarelliG , UnferV , BozzutoG , MolinariA , StringaroA .Inositol activity in oligoasthenoteratospermia--an in vitro study. European Review for Medical and Pharmacological Sciences2010;14(10):891-6. [1128-3602: (Print)]">Colone 2010</a>; <a href="./references#CD007411-bbs2-0210" title="CondorelliRA , La VigneraS , MongioiLM , VitaleSG , LaganaAS , CiminoL , et al.Myo-inositol as a male fertility molecule: speed them up!European Review for Medical and Pharmacological Sciences2017;21(2 Suppl):30-5. [2284-0729: (Electronic)]">Condorelli 2017</a>). Corns, beans, fruits, and nuts are the main dietary sources of myo‐inositol (<a href="./references#CD007411-bbs2-0284" title="Vazquez-LevinMH , Veron GL .Myo-inositol in health and disease: its impact on semen parameters and male fertility. Andrology2020;8(2):277-98.">Vazquez‐Levin 2020</a>) </p> <p><b>Polyunsaturated fatty acids (PUFAs)</b><br/>Polyunsaturated fatty acids (PUFAs) are subdivided into omega‐3 (docosahexaenoic acid, DHA), omega‐6 and omega‐9. Omega‐9 is synthesised by animals, but omegas‐3 and ‐6 needs to be supplemented in the diet. The main sources of these are vegetables and fish oils (<a href="./references#CD007411-bbs2-0288" title="WathesDC , AbayasekaraDR , AitkenRJ .Polyunsaturated fatty acids in male and female reproduction. Biology of Reproduction2007;77(2):190-201.">Wathes 2007</a>). PUFAs increase the plasma fluidity of the sperm membrane. However, this fluidity makes the sperm susceptible to ROS and lipid peroxidation that can damage the sperm. Wathes and colleagues state that "It appears that PUFAs are a two‐edged sword ‐ some are essential, but too many are potentially harmful" (<a href="./references#CD007411-bbs2-0288" title="WathesDC , AbayasekaraDR , AitkenRJ .Polyunsaturated fatty acids in male and female reproduction. Biology of Reproduction2007;77(2):190-201.">Wathes 2007</a>, page 198). It seems to be that PUFAs have a pro‐oxidant rather than a direct antioxidant effect. Although it is suggested that omega 3 might have a free radical‐scavenging potential (<a href="./references#CD007411-bbs2-0225" title="GiordanoE , VisioliF .Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukotrienes and Essential Fatty Acids2014;90(1):1-4.">Giordano 2014</a>; <a href="./references#CD007411-bbs2-0272" title="RichardD , KefiK , BarbeU , BauseroP , VisioliF .Polyunsaturated fatty acids as antioxidants. Pharmacological Research2008;57(6):451-5.">Richard 2008</a>). </p> <p><b>Resveratrol</b><br/>Resveratrol is a natural phytoalexin with antioxidant properties. Several <i>in vitro</i> studies with human cryopreserved sperm and <i>in vivo</i> studies in animal models suggest that resveratrol improves sperm motility and enhances antioxidant defences (<a href="./references#CD007411-bbs2-0199" title="BrancoCS , GarcezME , PasqualottoFF , ErdtmanB , SalvadorM .Resveratrol and ascorbic acid prevent DNA damage induced by cryopreservation in human semen. Cryobiology2010;60(2):235-7.">Branco 2010</a>; <a href="./references#CD007411-bbs2-0207" title="CollodelG , FedericoMG , GeminianiM , MartiniS , BonechiC , RossiC , et al.Effect of trans-resveratrol on induced oxidative stress in human sperm and in rat germinal cells. Reproductive Toxicology2011;31(2):239-46.">Collodel 2011</a>; <a href="./references#CD007411-bbs2-0266" title="OuriqueGM , FinamorIA , SaccolEM , RiffelAP , PêsTS , GutierrezK , et al.Resveratrol improves sperm motility, prevents lipid peroxidation and enhances antioxidant defences in the testes of hyperthyroid rats. Reproductive Toxicology2013;37:31-9.">Ourique 2013</a>). It is naturally found in our diet in the form of grapes, berries, several nuts, and wine (<a href="./references#CD007411-bbs2-0266" title="OuriqueGM , FinamorIA , SaccolEM , RiffelAP , PêsTS , GutierrezK , et al.Resveratrol improves sperm motility, prevents lipid peroxidation and enhances antioxidant defences in the testes of hyperthyroid rats. Reproductive Toxicology2013;37:31-9.">Ourique 2013</a>). Worldwide, resveratrol is better known from research on the effect of daily intake of red wine, "the Mediterranean diet", in cardiovascular disease (<a href="./references#CD007411-bbs2-0193" title="BertelliAA , DasDK .Grapes, wines, resveratrol, and heart health. Journal of Cardiovascular Pharmacology2009;54(6):468-76.">Bertelli 2009</a>). Reversible gastrointestinal side effects are reported, however evidence on side effects is limited (<a href="./references#CD007411-bbs2-0232" title="HausenblasHA , SchouldaJA , SmoligaJM .Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta‐analysis. Molecular Nutrition &amp; Food Research2014;59(1):147-59.">Hausenblas 2014</a>). </p> <p><b>Vitamin B (complex)</b><br/>Vitamin B is a water‐soluble vitamin and consists of several precursors and coenzymes such as thiamine (B1), riboflavin (B2) and cobalamin (B12). Vitamin B plays an important role in the homocysteine metabolism. It is suggested that total plasma homocysteine may have a pro‐oxidant effect and may play a role in the release of ROS (<a href="./references#CD007411-bbs2-0231" title="HankeyGJ , EikelboomJW .Homocysteine and vascular disease. Lancet1999;354(9176):407-13.">Hankey 1999</a>). Increased intake of vitamin B has a homocysteine‐lowering effect, with folate (also known as vitamin B9) shown to have the strongest effect, however vitamins B6, B12, and B2 have all been shown to be independently predictive of plasma homocysteine (<a href="./references#CD007411-bbs2-0231" title="HankeyGJ , EikelboomJW .Homocysteine and vascular disease. Lancet1999;354(9176):407-13.">Hankey 1999</a>). Vitamin B is mainly found in meat products, other food sources are beans, potatoes, bananas, and mushrooms. </p> <p><b>Vitamin D</b><br/>Vitamin D is a fat‐soluble vitamin, with the natural main source being dermal synthesis (sunlight). The active form of vitamin D is 1,25‐dihydroxyvitamin D, also called vitamin D3. Halicka and colleagues suggest that vitamin D3 has antioxidant activity, mainly by inducing the antioxidant protein superoxide dismutase (<a href="./references#CD007411-bbs2-0230" title="HalickaHD , ZhaoH , LiJ , TraganosF , StudzinskiGP , DarzynkiewiczZ .Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3. Aging2012;4(4):270-8.">Halicka 2012</a>). However, there are no other studies about the antioxidant properties of vitamin D in male fertility. Clearly, vitamin D plays an important role in male fertility and serum levels of vitamin D are positively associated with semen quality (<a href="./references#CD007411-bbs2-0212" title="deAngelisC , GaldieroM , PivonelloC , GarifalosF , MenafraD , CariatiF , et al.The role of vitamin D in male fertility: A focus on the testis. Reviews in Endocrine and Metabolic Disorders2017;18(3):285-305.">de Angelis 2017</a>). However, most of the studies do not mention the antioxidant properties of vitamin D, but rather relate the effect to the synthesis of sex steroids or the regulation of calcium. </p> </section> <section id="CD007411-sec-0012"> <h3 class="title" id="CD007411-sec-0012">How the intervention might work</h3> <p>It must be noted that a low production of reactive oxygen species (ROS) is physiological and required for adequate sperm function by supporting capacitation, maturation and hyperactivation (<a href="./references#CD007411-bbs2-0184" title="AitkenJ , FisherH .Reactive oxygen species generation and human spermatozoa: the balance of benefit and risk. Bioessays1994;16(4):259-67. [0265-9247: (Print)]">Aitken 1994</a>; <a href="./references#CD007411-bbs2-0216" title="Du PlessisSS , AgarwalA , HalabiJ , TvrdaE .Contemporary evidence on the physiological role of reactive oxygen species in human sperm function. Journal of Assisted Reproduction and Genetics2015;32(4):509-20.">Du Plessis 2015</a>). However, OS occurs when the balance between ROS production and antioxidant defence is disturbed. This applies to sperm cells in particular. </p> <p>If OS at the heart of the increased sperm DNA damage and the decrease of pregnancy and live birth rates, then supporting the antioxidant defence system with exogenous antioxidants would seem logical. An extra dietary intake of antioxidants or a healthy diet in general has shown to be strongly associated with semen quality in healthy men (<a href="./references#CD007411-bbs2-0220" title="EskanaziB , KiddSA , MarksAR , SloterE , BlockG , WyrobeckAJ .Antioxidant intake is associated with semen quality in healthy men. Human Reproduction2005;20(4):1006-12.">Eskenazi 2005</a>; <a href="./references#CD007411-bbs2-0242" title="IrvineDS .Epidemiology and aetiology of male infertility. Human Reproduction1998;13 Suppl 1:33-44. [0268-1161: (Print)]">Irvine 1998</a>; <a href="./references#CD007411-bbs2-0250" title="LewisSE , SterlingES , YoungIS , ThompsonW .Comparison of individual antioxidants of sperm and seminal plasma in fertile and infertile men. Fertility and Sterility1997;67(1):142-7.">Lewis 1997</a>; <a href="./references#CD007411-bbs2-0260" title="MendiolaJ , Torres-CanteroAM , VioqueJ , Moreno-GrauJM , TenJ , RocaM , et al.A low intake of antioxidant nutrients is associated with poor semen quality in patients attending fertility clinics. Fertility and Sterility2010;93(4):1128-33.">Mendiola 2010</a>; <a href="./references#CD007411-bbs2-0268" title="PasqualottoFF , SharmaRK , KobayashiH , Nelson DR JrAJT , AgarwalA .Oxidative stress in normospermic men undergoing infertility evaluation. Journal of Andrology2001;22(2):316-22.">Pasqualotto 2001</a>; <a href="./references#CD007411-bbs2-0276" title="Salas-HuetosA , BullóM , Salas-SalvadóJ .Dietary patterns, foods and nutrients in male fertility parameters and fecundability: a systematic review of observational studies. Human Reproduction Update 1 July 2017;23(4):371–89.">Salas‐Huetos 2017</a>; <a href="./references#CD007411-bbs2-0291" title="ZarebaP , ColaciDS , AfeicheM , GaskinsAJ , JorgensenN , MendiolaJ , et al.Semen quality in relation to antioxidant intake in a healthy male population. Fertility and Sterility2013;100(6):1572-9.">Zareba 2013</a>). In conclusion, there is a fine balance between preventing OS by antioxidants, removing excessive amounts of ROS, and maintaining a small amount of ROS for their physiological effect on sperm functions. Since "reductive stress" as a rebound effect of antioxidants has been reported, large or high doses of antioxidants might better be avoided (<a href="./references#CD007411-bbs2-0211" title="DattiloM , GiuseppeD , EttoreC , MénézoY .Improvement of gamete quality by stimulating and feeding the endogenous antioxidant system: mechanisms, clinical results, insights on gene-environment interactions and the role of diet. Journal of Assisted Reproduction and Genetics2016;33(12):1633-48.">Dattilo 2016</a>; <a href="./references#CD007411-bbs2-0224" title="GhyczyM , BorosM .Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. British Journal of Nutrition2001;85(4):409-14.">Ghyczy 2001</a>; <a href="./references#CD007411-bbs2-0233" title="HenkelR , Sandhu IS , AgarwalA .The excessive use of antioxidant therapy: A possible cause of male infertility?Andrologia2019;51(1):e13162.">Henkel 2019</a>). </p> </section> <section id="CD007411-sec-0013"> <h3 class="title" id="CD007411-sec-0013">Why it is important to do this review</h3> <p>In an effort to enhance fertility, couples are increasingly offered treatment with assisted reproductive techniques (ART). However, these techniques are expensive and do not cure the causes of subfertility, but rather overcome some of its barriers. Since integrity of sperm DNA is one of the major determinants of normal fertilisation and embryo growth in natural and assisted conception (<a href="./references#CD007411-bbs2-0176" title="AgarwalA , SaidT .Role of sperm chromatin abnormalities and DNA damage in male infertility. Human Reproduction Update2003;9(4):331-45.">Agarwal 2003</a>; <a href="./references#CD007411-bbs2-0185" title="AitkenRJ , De IuliisGN , FinnieJM , HedgesA , McLachlanRI .Analysis of the relationships between oxidative stress, DNA damage and sperm vitality in a patient population: development of diagnostic criteria. Human Reproduction2010;25(10):2415-26.">Aitken 2010</a>; <a href="./references#CD007411-bbs2-0221" title="EvensonD , WixonR .Meta-analysis of sperm DNA fragmentation using the sperm chromatin structure assay. Reproductive Biomedicine Online2006;12(4):466-72.">Evenson 2006</a>), there is a clear rationale for antioxidant therapy. </p> <p>One of the other reasons for this review, apart from finding out if antioxidant therapy can overcome some of the barriers of subfertility, is that the global vitamin and supplement market has grown exponentially over the last years. The market value is expected to reach 278 billion USD by 2024 (<a href="./references#CD007411-bbs2-0228" title="Grand View Research.Dietary Supplements Market Analysis By Ingredient (Botanicals, Vitamins, Minerals, Amino Acids, Enzymes), By Product (Tablets, Capsules, Powder, Liquids, Soft Gels, Gel Caps), By Application (Additional Supplement, Medicinal Supplement, Sports Nutrition), By End-Use (Infant, Children, Adults, Pregnant Women, Old-Aged) And Segment Forecasts To 2024. https://www.grandviewresearch.com2016:0-200.">Grand View Research 2016</a>). The low costs and low apparent risks of supplements are appealing to both, patients and healthcare providers. However, most antioxidants are uncontrolled by regulation and the evidence for their effectiveness is not based on randomised controlled trials (RCTs). Vitamins and supplements are dispensed through various retail outlets, including health food shops, online retailers, health centres, fitness clubs, supermarkets, and pharmacies (<a href="./references#CD007411-bbs2-0278" title="ShowellMG , Mackenzie-ProctorR , JordanV , HartRJ .Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD007807. [DOI: 10.1002/14651858.CD007807.pub3]">Showell 2017</a>). </p> <p>The purpose of this Cochrane Review is to assess the effectiveness and safety of different antioxidants and dosages used by men of subfertile couples, through evaluation of live birth rates, clinical pregnancy rates and adverse events. This is an update of a review first published in 2011 (<a href="./references#CD007411-bbs2-0300" title="ShowellMG , BrownJ , YazdaniA , StankiewiczMT , HartRJ .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2011, Issue 1. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub2]">Showell 2011</a>), updated in 2014 (<a href="./references#CD007411-bbs2-0301" title="ShowellMG , Mackenzie-ProctorR , BrownJ , YazdaniA , StankiewiczMT , HartRJ .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub3]">Showell 2014</a>), and in 2019 (<a href="./references#CD007411-bbs2-0302" title="Smits RM , Mackenzie-ProctorR , YazdaniA , StankiewiczMT , JordanV , ShowellMG .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub4]">Smits 2019</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007411-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007411-sec-0014"></div> <p>To evaluate the effectiveness and safety of supplementary oral antioxidants compared with placebo, no treatment or another antioxidant in subfertile men. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007411-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007411-sec-0015"></div> <section id="CD007411-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007411-sec-0017"> <h4 class="title">Types of studies</h4> <section id="CD007411-sec-0018"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD007411-list-0001"> <li> <p>Randomised controlled trials (RCTs).</p> </li> <li> <p>Cross‐over trials are included: however, we only used first‐phase data in the analysis. Achieving outcomes such as pregnancy and live birth would preclude entry of couples into the next trial phase (<a href="./references#CD007411-bbs2-0213" title="DiasS , McNameeR , VailA .Evidence of improving quality of reporting of randomised controlled trials in subfertility. Human Reproduction2006;21(10):2617-27.">Dias 2006</a>). </p> </li> </ul> </p> </section> <section id="CD007411-sec-0019"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD007411-list-0002"> <li> <p>Any quasi‐randomised trials.</p> </li> </ul> </p> </section> </section> <section id="CD007411-sec-0020"> <h4 class="title">Types of participants</h4> <section id="CD007411-sec-0021"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD007411-list-0003"> <li> <p>Studies that included subfertile men (male factor subfertility),part of a couple who had been referred to a fertility clinic and might or might not be undergoing assisted reproductive techniques (ART), such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), or intrauterine insemination (IUI). </p> </li> <li> <p>Male factor subfertility was defined as men who were part of a couple referred to a fertility clinic with abnormal semen parameters, including elevated sperm DNA fragmentation or other seminal biomarkers of oxidative stress. Men with subfertility and varicocele were also included </p> </li> </ul> </p> <p>In situations where individuals were randomised again following failed cycles, the data would not be pooled in a meta‐analysis unless individual data could be excluded. </p> </section> <section id="CD007411-sec-0022"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD007411-list-0004"> <li> <p>Studies enrolling only men attending a fertility clinic exclusively as the result of female partner or idiopathic infertility. </p> </li> <li> <p>Studies enrolling men taking any other fertility‐enhancing drugs.</p> </li> <li> <p>Studies enrolling men who had chemotherapy treatment in the past.</p> </li> </ul> </p> </section> </section> <section id="CD007411-sec-0023"> <h4 class="title">Types of interventions</h4> <p><i>Inclusion criteria</i> </p> <p> <ul id="CD007411-list-0005"> <li> <p>Any type or dose of oral antioxidant supplementation (individual or combined) that can be obtained without prescription and is not regulated as a pharmaceutical drug, versus placebo or no treatment. </p> </li> <li> <p>Any type or dose of oral antioxidant supplementation (individual or combined) versus another type or dose of oral antioxidant (head‐to‐head). </p> </li> </ul> </p> <p>Interventions were considered 'combined antioxidants' if they included three or more antioxidants in the intervention arm. </p> <p><i>Exclusion criteria</i> </p> <p> <ul id="CD007411-list-0006"> <li> <p>Interventions that included plant extracts (for example garlic) or herbal substances.</p> </li> </ul> </p> <p>Studies that included antioxidants plus a plant extract (for example garlic) were included if the antioxidant agent was the main focus of the investigation. </p> <p><b>Definition of antioxidant in male fertility:</b> a substance that has the ability to protect spermatozoa against endogenous oxidative damage by directly neutralising hydroxyl, superoxide, and hydrogen peroxide radicals, chelation of redox metals or by functioning as a component of an antioxidant enzyme. </p> </section> <section id="CD007411-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD007411-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007411-list-0007"> <li> <p>Live birth rate per couple randomised, defined as delivery of a live fetus after 20 completed weeks of gestation. Live births are counted as birth events, i.e. twin live birth is counted as one live birth event. </p> </li> </ul> </p> </section> <section id="CD007411-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007411-list-0008"> <li> <p>Clinical pregnancy rate per couple, defined as a viable intrauterine pregnancy, diagnosed by ultrasonographic examination of at least one fetus with a discernable heartbeat. A twin pregnancy is counted as one pregnancy event. </p> </li> <li> <p>Any adverse event (including miscarriage) reported by the study</p> </li> <li> <p>Level of sperm DNA fragmentation, defined as percentage (%) of sperm with abnormal DNA integrity estimated by either toluidine blue (TB) staining, sperm chromatin structure assay (SCSA) or terminal transferase dUTP nick end labelling (TUNEL) assay. </p> </li> <li> <p>Total sperm motility: any sperm movement in any direction (progressive plus forward plus non‐progressive motility), provided as percentage (%). </p> </li> <li> <p>Progressive sperm motility: sperm with forward progression, defined as WHO category A + B, provided as percentage (%) </p> </li> <li> <p>Sperm concentration: number of sperm (10<sup>6</sup>)/mL. </p> </li> </ul> </p> </section> </section> </section> <section id="CD007411-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs investigating oral antioxidant supplementation for subfertile men, without language restriction and in consultation with the Gynaecology and Fertility Group (CGF) Information Specialist <i>(</i>MGS). </p> <section id="CD007411-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant trials:</p> <p> <ul id="CD007411-list-0009"> <li> <p>The Cochrane Gynaecology and Fertility Group's (CGF) Specialised Register of Controlled Trials, ProCite platform (searched 15 February 2021) (<a href="./appendices#CD007411-sec-0122">Appendix 1</a>); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, issue 2 on 15 February 2021) in the Cochrane Library (now containing records from CINAHL), (<a href="./appendices#CD007411-sec-0123">Appendix 2</a>); </p> </li> <li> <p>MEDLINE, Ovid platform (searched from 1946 to 15 February 2021) (<a href="./appendices#CD007411-sec-0124">Appendix 3</a>); </p> </li> <li> <p>Embase, Ovid platform (searched from 1980 to 15 February 2021) (<a href="./appendices#CD007411-sec-0125">Appendix 4</a>); </p> </li> <li> <p>PsycINFO, Ovid platform (searched from 1806 to 15 February 2021) (<a href="./appendices#CD007411-sec-0126">Appendix 5</a>); </p> </li> <li> <p>AMED, Ovid platform (searched from 1985 to 15 February 2021) (<a href="./appendices#CD007411-sec-0127">Appendix 6</a>); </p> </li> <li> <p>Epistemonikos, Web platform (searched 18 February 2021) (<a href="./appendices#CD007411-sec-0128">Appendix 7</a>). </p> </li> </ul> </p> <p>The MEDLINE search was limited by the Cochrane highly sensitive search strategy filter for identifying randomised trials which appears in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (Version 5.1.0, Chapter 6, 6.4.11) (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The Embase and PsychINFO searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (https://www.sign.ac.uk/what‐we‐do/methodology/search‐filters/). </p> </section> <section id="CD007411-sec-0029"> <h4 class="title">Searching other resources</h4> <p>The following other resources were searched (last search February 2021):</p> <p> <ul id="CD007411-list-0010"> <li> <p>International trial registers: the ClinicalTrials database, a service of the US National Institutes of Health (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>) and the and the World Health Organization International Trials Registry Platform search portal (ICTRP) (<a href="https://protect-au.mimecast.com/s/rL-TCOMKv5h09LQoS9qK9d?domain=trialsearch.who.int" target="_blank">https://trialsearch.who.int/Default.aspx</a>)) (<a href="./appendices#CD007411-sec-0129">Appendix 8</a>; <a href="./appendices#CD007411-sec-0130">Appendix 9</a>); </p> </li> <li> <p>Google scholar, using the keywords 'antioxidants male infertility' and 'antioxidants sperm random'; </p> </li> <li> <p>Database for Abstracts of Reviews of Effects (DARE) for other reviews on this topic;</p> </li> <li> <p>'Grey' literature (unpublished and unindexed), through the openGREY database (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>) (<a href="./appendices#CD007411-sec-0131">Appendix 10</a>); </p> </li> <li> <p>ProQuest Dissertations and Theses (http://search.proquest.com.ezproxy.auckland.ac.nz/pqdtft/advanced?accountid=8424) was also searched (<a href="./appendices#CD007411-sec-0132">Appendix 11</a>); </p> </li> <li> <p>Web of Knowledge for conference proceedings and published trials (<a href="./appendices#CD007411-sec-0133">Appendix 12</a>); </p> </li> <li> <p>Appropriate journals were handsearched for trial conference abstracts in consultation with the CGF Information Specialist. </p> </li> </ul> </p> <p>We handsearched reference lists of relevant trials and systematic reviews retrieved by the search and contacted experts in the field to obtain additional trials. </p> </section> </section> <section id="CD007411-sec-0030"> <h3 class="title" id="CD007411-sec-0030">Data collection and analysis</h3> <section id="CD007411-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Review authors WL and RS did an initial screen of titles and abstracts retrieved by the search. The search was conducted by MGS and WL. We retrieved the full texts of all potentially eligible studies. Two review authors (WL and RM‐P) independently examined these full‐text articles for compliance with the inclusion criteria and selected eligible studies. We corresponded with study investigators as required, to clarify study eligibility. Disagreements were resolved by discussion. If any reports required translation, we described the process used for data collection. We documented the selection process with a “PRISMA” flow chart (see <a href="#CD007411-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007411-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD007411-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD007411-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (WL, KF and JB) independently extracted data from eligible studies using a data extraction form designed and pilot‐tested by the authors. Any disagreements were resolved by discussion. Data extracted included study characteristics and outcome data (see data extraction table for details, <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-sec2-0026" target="_blank">Characteristics of included studies</a> and <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-sec2-0027" target="_blank">Characteristics of excluded studies</a>). Where studies had multiple publications, the review authors collated the multiple reports under a single study ID with multiple references. </p> <p>We corresponded with study investigators for further data on methods and/or results, as required. </p> </section> <section id="CD007411-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (WL, KF and JB) independently assessed the included studies for risk of bias using the Cochrane risk of bias assessment tool to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other potential sources of bias (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Judgements were assigned as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Section 8.5 (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Disagreements were resolved by discussion; when needed we consulted a third party to achieve agreement (MGS, VJ or RM‐P). We described all judgements fully and present the conclusions in the risk of bias table (<a href="./references#CD007411-sec-0143" title="">Characteristics of included studies</a>), which is incorporated in the interpretation of review findings by means of sensitivity analyses (see below). We sought published protocols. </p> <p>We took care to search for within‐study selective reporting, for example, trials failing to report outcomes such as live birth or reporting them in insufficient detail to allow inclusion. Where protocols were available, we assessed studies for differences between study protocols and published results. </p> <p>In cases where included studies failed to identify the primary outcome of live birth, but did report pregnancy rates, we carried out an informal assessment to determine whether pregnancy rates were similar to those in studies that reported live birth. </p> <p>We considered that the blinding status of participants could influence findings for the outcomes of live birth, pregnancy and adverse events, as antioxidants are easily available, and it would be possible for participants to self‐medicate. Therefore, if the participants were not blinded or the study was not placebo‐controlled, or both, we considered the study to be at high risk of bias. </p> </section> <section id="CD007411-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We collected dichotomous data for live birth, pregnancy rate, miscarriage and adverse events and for the continuous data for sperm quality measurements we collected mean differences (MDs) and the associated standard deviations (SDs). </p> <p>Sperm parameter outcomes, if reported, were analysed at the time points of three, six and nine months post‐randomisation. All studies were analysed in this way regardless of whether the participants were treated for three, six or nine months. </p> </section> <section id="CD007411-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis of the outcomes of live birth, pregnancy and adverse events was per couple randomised, counting multiple births as one live birth event. The sperm outcome analyses were per man randomised. Only the first‐phase data from cross‐over trials were included. </p> </section> <section id="CD007411-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat (ITT) basis as far as possible (i.e. including all randomised participants in analyses, in the groups to which they were randomised). Attempts were made to obtain missing data from the original trialists and the results of author contact are reported in <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-sec2-0026" target="_blank">Characteristics of included studies</a>. When data were unobtainable, we undertook imputation of individual values for live birth only; live birth was assumed not to have occurred in participants without a reported outcome. For other outcomes, we analysed only the available data. Any imputation undertaken was subjected to sensitivity analysis (see below). </p> <p>If studies reported sufficient detail to calculate MDs but gave no information on an associated SD, we assumed the outcome to have a SD equal to the highest SD from other studies within the same analysis. </p> </section> <section id="CD007411-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I<sup>2</sup>. If an I<sup>2</sup> was 50% or higher, we assumed high heterogeneity, and conducted a sensitivity analysis. A high I<sup>2</sup> statistic suggests that variations in effect estimates may be due to differences between trials rather than to chance alone (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-bbs2-0126" target="_blank">Higgins 2011</a>). </p> </section> <section id="CD007411-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD007411-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We conducted statistical analysis of the data using Review Manager 5 (<a href="./references#CD007411-bbs2-0271" title="Review Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We expressed the dichotomous data for live birth, pregnancy rate, miscarriage and adverse events as Peto odds ratios (ORs) with 95% confidence intervals (CIs) and combined them in a meta‐analysis with Review Manager 5 software using the Peto method and a fixed‐effect model (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Continuous outcomes, i.e. sperm parameters, provided as median and interquartile range (IQR) or median and range were adjusted to mean and SD (<a href="./references#CD007411-bbs2-0286" title="WanX , WangW , LiuJ , TongT .Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medicl Research Methodology2014;14:135.">Wan 2014</a>). A fixed‐effect model was used on sperm outcomes. The Peto OR has mathematically sound properties that are consistent with benefit or harm and work well in small samples with rare events. This effect measure is appropriate when considering subfertility. For continuous data (for example sperm quality measurements) MDs between treatment groups were calculated with associated SDs and 95% CIs. The results were displayed on forest plots where possible. </p> <p>We considered pregnancy outcomes to be positive, and higher pregnancy rates of benefit. We considered the outcomes of miscarriage and adverse events to be negative effects, and higher numbers harmful. We combined data for the following comparisons. </p> <p> <ul id="CD007411-list-0011"> <li> <p>Antioxidants versus placebo or no treatment</p> </li> <li> <p>Antioxidants versus antioxidants (head‐to‐head)</p> </li> </ul> </p> <p>Adverse events as reported in the studies were included in the two comparisons above.</p> <p>The total sperm motility, progressive sperm motility and concentration outcomes were divided into three groups: measurement after starting treatment, at three, six and nine months or more, as reported by the studies. Studies were analysed together if they reported these outcomes at the same point in time, for example a study that stopped treatment at three months but measured at six or nine months was measured in the same analysis as those that were treated for six or nine months. </p> <p>We displayed increases in the odds of a particular outcome, which may be beneficial (e.g. live birth) or detrimental (e.g. adverse events), graphically in meta‐analyses to the right of the centre line, and decreases in the odds of a particular outcome to the left of the centre line. </p> <p>The aim was to define analyses that were comprehensive and mutually exclusive, so that we could slot all eligible study results into one stratum only. We specified comparisons so that any studies falling within each stratum could be pooled for meta‐analysis. Stratification allowed for consideration of effects within each stratum, as well as or instead of an overall estimate for comparison. </p> <p>If individuals had been randomly re‐assigned after failed cycles, we did not pool the data in a meta‐analysis. </p> <p>Statistical analysis was performed using Review Manager 5.4.1 (<a href="./references#CD007411-bbs2-0271" title="Review Manager 5 (RevMan 5).Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD007411-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where data were available, we conducted subgroup analyses to determine the separate evidence within the following subgroups. </p> <p> <ul id="CD007411-list-0012"> <li> <p>Studies that included different types of antioxidant</p> </li> <li> <p>Studies that included couples who were also receiving IVF/ICSI treatment (for the outcomes of live birth and clinical pregnancy) </p> </li> <li> <p>Over time analysis for sperm outcomes of motility and concentration, at three, six and nine months </p> </li> </ul> </p> <p>If we detected substantial heterogeneity, we explored possible explanations in subgroup analyses (e.g. differing populations) and/or sensitivity analyses (e.g. differing risk of bias). We took any statistical heterogeneity into account when interpreting the results, especially if there was any variation in the direction of effect. </p> </section> <section id="CD007411-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses (using the fixed‐effect model in RevMan software) on the primary outcomes if we detected a high degree of heterogeneity (I<sup>2</sup> = 50% or more), excluding studies to assess if there is a change in effect: </p> <p> <ul id="CD007411-list-0013"> <li> <p>for studies with a high risk of bias, or</p> </li> <li> <p>for studies using no treatment as a control group instead of placebo (for outcomes of live birth and clinical pregnancy), or </p> </li> <li> <p>for studies enrolling men who are part of a couple undergoing IUI, or</p> </li> <li> <p>enrolling men with varicocele, or</p> </li> <li> <p>for studies that reported both live birth and clinical pregnancy rate in order to assess any overestimation of effect and reporting bias, or </p> </li> <li> <p>for studies where results had been imputed, or</p> </li> <li> <p>for studies that reported remarkably low SDs as the review authors considered that these data were potentially erroneous (a post hoc sensitivity analysis). </p> </li> </ul> </p> </section> <section id="CD007411-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings; table using GRADEpro (<a href="./references#CD007411-bbs2-0227" title="GRADEpro Guideline Development Tool.GRADEpro. McMaster University: developed by Evidence Prime, Inc., 2015. Available from gradepro.org.">GRADEpro GDT 2015</a>) and Cochrane methods (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). This table evaluates the overall certainty of the body of evidence for the main review outcomes (live birth, clinical pregnancy, and the adverse events) for the main review comparison (antioxidant compared with placebo or no treatment). We assessed the certainty of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias. Judgements about evidence certainty (high, moderate, low or very low) were made by three review authors (WL, KF and JB) working independently, with disagreements resolved by discussion. Judgements were justified, documented, and incorporated into reporting of results for each outcome. </p> <p>We extracted study data, formatted our comparisons in data tables and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007411-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007411-sec-0043"></div> <section id="CD007411-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD007411-sec-0045"> <h4 class="title">Results of the search</h4> <section id="CD007411-sec-0046"> <h5 class="title">2011 version of review</h5> <p>We assessed 590 abstracts for inclusion from the title and abstract found in a search dated from inception to August 2010. The MEDLINE search produced 406 abstracts; there were six abstracts from CENTRAL, three from CINAHL, 62 from Embase, 107 from the Cochrane Gynaecology and Fertility Group' (CGF) database and three from PsycINFO. Two conference abstracts were found from handsearching the conference proceedings of the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM). One title was found from reference lists in reviews. After removal of inappropriate and duplicate studies, we retrieved the full texts of 53 studies. Five non‐English studies were assessed for inclusion: two Chinese, one Bulgarian, one Japanese and one Iranian. The two Chinese studies (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>), the Japanese study (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>), and the Iranian study (<a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>) were included in the analysis. The Bulgarian study (<a href="./references#CD007411-bbs2-0138" title="NikolovaV , StanislavovR , VatevI , NalbanskiB , PunevskaM .Sperm parameters in male idiopathic infertility after treatment with prelox. Akusherstvo i Ginekologiia2007;46(5):7-12. ">Nikolova 2007</a>) was excluded as it did not use random allocation (see <a href="./references#CD007411-sec-0144" title="">Characteristics of excluded studies</a>). We excluded 15 articles and found four ongoing studies in searches of the clinical trial registers. </p> <p>A total of 34 studies were included in the 2011 version of the review (<a href="./references#CD007411-bbs2-0300" title="ShowellMG , BrownJ , YazdaniA , StankiewiczMT , HartRJ .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2011, Issue 1. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub2]">Showell 2011</a>). </p> </section> <section id="CD007411-sec-0047"> <h5 class="title">2014 update</h5> <p>We assessed 483 abstracts for inclusion from the title and abstract found in a search dated from 1 August 2010 to 30 January 2014. After duplicates were removed 338 remained. We assessed 34 of these papers in full text. </p> <p>Eleven of the full‐text reports assessed studies were in a language other than English and required translation, five of these were in Chinese, two in Persian and one each in Japanese, Russian, Italian, and Portuguese (see <a href="#CD007411-sec-0119">Acknowledgements</a> for those who helped with translation). Five of the Chinese studies were excluded: three (<a href="./references#CD007411-bbs2-0105" title="ChenXF , LiZ , PingP , DaiJC , ZhangFB , ShangXJ , et al.Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases. Zhong Hua Nan Ke Xue2012;18(5):428-31. ">Chen 2012</a>; <a href="./references#CD007411-bbs2-0149" title="TangKF , XingY , WuCY , LiuRZ , WangXY , XingJP .[Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia]. Zhong Hua Nan Ke Xue2011;17(7):615-8. ">Tang 2011</a>; <a href="./references#CD007411-bbs2-0155" title="WangY , YangS , CaiW , QuC , LiJ , ChangX , et al.[Clinical efficacy of L-carnitine combined with tamoxifen in treatment of oligoasthenozoospermia] LA: Chi. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010a</a>) due to an inappropriate intervention, one was not randomised (<a href="./references#CD007411-bbs2-0157" title="WuZM , LuX , WangYW , SunJ , TaoJW , YinFH , et al.Short-term medication of L-carnitine before intracytoplasmic sperm injection for infertile men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2012;18(3):253-6. ">Wu 2012</a>), and one had an inappropriate population (<a href="./references#CD007411-bbs2-0124" title="LuSM , LiX , ZhangHB , HuJM , YanJH , LiuJL , et al.[Use of L-carnitine before percutaneous epididymal sperm aspiration-intracytoplasmic sperm injection for obstructive azoospermia]. Zhonghua nan ke xue - National Journal of Andrology2010;16(10):919-21. ">Lu 2010</a>). The Portuguese study (<a href="./references#CD007411-bbs2-0150" title="VerzelettiFB , PolettoRS , BertolinTE , FornariF .Evaluation of sperm quality in adults after use spirulina platensis and resveratrol. Jornal Brasileiro de Reproducao Assistida2012;16(5):271-7. ">Verzeletti 2012</a>) was excluded as it used a herbal intervention. Five non‐English studies were included: one in Persian (<a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>), one Japanese (<a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>), one Italian (<a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>), one Russian (<a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>), and one Chinese (<a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>). </p> <p>We excluded 20 articles, and included 14 articles. An updated search was run in August 2014 where six studies (<a href="./references#CD007411-bbs2-0097" title="AnarteC , DomingoA , AgirregoikoaJA , De PabloJ , BarrenetxeaG .Regular consumption of docosahexaenoic acid (DHA) improves semen quality. Fertility and Sterility2013;100 Suppl 3:S443. ">Anarte 2013</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0116" title="IaconoF , RuffoA , PreziosoD , IllianoE , RomeoG , RomisL , et al.Combination therapy with antiestrogen and a natural composite containing tribulus terrestris, alga ecklonia bicyclis, biovis and myo-inositol in the treatment of male idiopathic infertility. Journal of Sexual Medicine2014;1:92. ">Iacono 2014</a> <a href="./references#CD007411-bbs2-0130" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Effect of Coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. Andrologia2014;46(2):177-83. ">Nadjarzadeh 2014</a>; <a href="./references#CD007411-bbs2-0131" title="NashivochnikovaNA , KrupinVN , SelivanovaSA .[Efficiency of spematon in male infertility]. Urologiia (Moscow, Russia: 1999)2014;2:52-4. [PMID: 24956674]">Nashivochnikova 2014</a>; <a href="./references#CD007411-bbs2-0136" title="Nematollahi-MahaniSN , AzizollahiGH , BaneshiMR , SafariZ , AzizollahiS .Effect of folic acid and zinc sulphate on endocrine parameters and seminal antioxidant level after varicocelectomy. Andrologia2014;46(3):240-5. ">Nematollahi‐Mahani 2014</a>) were placed in 'Studies awaiting assessment'. There were six ongoing studies found in the new searches. </p> <p>We included 14 new trials in the 2014 update: <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0143" title="SafarinejadMR .Effect of pentoxifylline on semen parameters, reproductive hormones and seminal plasma antioxidant capacity in men with idiopathic infertility: a randomized double-blind placebo-controlled study. International Urology and Nephrology2011;43:315-28. ">Safarinejad 2011</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>. </p> <p>A total of 48 studies were included in the 2014 update (<a href="./references#CD007411-bbs2-0301" title="ShowellMG , Mackenzie-ProctorR , BrownJ , YazdaniA , StankiewiczMT , HartRJ .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2014, Issue 12. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub3]">Showell 2014</a>). </p> </section> <section id="CD007411-sec-0048"> <h5 class="title">2018 update</h5> <p>We assessed 979 abstracts for inclusion from the title and abstract found in a search dated from January 2014 until February 2018. One extra study was found through the grey literature search. After duplicates were removed, 718 articles remained. We assessed 58 of these papers in full text. One of the full‐text articles assessed studies was in Chinese (<a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>) and one in Russian (<a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>); both required translation. We excluded 22 studies (28 articles), and included 19 studies (29 articles). Twelve studies were classified as ongoing studies. One study was placed in 'Studies awaiting assessment' (<a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>). </p> <p>We removed and excluded four pentoxifylline studies that were previously included in the 2014 update and the original review (<a href="./references#CD007411-bbs2-0126" title="MerinoG , Martinez ChequerJC , BarahonaE , BermudezJA , MoranC , Carranza-LiraS .Effects of pentoxifylline on sperm motility in normogonadotropic asthenozoospermic men. Archives of Andrology1997;39(1):65-9. ">Merino 1997</a>; <a href="./references#CD007411-bbs2-0127" title="MicicS , Hadzi-DjokicJ , DotlicR , TulicC .Pentoxifyllin treatment of oligoasthenospermic men. Acta Europaea Fertilitatis1988;19(3):135-7. ">Micic 1988</a>; <a href="./references#CD007411-bbs2-0143" title="SafarinejadMR .Effect of pentoxifylline on semen parameters, reproductive hormones and seminal plasma antioxidant capacity in men with idiopathic infertility: a randomized double-blind placebo-controlled study. International Urology and Nephrology2011;43:315-28. ">Safarinejad 2011</a>; <a href="./references#CD007411-bbs2-0154" title="WangC , ChanCW , WongKK , YeungKK .Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertility and Sterility1983;40(3):358-65. ">Wang 1983</a>). Furthermore, we removed two previously included studies due to the discovery that the population did not meet the inclusion criteria: they included men with idiopathic infertility with normal sperm parameters, and no male factor infertility. (<a href="./references#CD007411-bbs2-0106" title="CiftciH , VeritA , SavasM , YeniE , ErelO .Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology2009;74(1):73-6. ">Ciftci 2009</a>; <a href="./references#CD007411-bbs2-0119" title="Keskes-AmmarL , Feki-ChakrounN , RebaiT , SahnounZ , GhozziH , HammamiS , et al.Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. Archives of Andrology2003;49(2):83-94. ">Keskes‐Ammar 2003</a>). </p> <p>We included 19 new trials in the 2018 update: <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>. </p> <p>A total of 61 studies were included in the 2018 update (<a href="./references#CD007411-bbs2-0302" title="Smits RM , Mackenzie-ProctorR , YazdaniA , StankiewiczMT , JordanV , ShowellMG .Antioxidants for male subfertility. Cochrane Database of Systematic Reviews2019, Issue 3. Art. No: CD007411. [DOI: 10.1002/14651858.CD007411.pub4]">Smits 2019</a>). </p> </section> <section id="CD007411-sec-0049"> <h5 class="title">2021 update</h5> <p>We assessed 1445 abstracts for inclusion from the title and abstract found in a search dated from February 2018 until February 2021. After duplicates were removed, 1055 articles remained. We assessed 42 of these papers in full text. </p> <p>Three of the full‐text articles assessed studies were in Chinese (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>) and three were in Russian (<a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>); all required translation. One study was found eligible through reference checking and was included (<a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>). In total, we excluded nine articles and included 29 studies (34 articles). One study was placed in "Studies awaiting classification", because of unclear study population (<a href="./references#CD007411-bbs2-0159" title="KuzmenkoAV , KuzmenkoVV , GyaurgievTA .The effectiveness of the Speroton complex in the management of male factor infertility. Urologiia (Moscow, Russia : 1999)2018;3:78‐82. ">Kuzmenko 2018</a>). See the PRISMA flow chart (<a href="#CD007411-fig-0001">Figure 1</a>). </p> <p>One previously excluded study was added as a sub‐study to an included study (<a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>). </p> <p>In the current update, six of the 12 previously ‘ongoing studies’ were included (<a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). One study remained as an ongoing study (<a href="./references#CD007411-bbs2-0170" title="SmitsRM , FleischerK , BraatDDM .The impact of a nutritional supplement (Impryl®) on male fertility. https://clinicaltrials.gov. ">NCT03337360</a>). The manuscript of one trial was submitted, but not yet published and was therefore placed in “Studies awaiting classification” (<a href="./references#CD007411-bbs2-0161" title="Mathieu-d’ArgentE .Impact of folates in the care of the male infertility (FOLFIV). https://clinicaltrials.gov. ">NCT01407432</a>). Three other former ongoing studies were placed in “Studies awaiting classification” with a status of “completed” and “recruitment stopped” in the trial registry (<a href="./references#CD007411-bbs2-0158" title="BaumgraßH .Randomized, placebo-controlled, double-blind, multi-centre pilot study to investigate the effect of AM019016 on male spermatogenesis in subjects with diagnosed unspecific (idiopathic) subfertility. www.who.int/trialsearch. ">DRKS00011616</a>; <a href="./references#CD007411-bbs2-0160" title="AguilarMM .Assessment of the efficacy of dietary supplement spermotrend in the treatment of male infertility. ClinicalTrials.gov. ">NCT00975117</a>; <a href="./references#CD007411-bbs2-0162" title="PalumboM .Myo-inositol on human semen parameters [Effect of of treatment with Myo-inositol on human semen parameters in patients undergoing IVF cycles]. https://clinicaltrials.gov. ">NCT01828710</a>). One former ongoing study was excluded, because of withdrawal on the trial registry website (<a href="./references#CD007411-bbs2-0169" title="JawaidM .Neotililty trial: effect of coenzyme Q10 on semen parameters in men with idiopathic infertility (neotility). https://clinicaltrials.gov. ">NCT03104998</a>). </p> <p>The authors from the one study placed in "Studies awaiting assessment" in the previous update (<a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>) were contacted and confirmed that the study was a randomised clinical trial. </p> <p>We added 11 new ongoing studies (<a href="./references#CD007411-bbs2-0163" title="CTRI/2019/03/018303.A clinical trial to study the association between reactive oxygen species and semen quality and the effect of vitamin C therapy in male infertility patients [Assessment of seminal plasma myeloperoxidase level (ROS)and the effect of vitamin C therapy on semen quality in infertile men]. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=31766&amp;EncHid=&amp;modid=&amp;compid=%27,%2731766det%27 (first received 27 March 2019). ">CTRI/2019/03/018303</a>; <a href="./references#CD007411-bbs2-0164" title="IRCT20120215009014N.Effect of CO-Q 10 supplementation spermogram parameters and sexual function in infertile men [Effect of CO-Q 10 supplementation versus placebo on spermogram parameters and sexual function in infertile men: a double-blind randomized clinical trial]. http://en.irct.ir/trial/44080 (first received 16 December 2019). ">IRCT20120215009014N322</a>; <a href="./references#CD007411-bbs2-0165" title="IRCT20140622018187N9.The effect of vitamin C supplementation on quality of spermogram in infertile men with asthenozoospermia with a balanced diet in Mother and Child hospital, Shiraz, 1392. https://www.irct.ir/trial/48413 (first received 9 June 2020). ">IRCT20140622018187N9</a>; <a href="./references#CD007411-bbs2-0166" title="IRCT20190406043177N.Effect of alpha lipoic acid on male infertility [The effect of alpha lipoic acid on sperm parameters, DNA integrity and oxidative stress in infertile men with increased level of sperm DNA damage]. http://en.irct.ir/trial/39346 (first received 22 June 2019). ">IRCT20190406043177N1</a>; <a href="./references#CD007411-bbs2-0167" title="Irct20190714044209N.Evaluating the therapeutic effect of theophylline and zinc sulfate co-administration in infertile men. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190714044209N12020. ">IRCT20190714044209N1</a>; <a href="./references#CD007411-bbs2-0168" title="IRCT20200911048689N1.The effect of vitamin E on sperm in men with varicocele [Effect of vitamin E on quality and quantity of sperm in infertile men after varicocelectomy]. https://en.irct.ir/trial/50895 (first received 10 October 2020). ">IRCT20200911048689N1</a>; <a href="./references#CD007411-bbs2-0171" title="Nct.Omega-3 PUFA for treatment of patients with Idiopathic oligoasthenoteratospermia. https://clinicaltrials.gov/show/NCT036346442018. ">NCT03634644</a>; <a href="./references#CD007411-bbs2-0172" title="NCT.Impact of a nutritional supplements' combination (FERTILIS) on male infertility. https://clinicaltrials.gov/show/NCT041933582019. ">NCT04193358</a>; <a href="./references#CD007411-bbs2-0173" title="NCT04256278.Administration of antioxidants to infertile men and sperm quality [Does antioxidant administration improve sperm quality in infertile men]. https://clinicaltrials.gov/ct2/show/NCT04256278 (first received 5 February 2020). ">NCT04256278</a>; <a href="./references#CD007411-bbs2-0174" title="NCT04509583.The role of micro nutrient supplement in improvement of the sperm DNA fragmentation [Is micro nutrient supplement effective in improving the sperm dna fragmentation]. https://clinicaltrials.gov/ct2/show/NCT04509583 (first received 12 August 2020). ">NCT04509583</a>; <a href="./references#CD007411-bbs2-0175" title="PACTR201802003076341.Effects of different antioxidants on sperm parameters in infertile males [Effects of different antioxidants on sperm parameters in infertile males]. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3076 (first received 12 Februuary 2018). ">PACTR201802003076341</a>). </p> <p>We included 29 new studies (34 articles) in this update: <a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>. </p> <p>A total of 90 studies have been included in this update (<a href="./references#CD007411-sec-0143" title="">Characteristics of included studies</a>). A total of 67 studies were excluded (<a href="./references#CD007411-sec-0144" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD007411-sec-0050"> <h4 class="title">Included studies</h4> <section id="CD007411-sec-0051"> <h5 class="title">Study design and setting</h5> <p>The studies came from 31 different countries. Twenty‐one studies were from Iran (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>). Ten studies were based in Italy (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>). Nine studies were from China (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). Six were from Russia (<a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>), four from Iraq (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>), and four from the USA (<a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). Three studies each were from India (<a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>), Japan (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>), the UK (<a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>) and Spain (<a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>). Two studies each were from Kuwait (<a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>), Greece (<a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>) and Turkey (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>). A single study was set in each of the following countries: Australia (<a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>), Belgium (<a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>), Canada (<a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>), Denmark (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>), Egypt (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>), France (<a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>), Germany (<a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>), Hungary (<a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>), Mexico (<a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>), the Netherlands (<a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>), Panama (<a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>), Saudi Arabia (<a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>), Serbia (<a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>), Slovenia (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>), Sweden (<a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), Thailand (<a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>), Tunisia (<a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>), and Ukraine (<a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>). </p> <p>All included studies were randomised. Five studies had a randomised cross‐over design (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>). In the meta‐analysis only the first phase data were used as all studies reported first and second phase data separately. The remaining 85 studies used a randomised parallel group design. One study (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>) had a large imbalance between the intervention and control groups at the randomisation stage; 150 men were randomised, 90 into the treatment group and 60 into the control group. This appeared to be a blocked 3:2 allocation ratio. This method of randomisation was not explained in the report. Attempts were made to contact the author, but there has been no reply. Fifteen studies (<a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>) were three‐armed, 11 (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) were four‐armed and one study was five‐armed (<a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). </p> <p>The duration of the treatment period ranged from three weeks with a three‐week follow up (<a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>) to 12 months treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>). The longest follow‐up periods were in the studies by Blomberg Jensen and Safarinejad with respectively a five‐month (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>) and six and a half‐month (<a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>) treatment duration and both with 14 months of follow‐up. Ten studies reporting on either live birth rate or clinical pregnancy rate, only mentioned follow‐up consultations during their treatment, however they did not report the length of follow‐up after treatment (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> <p>Funding sources were stated by 36 studies (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). Eight of these studies stated that funding was from a commercial source (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), and the remaining 28 obtained funding through non‐commercial avenues or university grants. Nine studies specifically reported no funding (<a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>). Forty‐five studies did not mention any funding sources. </p> </section> <section id="CD007411-sec-0052"> <h5 class="title">Participants</h5> <p>The 90 studies included 10,303 subfertile men, 6262 in the intervention groups and 4041 men in the control groups. The age range of the participants was 18 to 65 years. Studies included couples who had attended a fertility clinic, with a fertile partner and had been trying to conceive with regular intercourse for over one year. Most men in the included studies had a deficient level of spermatozoa in the seminal fluid (oligospermia) or a low motility of sperm in the seminal fluid (asthenospermia). Five studies included men with an increased level of DNA fragmentation or oxidative stress (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), and one study included men with low acrosin activity (<a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>). Three studies also included fertile (<a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) or normospermic men (<a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>, <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>) with subgroup analysis. Studies excluded men with any inflammatory disease, antibody problems or chromosomal problems; and most studies stated that they did not enrol men who smoked, took any additional medication or drank alcohol. </p> <p>Two studies enrolled men with varicocele (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>), 10 studies enrolled men post‐varicocelectomy (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>), and one study enrolled men with chronic prostatitis (<a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>). Eight studies (<a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>) enrolled men who, as part of a couple, were undergoing in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI). One study specifically enrolled men who were undergoing ICSI with sperm obtained with testicular extraction (TESE) (<a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>). Three studies enrolled men who were part of a couple undergoing intrauterine insemination (IUI) (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). </p> <p>Further details of inclusion and exclusion criteria are available in <a href="./references#CD007411-sec-0143" title="">Characteristics of included studies</a>. </p> </section> <section id="CD007411-sec-0053"> <h5 class="title">Interventions</h5> <p>A wide variety of antioxidants were used in the included studies. Comparisons covered antioxidants versus placebo or no treatment and head‐to‐head comparisons (antioxidant versus antioxidant). </p> <p>The comparison 'antioxidants versus placebo or no treatment' included the following antioxidants: arginine, carnitines (L‐carnitine, L‐acetyl carnitine, L‐carnitine plus L‐acetyl carnitine), carotenoids (β‐carotene), coenzyme Q10 (CoQ10), cysteines (ethylcysteine and N‐acetylcysteine (NAC)), folic acid, magnesium, melatonin, polyunsaturated fatty acids (PUFAs) (alpha‐lipoic‐acid and docosahexaenoic acid (DHA)), resveratrol, selenium, vitamin B, vitamin C, vitamin D with calcium, vitamin E and zinc. </p> <p>Combined antioxidants were used in 23 studies. They were labelled as Proxeed Plus (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>), Menevit (<a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>), Selznic (<a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>), SpermActin‐forte (<a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>), Spermotrend (<a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>), Androdos (<a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>), Androferti (<a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), Profertil (<a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>), and Brudy Plus (<a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>). Eleven of these 23 studies used combined antioxidants without any brand name or labelling; vitamin E combined with selenium and folic acid (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>, <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>), a combination of vitamin E, C and zinc (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>), l‐carnitine, acetyl‐Lcarnitine, vitamin C, folic acid, selenium, coenzyme Q10 and vitamin B12 (<a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>), “Verum TDS”: l‐carnitine, l‐acetyl‐carnitine, l‐arginine, glutathione, coenzyme Q10, zinc, vitamin B9, vitamin B12 and selenium (<a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>), an antioxidant supplement containing vitamin E, vitamin C, selenium and l‐carnitine (<a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>), vitamin C/D/E, selenium, L‐carnitine, zinc, folic acid and lycopene (<a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>), "N‐acetylcysteine (NAC) with vitamins and micronutrients" (<a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>), selenium plus vitamin A/C/E (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>), a fixed dose combination (FDC) of coenzyme Q10, L‐carnitine, lycopene and zinc (<a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>), and "essential fatty acid (EFA) mixture combined with α‐tocopherol (vitamin E) and β‐carotene, acetylcysteine and other antioxidants" (<a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>). <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a> did not specify the brand name or content of the "combined oral antioxidant". </p> <p>The second comparison, head‐to‐head, included t26 studies. The head‐to‐head comparisons were included in an attempt to assess whether one antioxidant was more effective than another. They looked at effects of ethylcysteine versus vitamin E (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>), 200 mg versus 400 mg of coenzyme Q10 (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>), coenzyme Q10 versus selenium (<a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>), zinc versus folic acid versus zinc plus folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>), L‐carnitine versus L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>), l‐carnitine versus coenzyme Q10 versus l‐carnitine plus coenzyme Q10 versus vitamin B1 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>), 400 mg versus 800 mg of DHA (<a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>), 1000 mg versus 200 mg of vitamin C (<a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>), vitamin D plus calcium versus vitamin C plus vitamin E (<a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>), DHA plus vitamin E versus DHA versus vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>), SpermActin Forte versus SpermActin Forte plus "vitamin complex" (<a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>), 0.5 g versus 1 g versus 2 g of DHA (<a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>), L‐carnitine plus acetyl‐L‐carnitine versus vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>), L‐carnitine versus vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>), vitamin E plus selenium versus vitamin B (<a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>), zinc versus zinc plus vitamin E versus zinc plus vitamin E and vitamin C (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>), glutathione versus coenzyme Q10 (<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>), N‐acetylcysteine versus selenium versus selenium plus N‐acetylcysteine (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>), selenium versus combined antioxidants (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>), l‐carnitine versus vitamin E (<a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>), Profertil (combined antioxidant) versus l‐carnitine (<a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>), L‐carnitine plus vitamin E versus vitamin E (<a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>), acetyl‐cysteine versus essential fatty acid (EFA) plus α‐tocopherol (vitamin E) plus β‐carotene versus acetylcysteine plus EFA plus antioxidants (<a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>), and vitamin E versus vitamin E plus amino acids (<a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> <p>In summary:</p> <p> <ul id="CD007411-list-0014"> <li> <p>42/90 studies compared antioxidants with placebo;</p> </li> <li> <p>10/90 studies compared antioxidants with no treatment;</p> </li> <li> <p>11/90 studies compared one antioxidant with another antioxidant (head‐to‐head);</p> </li> <li> <p>27/90 multi‐arm studies: 19 of these compared antioxidants versus placebo, six compared antioxidants versus no treatment, one study compared antioxidants versus a diet rich in antioxidants versus placebo, and one study compared different types of antioxidants without use of a placebo or no treatment group. </p> </li> </ul> </p> </section> <section id="CD007411-sec-0054"> <h5 class="title">Outcomes</h5> <p>The primary outcome for this review was as follows.</p> <p> <ul id="CD007411-list-0015"> <li> <p>Live birth per couple. Fourteen studies reported data for live birth in the antioxidant versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>). One of these studies could also be included in the head‐to‐head comparison of live birth rate (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>). In one study, the unpublished data on live births following ICSI treatment were used (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>). The data from <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a> and <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a> could not be used in the meta‐analysis, as the number of patients in whom the outcome was assessed was not reported. </p> </li> </ul> </p> <p>Secondary outcomes for this review were as follows.</p> <p> <ul id="CD007411-list-0016"> <li> <p>Clinical pregnancy rate per couple, as reported by 22 studies in the antioxidant versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). Two of these studies could also be included in the head‐to‐head comparison of clinical pregnancy rate (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>); two more studies in the head‐to‐head comparison reported on clinical pregnancy rate (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>). From one study, the unpublished data on clinical pregnancy following ICSI treatment were used (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>). The data from <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a> and <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a> could not be used in the meta‐analysis, as the number of patients with male subfertility in whom the outcome was assessed, was not reported. Data for biochemical and undefined pregnancy can be seen in <a href="#CD007411-tbl-0002">Table 1</a>. </p> </li> <li> <p>Adverse events (miscarriage, ectopic pregnancy, stillbirth, gastrointestinal discomfort, euphoria, headache, upper respiratory infection and nasopharyngitis) were reported by 23 studies (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>) in the antioxidant versus placebo or no treatment comparison. <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a> and <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> reported different types of gastrointestinal discomfort separately, which made the data unuseable for meta‐analysis. Adverse events were not reported as an outcome in any of the studies in the head‐to‐head comparisons, except that the study by Li (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>) reported that no side effects were found in either the treatment or control groups. </p> </li> <li> <p>DNA fragmentation at three months or less was reported by 13 studies (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), comparing antioxidants versus placebo or no treatment. One study in the head‐to‐head comparison reported on DNA fragmentation (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>). Data from one study were not usable as the investigators used the Comet assay and reported DNA tail length, which is not a percentage and can therefore not be pooled with the other results (<a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>)(<a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a>). </p> </li> <li> <p>DNA fragmentation at six months was reported by four studies (<a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>), comparing antioxidants versus placebo or no treatment. </p> </li> <li> <p>Total sperm motility at three months or less was reported by 30 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>) and by 14 studies in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> </li> <li> <p>Total sperm motility at six months was reported by 19 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). Four studies reported this in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). </p> </li> <li> <p>Total sperm motility at nine months or more was reported by five studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). One study reported this in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>). </p> </li> <li> <p>Progressive sperm motility at three months or less was reported by 26 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>). Thirteen studies reported this in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> </li> <li> <p>Progressive sperm motility at six months was reported by 13 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). Two studies reported this in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>). </p> </li> <li> <p>Progressive sperm motility at nine months or more was reported by two studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>). One study reported this in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>). </p> </li> <li> <p>Sperm concentration at three months or less was reported by 34 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>), and 14 in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>). </p> </li> <li> <p>Sperm concentration at six months was reported as an outcome by 20 studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>;  <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>;  <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>), and four studies in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). </p> </li> <li> <p>Sperm concentration at nine months or more was reported by five studies in the antioxidants versus placebo or no treatment comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>), and one study in the head‐to‐head comparison (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>). </p> </li> </ul> </p> <div class="table" id="CD007411-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data for undefined or biochemical pregnancy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Undefined or biochemical pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="bottom"> <p><b>Antioxidant</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="bottom"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Peto OR [CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><i>Antioxidant(s) versus placebo or no treatment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Combined antioxidants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.17 [0.16 to 413.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 [0.88 to 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 [0.32 to 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 [0.17 to 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Arginine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.82 [0.11 to 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Carnitines</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.74 [0.04 to 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8.57 [0.82 to 89.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.37 [1.61 to 43.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7.20 [0.95 to 54.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7.50 [2.01 to 27.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Coenzyme Q10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Vitamin C + Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.26 to 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Head‐to‐head antioxidant(s)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>L‐acetyl carnitine + L‐carnitine vs Vitamin E + Vitamin C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 [0.81 to 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>L‐carnitine + Vitamin E vs Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.01 [2.49 to 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E + amino acids vs Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 [0.41 to 15.35]</p> </td> </tr> </tbody> </table> </div> <p>Data were extracted from 67 of the included studies. The 23 remaining studies either did not report any data or the number of patients in whom the outcome was assessed was not reported (<a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>). In the current update, we calculated the mean and standard deviation from data presented as median and (interquartile) range from six studies included in previous versions of this review (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). Another study reported data for a treatment duration of three to six months, but did not specify this any further and therefore data could not be used in the meta‐analysis (<a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>). </p> <p>See <a href="./references#CD007411-sec-0143" title="">Characteristics of included studies</a> and the analyses 'data not usable for meta‐analysis'(<a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a>; <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a>; <a href="./references#CD007411-fig-0028" title="">Analysis 1.16</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a>; <a href="./references#CD007411-fig-0034" title="">Analysis 1.22</a>). <a href="#CD007411-tbl-0003">Table 2</a> also describes the outcomes and conclusions of all included studies. Attempts were made to contact all authors of the included studies for further details and clarification. </p> <div class="table" id="CD007411-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes and conclusions from all included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design, population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes described in methods section</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported on in results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>In meta‐analysis Y or N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conclusions</b> </p> <p>+ = positive effect</p> <p>‐ = negative or no effect</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men post‐varicocelectomy</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALA improved sperm motility compared to baseline. No significant difference in sperm parameters between ALA and placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>ALA does not improve semen quality compared to placebo after varicocelectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, head‐to‐head</p> <p>Infertile men, high ROS levels</p> <p>N = 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethylcystein did not improve sperm density and motility but "sperm function" increased and ROS levels decreased, compared to vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Ethylcysteine shown to be effective for improvement of sperm parameters when compared to vitamin E </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CoQ10 200 and 400 mg improved sperm concentration and motility, greater improvement with 400 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>CoQ10 improves sperm parameters, greater improvement with a 400 mg dose compared to 200 mg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ number of drop‐outs unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CoQ10 and selenium each improved sperm concentration and motility, greater improvement with CoQ10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>CoQ10 and selenium improve sperm parameters, greater improvement with CoQ10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D did not improve sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Vitamin D does not improve sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men post‐varicocelectomy</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co‐administration of folic acid, selenium and vitamin E improved sperm concentration and motility </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>A combination of folic acid + selenium + vitamin E improves sperm parameters after varicocelectomy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Idiopathic asthenozospermia, IUI</p> <p>N = 30</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, chemical and clinical pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, chemical and clinical pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC increased sperm concentration and motility.</p> <p>Clinical pregnancy was not significantly different between the groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>NAC improves semen quality and improves pregnancy rates prior to IUI, no improvement of pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm trial</p> <p>Men post‐varicocelectomy</p> <p>N = 160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild improvement in sperm parameters with the use of antioxidants zinc, folic acid or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Co‐administration of zinc and folic acid improved sperm parameters and increased varicocelectomy outcomes, only zinc an improvement in pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic OAT</p> <p>N = 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No improvement of sperm parameters with the use of selenium, folic acid and vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Co‐administration of selenium, folic acid and vitamin E were not effective to improve sperm parameters </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in motility in LAC group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Long‐term carnitine is effective in increasing sperm motility. No evidence of increased live birth or clinical pregnancy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile and unexplained</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co enzyme Q10 increased sperm motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Q10 is effective in improving sperm kinetic features in asthenospermia. No evidence of increased live birth or clinical pregnancy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Subfertile men with varicocele</p> <p>N = 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical spontaneous pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters significantly improved after surgery compared to before surgery in both the NAC and control groups. NAC might have an additional value by improving sperm motility post‐varicocelectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The results of this study revealed that NAC improved chromatin integrity and pregnancy rate when administered as adjunct therapy post‐varicocelectomy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Severe idiopathic oligoasthenospermia</p> <p>N = 42</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A significant improvement in morphology concentration, motility in the carnitine group</p> <p>No side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Quality of semen is positively associated with fertilisation and implantation rates in assisted reproduction </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with impaired semen quality</p> <p>N = 307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, reproductive hormones, live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, reproductive hormones, live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters, concentration provided as median + IQR and converted to mean + SD </p> <p>Y ‐ live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D was not associated with changes in semen parameters, although spontaneous pregnancies tended to be higher in couples in which the man was in the treatment group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Vitamin D did not improve semen quality. The positive impact of vitamin D supplementation on live birth rate and serum inhibin B in oligozoospermic and vitamin D–deficient men may be of clinical importance and warrant verification by others. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, tamoxifen excluded</p> <p>Men with abnormal semen analysis</p> <p>N = 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA damage (Comet assay)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA tail length</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Folate alone significantly decreased DNA tail length at 3‐months. Sperm motility was significantly increased after 3‐months Folate alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Our study indicated that folate in combination with Tamoxifen citrate could improve sperm quality including semen parameters and sperm DNA integrity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT, 50% included with varicocele</p> <p>N = 104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm concentration, total sperm count, progressive and total motility were significantly increased in supplemented (Proxeed Plus) patients. Increased pregnancy rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Supplementation with metabolic and antioxidant compounds could be efficacious when included in strategies to improve fertility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Idiopathic OAT men with varicocele</p> <p>N = 325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median +IQR converted to mean + SD)</p> <p>N ‐ pregnancy rate, unclear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in sperm parameters for carnitines when compared to placebo.</p> <p>Carnitine groups had a significantly higher pregnancy rate than placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The antioxidant plus anti‐inflammatory group was more effective in improving sperm parameters and pregnancy than those of carnitines alone or placebo however carnitines alone were more effective than placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y/N ‐ sperm parameters, results not available for all groups and parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm parameters and DNA fragmentation in the L‐carnitine plus CoQ10 group compared to placebo. </p> <p>Combination and L‐carnitine groups had remarkably higher pregnancy rate than placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combination of LC and CoQ10 improve semen parameters and outcome of clinical pregnancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Asthenozoospermic men</p> <p>N = 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHA showed no effect on sperm motility or concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>DHA supplementation increased DHA levels in the sperm but not motility or concentration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with varicocele</p> <p>N = 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin C was not effective on sperm count but improved sperm motility and morphology significantly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Ascorbic acid can play a role as adjuvant treatment after varicocelectomy in infertile men </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with sperm agglutination</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The group receiving 1000 mg of AA showed more improvement in parameters than the 200mg group and the placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin C can improve sperm parameters, especially dosage of 1000 mg.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Men with idiopathic oligoasthenozoospermia</p> <p>N = 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse reactions, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse reactions, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D is a safe option for the treatment of idiopathic oligoasthenozoospermia and can effectively improve the semen quality especially the progressive sperm motility </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin D can improve forward movement sperm number and percentage, improve the woman's clinical pregnancy rate, and is well tolerated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment, vardenafil/sildenafil arms excluded</p> <p>Men with oligoasthenospermia</p> <p>N = 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An improvement in sperm concentration with carnitine versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Enhancement of Leydig cell secretory function may increase sperm concentration and motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men with varicocele</p> <p>N = 56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, unknown if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The administration of vitamin E increased all of the parameters; however not statistically significant </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Vitamin E supplementation does not improve the sperm parameters after varicocelectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Asthenoszoospermic men</p> <p>N = 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, sperm membrane and serum fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data not usable, no continuous data but categories from 'significantly improvement' to 'worsened' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters improved with DHA + vitamin E supplementation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm parameters improve with DHA + vitamin E supplementation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Asthenozoospermic men</p> <p>N = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only imputed data provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of sperm concentration in the DHA + vitamin E group compared to groups treated with DHA+placebo, vitamin E+placebo and placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combined DHA and vitamin E improve sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Normozoospermic, oligozoospermic and asthenozoospermic men</p> <p>N = 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ pregnancy rate</p> <p>Both not included because data included normospermic men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of oligozoospermic men improved sperm concentration and sperm count to normozoospermic levels. This trend was also observed in asthenozoospermic men, but nog significantly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E treatment by oral administration improves semen parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with persistent oligospermia after embolisation of varicocele</p> <p>N = 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only medians given</p> <p>N ‐ pregnancy, unclear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant difference in sperm count in combined antioxidant group but not in motility.</p> <p>One pregnancy in the NAC group</p> <p>No significant adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>NAC does not improve pregnancy rate, no significant adverse events, but do significantly increase sperm count </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Men with varicocele</p> <p>N = 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+SD)</p> <p>Y ‐ DNA fragmentation (median+IQR converted to mean+ SD)</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SpermActine (SA) resulted in a 22.3% decrease in the level of sperm DNA fragmentation at 3 months. SA + vitamin complex resulted in a 27% increase in the sperm concentration at 3 months. There were no side effects of pharmacotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant therapy leads to an improvement in the basic sperm parameters (sperm concentration and motility) and a decrease in the level of sperm DNA fragmentation in the short term. There were no side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with high oxidative stress and DNA fragmentation</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spermactin Forte significantly improvement sperm motility and decreased oxidative stress. There were more pregnancies in the intervention group (13 versus 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The use of the SpermActin Forte antioxidant improves sperm analysis in most patients. SpermActin Forte is an effective and safe method of treating male infertility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, outcomes provided as change + SD <a href="./references#CD007411-fig-0027" title="">Analysis 1.15</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a> </p> <p>N ‐ DNA fragmentation, outcomes provided as change + SD <a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of progressive sperm motility in the DHA 1g and 2g groups after 1 month and in the DHA 0.5 group after 3 months. Greater effect in asthenozoospermic men </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>DHA (0.5, 1 and 2g) had beneficial effects on sperm function without producing any adverse effects, obtaining more immediate results with higher doses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Idiopathic OAT men</p> <p>N = 138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined antioxidant significantly improved sperm count and total motility in both treatment arms (1 vs 2 tablets). Mild adverse events were reported, no severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Exogenous administration of fixed dose combination of antioxidants is safe and effective therapy in improving the male subfertility regarding sperm parameters. Only mild adverse events when using combined antioxidants </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Arm treated with diet enriched in antioxidants not used</p> <p>Men with idiopathic infertility and high ROS</p> <p>N = 175</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, not reported in results</p> <p>N ‐ DNA fragmentation, no results reported besides p‐value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in DNA fragmentation between the study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>No conclusions on antioxidants versus placebo. A diet rich in antioxidants and lifestyle modifications can bring almost the same effect as antioxidant supplements </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile males with high DNA fragmentation</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in concentration or motility however DNA fragmentation was significantly reduced in the vitamin C + E when compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>A short oral treatment of Vitamin C + E can reduce DNA fragmentation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic asthenozoospermia</p> <p>N = 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, reported "none", however not clear which side effects they aimed for </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters were significantly higher in ALA group. No side effects due to the oral administration of ALA were observed in any participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, tamoxifen arms excluded</p> <p>Infertile men with idiopathic OAT</p> <p>N = 128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, range of treatment 3 ‐ 6 months and not divided</p> <p>N ‐ pregnancy rate, unclear if pregnancy and no numbers but percentage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine did not improve sperm count or motility. Only tamoxifen or tamoxifen + L‐carnitine improved pregnancy rate, not significantly. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Administration of tamoxifen or L‐carnitine can improve sperm parameters and ICSI outcomes. Combining those result in maximum therapeutic effect </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Oligozoospermic men</p> <p>N = 769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, evaluation of MTHFR polymorphism, DNA fragmentation, pregnancy rate, live birth </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, evaluation of MTHFR polymorphism, DNA fragmentation, pregnancy rate, live birth </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmentation</p> <p>N ‐ pregnancy, clinical</p> <p>N ‐ live births</p> <p>All outcomes reported for MTHFR polymorphism groups only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Folic acid significantly increased sperm parameters, decreased oxidative stress and DNA fragmentation and lead to a higher pregnancy and live birth rate in the MTHFR 677 TT group. Effect not seen in other MTHFR groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Folic acid has a beneficial effect on oligozoospermia with MTHFR 677 TT genotype in terms of sperm parameters, DNA fragmentation and pregnancy outcomes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men scheduled for ART</p> <p>N = 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+SD)</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in clinical pregnancies or live births when combined vitamin C + vitamin E + zinc were compared to no treatment. No improvement of sperm parameters </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No difference in clinical pregnancy and live births. No improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Male infertility</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse effects, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only medians given <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a> </p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences in sperm outcomes were seen between the groups. 1 pregnancy in the vitamin E group and nil in the placebo (first phase data) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>No difference in semen parameters. There is evidence of increased live birth and clinical pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Varicocele patients with oligozoospermia</p> <p>N = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm parameters and higher clinical pregnancy rate in combined antioxidant group compared to no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant treatment provides an important contribution<br/>to varicocelectomy outcomes and improves pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic infertility</p> <p>N = 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The percentage of normal spermiograms was significantly higher in the combined antioxidant group. Higher spontaneous pregnancy rate in antioxidant group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combined l‐carnitine/l‐acetyl‐carnitine, l‐arginine,<br/>glutathione, CoQ10, zinc, folic acid, cyanocobalamin, and selenium improves sperm quality and increases pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Obstructive azoospermia, TESA/ICSI candidates</p> <p>N = 46</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy, live births</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy, live birth, embryo quality, early pregnancy loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>N ‐ adverse events, miscarriage. No data provided by authors.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy and live birth rate were 62,5% vs 59,1% and 54,1% vs 40,9% in the antioxidant and no treatment group, respectively. Higher early pregnancy loss rate in control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant therapy may have a positive effect for patients with obstructive azoospermia. It might improve ART outcome and decrease pregnancy loss </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events, after contact with author: clinical pregnancy rate and live births after ICSI </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ adverse events</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical differences in sperm parameters between astaxanthin + vitamin E group and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>The oral intake of astaxanthin did not affect any semen parameters in patients with OAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with abnormal sperm count or motility</p> <p>N = 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only scales given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference in sperm outcomes in vitamin B 12 groups or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement in sperm parameters after use of vitamin B12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Infertile men with OAT</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition of pregnancy given see <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The patient groups showed no differences in sperm outcomes between therapy (carnitine) and placebo groups. </p> <p>Six pregnancies in the carnitine group and nil in the placebo (first phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The pregnancies obtained during the carnitine therapy period could suggest that carnitines may also lead to improvement in sperm function and fertilisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition of pregnancy given <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four participants taking carnitine induced a pregnancy in their partner and nil in the placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>No evidence of improved sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with OAT</p> <p>N = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition given <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine and acetyl carnitine more effective than vitamin E + vitamin C for pregnancy, sperm parameters and no evidence of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine and acetyl carnitine more effective than vitamin E + vitamin C for pregnancy, sperm parameters and no evidence of adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with OAT</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statistical significance for carnitines over vitamin E + C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sperm parameters for carnitines compared to vitamin E + C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> <p>Infertile men with OAT</p> <p>N = 100</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters (concentration, motility) carnitines versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, SG1002 arm excluded</p> <p>Men with idiopathic OAT</p> <p>N = 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SDs given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resveratrol treatment did not significantly affect any of the parameters.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Resveratrol treatment did not significantly affect any of the parameters. SG1002 may reverse oligoasthenozoospermia. It seems to be more potent antioxidant than resveratrol </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 50</p> <p>Conference abstract + manuscript from author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences were found in traditional sperm parameters or lipid composition of the sperm membrane after DHA treatment, only reduction in the percentage of spermatozoa with DNA damage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Positive effect only on DNA fragmentation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, pentoxifylline arms excluded</p> <p>Infertile men with OAT</p> <p>N = 235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine only improved sperm motility, combined with pentoxifylline it improves all sperm parameters. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Positive effect only on sperm motility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with OAT</p> <p>N = 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>(median+IQR converted to mean + SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proxeed Plus significantly improved sperm volume, motility and DNA fragmentation compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Beneficial effects of carnitine<br/>derivatives (Proxeed plus) on progressive motility, vitality and sperm DNA fragmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men with idiopathic asthenospermia</p> <p>N = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sexual satisfaction</p> <p>Significant improvement in sperm motility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with Idiopathic OAT</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant changes in semen parameters of CoQ10 group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>CoQ10 further evidence suggesting that supplementation is associated with alleviating oxidative stress, although it does not show any significant effects on sperm concentration, motility and morphology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with history of infertility</p> <p>N = 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm concentration with lycopene compared to placebo. Increase of total motility in lycopene group compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Lycopene improves sperm parameters and oxidative stress biomarkers in infertile men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Men with OAT</p> <p>N = unclear, 20?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E + selenium significantly improves sperm motility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E + selenium associated with improved sperm motility when compared with vitamin B </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with asthenozoopermia</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters,</p> <p>pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only % increase or decrease, not usable</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm quality by zinc therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Zinc has a role in improving sperm parameters. Significant increase in pregnancy, not live birth </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Men with asthenozoospermia</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc therapy alone, in combination with vitamin E or with vitamin E+C were associated with comparably improved sperm parameters and less sperm DNA fragmentation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Zinc therapy reduces asthenozoospermia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Infertile men</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not defined as clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvements in mean sperm concentration and progressive sperm motility upon two months of L‐carnitine intake but no significant changes were found in sperm volume or morphology. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm outcomes and biochemical pregnancies. L‐carnitine intake effectively improved the mean sperm count and progressive sperm motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men planning ART treatment</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change in sperm motility. A pregnancy rate in the combined antioxidants (Androdoz) group was 45% compared to 25% in the control group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>Androdoz contributes to an increase in positive outcomes of ART program. "Androdoz improves the main criteria of sperm analysis and functional tests (HBA‐test)". </p> <p>This is based on the improvement of morphology</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with male factor infertility and varicocele</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SD given<br/>N ‐ DNA fragmentation, no SD given </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference between the two groups (varicocelectomy with L‐carnitine or with no adjuvant therapy). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Addition of 750 mg of L‐carnitine orally daily to standard inguinal varicocelectomy does not add any extra benefit in terms of improvement in semen analysis parameters or<br/>DNA damage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine significantly improves sperm concentration, Spermotrend and Maca improve sperm motility. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm concentration with L‐carnitine and motility with combined antioxidant Spermotrend</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Men with severe oligozoospermia</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, bar graph of % patients showing an increase in motility and density </p> <p>N ‐ pregnancy rate, not clear if clinical. Included in biochemical analysis <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arginine was no more effective than placebo for sperm parameters and biochemical pregnancy rates </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>There was no difference in the conception rates of the wives or changes in the quality of the semen during each period of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with proven male factor infertility</p> <p>N = 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters ( median+IQR converted to mean+ SD)</p> <p>Y ‐ DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm concentration, DNA fragmentation not significantly improved in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Zinc sulphate and folic acid supplementation did not ameliorate sperm quality in infertile men with severely compromised sperm parameters, OAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenospermia</p> <p>N = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rates, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not stated as clinical pregnancy</p> <p>N ‐ adverse events, not clear which side effects aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events or pregnancies in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Overall no difference vitamin E + C versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data provided as percentage improvement, <a href="./references#CD007411-fig-0028" title="">Analysis 1.16</a>; <a href="./references#CD007411-fig-0034" title="">Analysis 1.22</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significantly higher percentage improvement of progressive sperm motility and concentration with glutathione or CoQ10 compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Both glutathione and CoQ10 are effective treatment options for improving sperm motility, morphology and concentration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not specified which adverse events aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All semen parameters significantly improved with selenium and N‐acetyl‐cysteine treatment. Administering selenium plus N‐acetyl‐cysteine resulted in additive beneficial effects. Zero adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Supplemental selenium and N‐acetyl‐cysteine improve semen quality. Zero adverse events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not specified which adverse events aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm density and motility after coenzyme Q10 therapy. Zero adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Coenzyme Q10 supplementation resulted in a statistically significant improvement in certain sperm parameters. Zero adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not clear how many patients had gastrointestinal upsets in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm concentration and progressive motility after omega‐3 fatty acids therapy. Significantly more adverse events (gastrointestinal and pruritus) in the omega‐3 group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>These findings suggest a protective effect of omega‐3 fatty acid intake in idiopathic infertile men. More adverse events in omega‐3 group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters improved significantly after coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Coenzyme Q10 was significantly effective in men with unexplained oligoasthenoteratozoospermia for improving sperm density, sperm motility and sperm morphology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Male partner of couples planning infertility treatment. Data from subfertile men used.</p> <p>N = 2370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live births, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live births, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>N ‐ pregnancy, clinical;</p> <p>N ‐ live births</p> <p>N ‐ adverse events</p> <p>Data not provided for male factor infertility subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in sperm parameters between folic acid + zinc and placebo. No results on clinical outcomes in male factor subgroup </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Folic acid and zinc did not significantly improve semen quality. The findings also were similar when restricted to men with known male factor infertility or poor semen quality at baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with subfertility and low sperm motility</p> <p>N = 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not usable due to pooling of data in the two intervention groups <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm motility increased in both selenium‐treated groups, only significant if both treatment groups were combined. Sperm density unaffected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Selenium supplementation in subfertile men with low selenium status can improve sperm motility and the chance of successful conception. However, not all patients responded; 56% showed a positive response to treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic subfertile men</p> <p>N = 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y‐ sperm parameters</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in concentration in zinc group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Normal sperm percentage and total sperm concentration increased after zinc sulphate treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with low sperm motility</p> <p>N = 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, biochemical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant or clinically significant increase in motility or total motile sperm counts between baseline, 12 weeks, or 24 weeks in the carnitine or placebo arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Carnitine supplementation demonstrated no clinically or statistically significant effect on sperm motility or total motile sperm counts. No difference in pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with chronic prostatitis and infertility</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SD given <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One‐month course of therapy produced no side effects, had a positive effect on low fertility of ejaculate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Selenium + zinc improve</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment, Avanafil excluded</p> <p>Oligoasthenospermic infertile men</p> <p>N = 39</p> <p>Abstract only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in L‐carnitine group regarding sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No direct conclusion made about L‐carnitine. From result section concluded: no impact on sperm parameters after use of L‐carnitine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with one abnormal semen parameter</p> <p>N = 171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>(data shared by authors after requested via e‐mail)</p> <p>Y ‐ pregnancy, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in sperm motility, DNA fragmentation, pregnancy rate and live birth rate between combined antioxidants and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement in semen parameters in infertile males. This study suggests that combination antioxidants does not improve pregnancy or live birth rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with DNA fragmentation ≥ 25%</p> <p>N = 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>N ‐ pregnancy rate, biochemical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference between the antioxidant and placebo group was seen for semen parameters including DNA fragmentation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Six months treatment with combined antioxidants had no effect on sperm parameters including DNA fragmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Asthenospermic men</p> <p>N = 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> <p>Y ‐ adverse events: miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E significantly decreased the MDA concentration in spermatozoa and improved sperm motility. Significant increase pregnancy/live birth rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E increases sperm motility, pregnancy rate and live birth rate compared to placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Infertile men with low acrosin activity</p> <p>N = 232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of progressive sperm otility in men treated with L‐carnitine compared to vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine can effectively elevate sperm acrosin activity in male infertility patients, particularly in those with asthenozoospermia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Male factor infertility</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregnancy rate, adverse events, live birth provided by author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidant group recorded a statistically significant improvement in viable pregnancy rate. Side‐effects on the Menevit antioxidant were rare (8%) and mild in nature. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Menevit antioxidant appears to be a useful ancillary treatment that significantly improves pregnancy rates in couples undergoing IVF‐ICSI treatment. Side‐effects on the Menevit antioxidant were rare (8%) and mild in nature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, head‐to‐head</p> <p>Profertil + avanafil and avafanil only groups not used</p> <p>Idiopathic OAT</p> <p>N = 217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmentation</p> <p>Not reported in how many patients sperm outcomes were assessed</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significantly higher total and progressive sperm motility in Profertil group compared to L‐carnitine and no treatment. No difference in pregnancy rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Profertil or Profertil combined with avanafil or or avanafil alone improves sperm membrane permeability with an improvement in sperm motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with at least one abnormal sperm parameter</p> <p>N = 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmenation</p> <p>Only results after cryotolerance test provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical differences between results after Brudy plus (combined antioxidant) and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>No conclusions on outcomes of interest.</p> <p>Brudy Plus increases cryotolerance, promotes the normal formation of the genetic material and reduces the frequency of ultrastructural sperm disorders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with asthenozoospermia</p> <p>N = 135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not clear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events, zero found, however not clear which they aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in L‐carnitine + vitamin E group for sperm motility, no difference for sperm density and morphology. Pregnancy rate significantly higher in L‐carnitine + vitamin E group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine (+vitamin E) significantly improves sperm motility and pregnancy rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Fertile and subfertile men</p> <p>N = 103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+ SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subfertile men demonstrated a significant 74% increase in total normal sperm count and a minor increase of 4% abnormal spermatozoa </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Total normal sperm count increases after combined zinc sulphate and folic acid treatment in both subfertile and fertile men </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head, pilot</p> <p>Men attending andrology clinic</p> <p>N = 22</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only before and after median data given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in sperm parameters after treatment (acetyl‐cysteine or DHA). DNA damage measured by 8‐OHdG (fmol/ug) was significantly decreased after supplementation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic infertility</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant changes in sperm characteristics were detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Magnesium neither leads to a significant improvement of sperm variables nor does it increase the pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic asthenozoospermia</p> <p>N = 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, definition unclear <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of total and progressive sperm motility in vitamin E and vitamin E + compound amino acids group. Greater increase in compound amino acids group. 5.7% pregnancy in combined group, 2% in vitamin E group. No adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Compound amino acid combined with vitamin E can safely and effectively improve sperm motility in idiopathic asthenospermia patients. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>DHA:</b> docosahexaenoic acid; <b>IUI:</b> intrauterine insemination; <b>NAC:</b> N‐acetylcysteine; <b>OAT:</b> oligoasthenoteratozoospermia; <b>ROS:</b> reactive oxygen species </p> </div> </div> </section> </section> <section id="CD007411-sec-0055"> <h4 class="title">Excluded studies</h4> <p>We retrieved the full text of studies that were identified as potentially eligible (see <a href="#CD007411-fig-0001">Figure 1</a>). In this update we excluded nine studies, in total we excluded 67 studies. Previously excluded study Raigani 2010, excluded based on ineligible outcome (MTHFR polymorphisms), was included as a sub‐study of the primary included study <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>. The most common reasons for exclusions were ineligible due to use of a different intervention, study design or population. See details in <a href="./references#CD007411-sec-0144" title="">Characteristics of excluded studies</a>. </p> <p>In summary:</p> <p> <ul id="CD007411-list-0017"> <li> <p>22/67 ineligible based on different intervention such as an added sperm wash or herbal extract; also pentoxifylline studies were excluded; </p> </li> <li> <p>15/67 ineligible based on different study design; they were not randomised;</p> </li> <li> <p>20/67 ineligible based on different population, either women, normospermic men or used the exact same population as other already included studies; in the search of this update; two of the studies was already included in the 2018 update; </p> </li> <li> <p>2/67 ineligible based on different outcome;</p> </li> <li> <p>6/67 ineligible based on different control group, fertile men without treatment or control group was not treated with placebo, no treatment or another antioxidant; </p> </li> <li> <p>2 previously 'ongoing studies' were placed in excluded studies because they were terminated due to insufficient recruiting (<a href="./references#CD007411-bbs2-0133" title="TsafrirA .Is a carnitine based food supplement (PorimoreTM) for infertile men superior to folate and zinc with regard to pregnancy rates in intrauterine insemination cycles?https://clinicaltrials.gov. ">NCT01075334</a>; <a href="./references#CD007411-bbs2-0134" title="IrgeD .Supplement intake in infertile men; the effect on sperm parameters, fertilization rate and embryo quality. https://clinicaltrials.gov. ">NCT01520584</a>). </p> </li> </ul> </p> <section id="CD007411-sec-0056"> <h5 class="title"><i>Ongoing studies</i> </h5> <p>Twelve studies were “ongoing studies” in the 2018 update. In the current update, six of the 12 previously ongoing studies were included (<a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). <a href="./references#CD007411-bbs2-0170" title="SmitsRM , FleischerK , BraatDDM .The impact of a nutritional supplement (Impryl®) on male fertility. https://clinicaltrials.gov. ">NCT03337360</a> continued as an ongoing study with the status of still recruiting. The former ongoing study <a href="./references#CD007411-bbs2-0169" title="JawaidM .Neotililty trial: effect of coenzyme Q10 on semen parameters in men with idiopathic infertility (neotility). https://clinicaltrials.gov. ">NCT03104998</a> was excluded based on withdrawal on the trial registry website. The former ongoing study <a href="./references#CD007411-bbs2-0161" title="Mathieu-d’ArgentE .Impact of folates in the care of the male infertility (FOLFIV). https://clinicaltrials.gov. ">NCT01407432</a> was placed in <a href="./references#CD007411-bbs1-0003" title="">Studies awaiting classification</a> after a message from the author that the manuscript had been submitted but not yet published. Former ongoing studies <a href="./references#CD007411-bbs2-0160" title="AguilarMM .Assessment of the efficacy of dietary supplement spermotrend in the treatment of male infertility. ClinicalTrials.gov. ">NCT00975117</a> and <a href="./references#CD007411-bbs2-0162" title="PalumboM .Myo-inositol on human semen parameters [Effect of of treatment with Myo-inositol on human semen parameters in patients undergoing IVF cycles]. https://clinicaltrials.gov. ">NCT01828710</a> were also placed in <a href="./references#CD007411-bbs1-0003" title="">Studies awaiting classification</a> with the status of “completed” on the trial registry website. The recruitment for former ongoing study <a href="./references#CD007411-bbs2-0158" title="BaumgraßH .Randomized, placebo-controlled, double-blind, multi-centre pilot study to investigate the effect of AM019016 on male spermatogenesis in subjects with diagnosed unspecific (idiopathic) subfertility. www.who.int/trialsearch. ">DRKS00011616</a> had stopped and was therefore placed in <a href="./references#CD007411-bbs1-0003" title="">Studies awaiting classification</a> as well. Authors were contacted for (unpublished) results, with no reply. </p> <p>We added 11 new ongoing studies (<a href="./references#CD007411-bbs2-0163" title="CTRI/2019/03/018303.A clinical trial to study the association between reactive oxygen species and semen quality and the effect of vitamin C therapy in male infertility patients [Assessment of seminal plasma myeloperoxidase level (ROS)and the effect of vitamin C therapy on semen quality in infertile men]. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=31766&amp;EncHid=&amp;modid=&amp;compid=%27,%2731766det%27 (first received 27 March 2019). ">CTRI/2019/03/018303</a>; <a href="./references#CD007411-bbs2-0164" title="IRCT20120215009014N.Effect of CO-Q 10 supplementation spermogram parameters and sexual function in infertile men [Effect of CO-Q 10 supplementation versus placebo on spermogram parameters and sexual function in infertile men: a double-blind randomized clinical trial]. http://en.irct.ir/trial/44080 (first received 16 December 2019). ">IRCT20120215009014N322</a>; <a href="./references#CD007411-bbs2-0165" title="IRCT20140622018187N9.The effect of vitamin C supplementation on quality of spermogram in infertile men with asthenozoospermia with a balanced diet in Mother and Child hospital, Shiraz, 1392. https://www.irct.ir/trial/48413 (first received 9 June 2020). ">IRCT20140622018187N9</a>; <a href="./references#CD007411-bbs2-0166" title="IRCT20190406043177N.Effect of alpha lipoic acid on male infertility [The effect of alpha lipoic acid on sperm parameters, DNA integrity and oxidative stress in infertile men with increased level of sperm DNA damage]. http://en.irct.ir/trial/39346 (first received 22 June 2019). ">IRCT20190406043177N1</a>; <a href="./references#CD007411-bbs2-0167" title="Irct20190714044209N.Evaluating the therapeutic effect of theophylline and zinc sulfate co-administration in infertile men. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190714044209N12020. ">IRCT20190714044209N1</a>; <a href="./references#CD007411-bbs2-0168" title="IRCT20200911048689N1.The effect of vitamin E on sperm in men with varicocele [Effect of vitamin E on quality and quantity of sperm in infertile men after varicocelectomy]. https://en.irct.ir/trial/50895 (first received 10 October 2020). ">IRCT20200911048689N1</a>; <a href="./references#CD007411-bbs2-0171" title="Nct.Omega-3 PUFA for treatment of patients with Idiopathic oligoasthenoteratospermia. https://clinicaltrials.gov/show/NCT036346442018. ">NCT03634644</a>; <a href="./references#CD007411-bbs2-0172" title="NCT.Impact of a nutritional supplements' combination (FERTILIS) on male infertility. https://clinicaltrials.gov/show/NCT041933582019. ">NCT04193358</a>; <a href="./references#CD007411-bbs2-0173" title="NCT04256278.Administration of antioxidants to infertile men and sperm quality [Does antioxidant administration improve sperm quality in infertile men]. https://clinicaltrials.gov/ct2/show/NCT04256278 (first received 5 February 2020). ">NCT04256278</a>; <a href="./references#CD007411-bbs2-0174" title="NCT04509583.The role of micro nutrient supplement in improvement of the sperm DNA fragmentation [Is micro nutrient supplement effective in improving the sperm dna fragmentation]. https://clinicaltrials.gov/ct2/show/NCT04509583 (first received 12 August 2020). ">NCT04509583</a>; <a href="./references#CD007411-bbs2-0175" title="PACTR201802003076341.Effects of different antioxidants on sperm parameters in infertile males [Effects of different antioxidants on sperm parameters in infertile males]. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3076 (first received 12 Februuary 2018). ">PACTR201802003076341</a>). In this 2021 update, a total of 12 studies are classified as 'ongoing studies'. </p> </section> <section id="CD007411-sec-0057"> <h5 class="title"><i>Awaiting classification</i> </h5> <p>One study was “awaiting classification” in the 2018 update of this review (<a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>). We included the study after confirmation by the authors that this was a randomised controlled trial. </p> <p>Four formerly ongoing studies were placed in <a href="./references#CD007411-bbs1-0003" title="">Studies awaiting classification</a> (<a href="./references#CD007411-bbs2-0158" title="BaumgraßH .Randomized, placebo-controlled, double-blind, multi-centre pilot study to investigate the effect of AM019016 on male spermatogenesis in subjects with diagnosed unspecific (idiopathic) subfertility. www.who.int/trialsearch. ">DRKS00011616</a>; <a href="./references#CD007411-bbs2-0160" title="AguilarMM .Assessment of the efficacy of dietary supplement spermotrend in the treatment of male infertility. ClinicalTrials.gov. ">NCT00975117</a>; <a href="./references#CD007411-bbs2-0161" title="Mathieu-d’ArgentE .Impact of folates in the care of the male infertility (FOLFIV). https://clinicaltrials.gov. ">NCT01407432</a>; <a href="./references#CD007411-bbs2-0162" title="PalumboM .Myo-inositol on human semen parameters [Effect of of treatment with Myo-inositol on human semen parameters in patients undergoing IVF cycles]. https://clinicaltrials.gov. ">NCT01828710</a>). The authors from <a href="./references#CD007411-bbs2-0161" title="Mathieu-d’ArgentE .Impact of folates in the care of the male infertility (FOLFIV). https://clinicaltrials.gov. ">NCT01407432</a> replied that the manuscript was under submission. The authors from the other three studies did not reply when contacted for further information. </p> <p>One study from the updated 2021 search was placed in <a href="./references#CD007411-bbs1-0003" title="">Studies awaiting classification</a> (<a href="./references#CD007411-bbs2-0159" title="KuzmenkoAV , KuzmenkoVV , GyaurgievTA .The effectiveness of the Speroton complex in the management of male factor infertility. Urologiia (Moscow, Russia : 1999)2018;3:78‐82. ">Kuzmenko 2018</a>). It was not clear whether the study population was infertile men with abnormal semen parameters. The full report of this study was requested from the authors, with no reply. </p> </section> </section> </section> <section id="CD007411-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-fig-0002" target="_blank">Figure 2</a> for a summary of risk of bias in individual studies, and <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007807.pub3/full#CD007807-fig-0003" target="_blank">Figure 3</a> for a summary of each risk of bias item across all included studies. </p> <section id="CD007411-sec-0059"> <h4 class="title">Allocation</h4> <section id="CD007411-sec-0060"> <h5 class="title">Sequence generation</h5> <p>All 90 included studies were randomised, six of these were cross‐over studies (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>), and the remaining studies were parallel design studies. </p> <p>Only 47 studies described their methods of sequence generation and were rated as low risk in this domain (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>) (see <a href="#CD007411-fig-0002">Figure 2</a> and <a href="#CD007411-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007411-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological risk of bias summary: review authors' judgements about each methodological bias item for each included study." data-id="CD007411-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological risk of bias summary: review authors' judgements about each methodological bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007411-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological risk of bias graph: review authors' judgements about each methodological bias item presented as percentages across all included studies." data-id="CD007411-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological risk of bias graph: review authors' judgements about each methodological bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>One study was rated as high risk in this domain, because the authors reported that "a placebo‐controlled group was maintained in parallel" (<a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>). The review team suspected that the placebo group in this study had not been randomised. Authors were contacted, with no reply to date. </p> <p>The remaining 42 studies were rated as unclear risk (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). </p> <p>The predominant method of randomisation was by computer‐generated blocks. <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a> reported a 2:1 ratio randomisation schedule, <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a> reported a 3:2 randomisation schedule, <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a> appeared to have a blocked 3:2 allocation, <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> appeared to have a 2:1 ratio, <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a> appeared to have a 3:1 ratio, <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> appeared to have a 5:2 ratio and <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a> appeared to have a 7:5 ratio. </p> </section> <section id="CD007411-sec-0061"> <h5 class="title">Allocation concealment</h5> <p>The methods of allocation concealment were generally quite poorly described in the included studies. Thirty‐two studies described both their methods of randomisation and allocation concealment and were rated as low risk in this domain (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). </p> <p>There were three studies with a high risk of allocation concealment: one due to the use of a randomisation table by the doctor (<a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>); one due to great baseline imbalance for sperm parameters between the intervention and control group (<a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>); and one due to the use of an open randomisation list, showing what the next randomisation would be (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>). </p> <p>The remaining 55 studies were rated as unclear risk (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). The methods of allocation concealment included anonymous coloured boxes, sealed opaque envelopes, and numbered bottles. </p> </section> </section> <section id="CD007411-sec-0062"> <h4 class="title">Blinding</h4> <section id="CD007411-sec-0063"> <h5 class="title">Performance bias</h5> <p>Forty‐three studies were described as randomised, double‐blind controlled trials in which clinicians and participants were blinded (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). In seven studies investigators, clinicians and participants were blinded (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). A total of fifty studies were rated as low risk (see <a href="#CD007411-fig-0003">Figure 3</a> and <a href="#CD007411-fig-0002">Figure 2</a>). In one of the low risk studies (<a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>), it was stated that a placebo was used as the control but only the participants were blinded. </p> <p>Twenty‐three other studies were rated high risk (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). Of these high‐risk studies, 18 studies used 'no treatment' as their comparator. Two studies were head‐to‐head trials and open‐labelled (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>). The double‐blinded trial <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a> used a placebo, however they reported that if a couple became pregnant then "the treatment was stopped; otherwise it was continued for 6 months. The placebo was given for 6 months." This does appear that they did not stop the placebo. This could suggest that the investigators had knowledge of whether the participants were in the placebo or antioxidant group, therefore this study was rated as high risk. </p> <p>Sixteen studies did not give a statement regarding blinding and were rated as unclear risk of bias (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). Seven of these studies used a placebo as the control but did not discuss blinding (<a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). </p> <p>As nutritional supplements with antioxidant properties are freely available, this could have introduced bias in the included studies. None of the included studies monitored or reported use of additional supplements other than the intervention during the study. However, most included studies reported the use of other nutritional supplement as an exclusion criterion and instructed participants to withhold from such supplement use during the study. </p> </section> <section id="CD007411-sec-0064"> <h5 class="title">Detection bias</h5> <p>The methods of blinding outcome assessment were generally poorly described in the included studies. Only 26 studies reported this aspect of blinding and were therefore classified as low risk (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). </p> <p>The other 64 studies were rated as unclear risk due to the lack of information (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> </section> </section> <section id="CD007411-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Fifty‐one studies were rated as low risk for incomplete outcome data (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>; <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>; <a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>). </p> <p>Thirty‐two studies were rated as unclear, most of them did report the number of dropouts, but did not provide the reasons (<a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>;<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>). </p> <p>Six studies were rated as high risk of attrition bias due to lack of compliance directly related to treatment and high dropout rates (16% to 42%) (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>). One study was rated as high risk of attrition bias despite the fact that high dropout rates were accounted for, because the results tables appeared to have additional missing data without clarification (<a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). </p> <p>None of the included studies reported on "missing not at random", which could be introduced by participants not returning for a subsequent semen analysis if a pregnancy occurred before that date. </p> <p>Only 10 studies (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>) actually stated that they used intention‐to‐treat (ITT) in their analysis. However, <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a> stated they had used ITT, but the data were not presented. Most of the other included studies accounted for the participants that withdrew from their studies and then analysed the groups using a per protocol approach. </p> <p>Five studies (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>) did not use ITT, however the numbers of dropouts were given for each intervention and control group, and therefore we were able to use ITT in the data analysis by making the assumption of no event for the binary outcomes. No imputation was carried out on the continuous outcome data; these were analysed as they were reported in the studies. </p> <p>Nine studies had over 20% withdrawal from their studies. <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> had a 30% dropout rate and reasons were provided for only 53 out of the 55 dropouts; these reasons included refusal due to the chance of taking a placebo and preference for assisted reproduction techniques (ARTs). There also remained some confusion in this study on the total numbers randomised and analysed. <a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a> and <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a> both had a dropout rate of around 32%; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> had a 30% dropout rate; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>, <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>, and <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a> had slightly over 20% withdrawal from their studies. </p> <p>One study (<a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>) had a large imbalance in numbers. There were found to be 52 in the treatment group and 35 in the placebo group once the code had been broken at the end of the study. There was no indication of how the randomisation was performed. The reasons given for dropout were only accounted for broadly: many couples had left the region and some simply failed to continue; no numbers were given for individual dropout reasons (see <a href="#CD007411-fig-0003">Figure 3</a> and <a href="#CD007411-fig-0002">Figure 2</a>). The numbers of participants that were initially randomised to each group were not available, so ITT for the dichotomous outcomes was not possible. </p> </section> <section id="CD007411-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Study protocols were only available for 18 out of the 90 included studies (<a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). The study protocol of <a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a> was published after completion of the study and was therefore rated as unclear risk. </p> <p>Thirteen studies were rated at high risk of reporting bias. <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a> performed subgroup analysis post‐treatment and <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> did not pre‐specify outcomes. Two of these 13 studies were rated at high risk of reporting bias because outcomes defined in the study protocol were not reported in the full text of the study (<a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>). Nine of these 13 studies were rated at high risk of reporting bias because outcomes defined in the methods section of the articles were not reported in the outcomes section, or the results of certain subgroups of the study population were omitted (<a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>). </p> <p>Seven studies were rated as unclear risk as they were conference abstracts (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>), and two studies were rated as unclear as it was possible that these were two publications of the same study that were reporting on different intervention arms (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>; <a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>). Obtaining help with Chinese translation did not clarify this and attempts to contact the authors were unsuccessful. The remaining 52 studies were rated as unclear risk in this domain because there were no published study protocols available. </p> </section> <section id="CD007411-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>There were no other sources of bias in the included studies.</p> <p>In summary, none of the included studies was rated as low risk of bias in all domains. More than half of the included studies (52 of the 90 included studies) was rated as unclear risk of bias in at least one domain. Thirty‐eight included studies were rated as high risk of bias in at least one domain (<a href="#CD007411-fig-0002">Figure 2</a>). </p> <p>In the comparison of antioxidant versus placebo or no treatment with the outcome of live birth, half of the studies was rated as unclear risk of bias in at least one domain. The other half of the studies in this comparison was rated as high risk of bias in at least one domain (<a href="#CD007411-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD007411-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant." data-id="CD007411-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant. </p> </div> </div> </div> </section> </section> <section id="CD007411-sec-0068"> <h3 class="title" id="CD007411-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD007411-tbl-0001"><b>Summary of findings 1</b> Antioxidants compared to placebo or no treatment for patients with male subfertility</a> </p> <section id="CD007411-sec-0069"> <h4 class="title">1 Antioxidants versus placebo or no treatment (natural conception and undergoing fertility treatment) </h4> <section id="CD007411-sec-0070"> <h5 class="title">1.1 Live birth; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0013" title="">Analysis 1.1</a> and <a href="#CD007411-fig-0004">Figure 4</a>, <a href="#CD007411-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD007411-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant." data-id="CD007411-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant. </p> </div> </div> </div> <p>Only 12 studies reported on live birth; seven of these had methodological inadequacies as they did not describe their methods of randomisation or allocation concealment. Three studies reported that all clinical pregnancies led to a live birth (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>). The meta‐analysis of the 12 studies showed that antioxidants were associated with increased live birth rate compared with placebo or no treatment (Peto odds ratio (OR) 1.43, 95% confidence interval (CI) 1.07 to 1.91, 1283 men, 12 RCTs, P = 0.02, I<sup>2</sup> = 44%, very low‐certainty evidence). This means that, for subfertile men with a baseline expected live birth rate of 16%, use of an antioxidant could increase this rate to between 17% and 27% (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). </p> <p>1.1.1 One study reported on this outcome comparing astaxanthin plus vitamin E versus placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>). There was no evidence of increased live birth rate (Peto OR 1.63, 95% CI 0.34 to 7.69, 36 men, P = 0.54, I<sup>2</sup> = not applicable).  </p> <p>1.1.2 One study reported on this outcome comparing carnitines versus placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>). There was no evidence of increased live birth rate (Peto OR 1.00, 95% CI 0.24 to 4.25; 60 men, P = 1.00, I<sup>2</sup> = not applicable). </p> <p>1.1.3 One study reported on this outcome comparing coenzyme Q10 versus placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>). There was no evidence of increased live birth rate (Peto OR 2.16, 95% CI 0.53 to 8.82; 60 men, P = 0.28, I<sup>2</sup> = not applicable). </p> <p>1.1.4 One study reported on this outcome comparing vitamin D plus calcium versus placebo (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>). There was no evidence of increased live birth rate (Peto OR 1.03, 95% CI 0.59 to 1.80, 330 men, P = 0.93, I<sup>2</sup> = not applicable). </p> <p>1.1.5 Two studies reported on this outcome comparing vitamin E versus placebo (<a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>). There appeared to be evidence of increased live birth rate (Peto OR 8.51, 95% CI 2.36 to 30.70, 140 men, 2 RCTs, P = 0.001, I<sup>2</sup> = 0%). </p> <p>1.1.6 One study reported on this outcome comparing zinc versus no treatment (<a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>). There was no evidence of increased live birth rate (Peto OR 3.74, 95% CI 1.02 to 13.74, 100 men, P = 0.05, I<sup>2</sup> = not applicable). </p> <p>1.1.7 Five studies reported on this outcome comparing combined antioxidants versus placebo or no treatment (<a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>). There was no evidence of increased live birth rate (Peto OR 1.28, 95% CI 0.86 to 1.91, 557 men, P = 0.23, I<sup>2</sup> = 63%). The results from <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a> also included three sets of twins in the combined antioxidant group and nil in the placebo group. Each twin birth was counted as one event as stated in the methods section in the review protocol. </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences Chi² = 11.76, P = 0.07). </p> <p>A sensitivity analysis was carried out using as‐treated data, which did not show a different result compared with the intention‐to‐treat data (Peto OR 1.49, 95% CI 1.10 to 2.00, 1090 men, 12 RCTs, P = 0.009, I<sup>2</sup> = 28%).  </p> <section id="CD007411-sec-0071"> <h6 class="title"><i>Sensitivity analysis for studies with no treatment as control</i> </h6> <p>Three studies (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>) used 'no treatment' as the control group instead of placebo. When these studies were removed from the analysis, no evidence of increased live birth remained when compared with placebo only (Peto OR 1.39, 95% CI 0.98 to 1.97, 937 men, 9 RCTs, P = 0.06, I<sup>2</sup> = 52%). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 9.50, P = 0.09). </p> </section> <section id="CD007411-sec-0072"> <h6 class="title"><i>Sensitivity analysis for studies reporting live birth and clinical pregnancy</i> </h6> <p>The 12 studies that reported live birth had an OR for live birth of 1.43, and in these same studies the OR for clinical pregnancy was 1.62. When we pooled all 20 studies reporting the clinical pregnancy rate there was a higher OR 1.89. This suggests that there is no overestimation of live birth. However, the true effect is unknown unless all studies reporting on clinical pregnancy rate also reported on live birth rate. </p> </section> <section id="CD007411-sec-0073"> <h6 class="title"><i>Sensitivity analysis for studies rated as high risk of bias</i> </h6> <p>When the four studies (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>) rated with a high risk of bias were removed from the analysis, there was no evidence of association between antioxidants and an increased live birth rate when compared with placebo (Peto OR 1.22, 95% CI 0.85 to 1.75, 827 men, 8 RCTs, P = 0.27, I<sup>2</sup> = 32%). </p> </section> </section> <section id="CD007411-sec-0074"> <h5 class="title">1.2 Live birth; in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)</h5> <p>See <a href="./references#CD007411-fig-0014" title="">Analysis 1.2</a>. </p> <p>There were only five studies in women undergoing IVF/ICSI which reported on live birth (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>). There appeared to be evidence of increased live birth rate, in those couples undergoing IVF/ICSI, with antioxidant use when compared with placebo (Peto OR 1.63, 95% CI 1.01 to 2.16, 5 RCTs, 372 men, P = 0.04, I<sup>2</sup> = 0%). </p> </section> <section id="CD007411-sec-0075"> <h5 class="title">1.3 Clinical pregnancy; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0015" title="">Analysis 1.3</a> and <a href="#CD007411-fig-0006">Figure 6</a> and <a href="#CD007411-fig-0007">Figure 7</a>. </p> <div class="figure" id="CD007411-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.3 Clinical pregnancy; type of antioxidant." data-id="CD007411-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.3 Clinical pregnancy; type of antioxidant. </p> </div> </div> </div> <div class="figure" id="CD007411-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical pregnancy; type of antioxidant." data-id="CD007411-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical pregnancy; type of antioxidant. </p> </div> </div> </div> <p>Only 20 studies (with 25 intervention arms) reported on clinical pregnancy rate; six of these had methodological inadequacies with high risk of bias for methods of randomisation, allocation concealment or blinding. The meta‐analysis of these studies showed that antioxidants were associated with an increased clinical pregnancy rate when compared with placebo or no treatment (Peto OR 1.89, 95% CI 1.45 to 2.47, 1706 men, 20 RCTs, 25 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 3%, low‐certainty evidence). This means that, for subfertile men with a baseline expected clinical pregnancy rate of 15%, use of an antioxidant could increase this rate to between 20% and 30% (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). </p> <p>1.3.1 One study reported on this outcome comparing astaxanthin plus vitamin E versus placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 1.32, 95% CI 0.35 to 4.96, 36 men, P = 0.68, I<sup>2</sup> = not applicable).  </p> <p>1.3.2 Two studies reported on this outcome comparing carnitines versus placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 1.17, 95% CI 0.30 to 4.59, 125 men, 2 RCTs, P = 0.82, I<sup>2</sup> = 0%). In <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>, the one and only event in the control group was used in the "Combined antioxidants" subgroup (1.5.11), as all results for clinical pregnancies were pooled. </p> <p>1.3.3 One study reported on this outcome comparing coenzyme Q10 versus placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 2.16, 95% CI 0.53 to 8.82, 60 men, 1 RCT, P = 0.28, I<sup>2</sup> = not applicable). </p> <p>1.3.4 One study reported on this outcome comparing folic acid versus placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>). There was no OR estimable due to the occurrence of zero pregnancies in both groups. </p> <p>1.3.5 One study reported on this outcome comparing magnesium versus placebo (<a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 8.73, 95% CI 0.17 to 445.08, 1 RCT, 26 men, P = 0.28, I<sup>2</sup> = not applicable). </p> <p>1.3.6 Two studies reported on this outcome comparing N‐acetylcysteine versus placebo or no treatment (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 2.00, 95% CI 0.71 to 5.63, 100 men, 2 RCTs, P = 0.19, I<sup>2</sup> = 0%). </p> <p>1.3.7 Two studies reported on this outcome comparing vitamin E versus placebo (<a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>). There appeared to be an increased clinical pregnancy rate (Peto OR 6.71, 95% CI 1.98 to 22.69, 2 RCTs, 117 men, P = 0.002, I<sup>2</sup> = 0%). </p> <p>1.3.8 Two studies reported on this outcome comparing zinc versus placebo or no treatment (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>). There appeared to be an increased clinical pregnancy rate (Peto OR 4.43, 95% CI 1.39 to 14.14, 2 RCTs, 153 men, P = 0.01, I<sup>2</sup> = 0%). </p> <p>1.3.9 One study reported on this outcome comparing zinc with folic acid versus placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>). There was no evidence of increased clinical pregnancy rate (Peto OR 3.86, 95% CI 0.15 to 99.84, 53 men, 1 RCT, P = 0.42, I<sup>2</sup> = not applicable). </p> <p>1.3.10 Ten studies reported on this outcome comparing combined antioxidants versus placebo or no treatment (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). There appeared to be an increased clinical pregnancy rate (Peto OR 1.67, 95% CI 1.22 to 2.28, 983 men, 10 RCTs, P = 0.001, I<sup>2</sup> = 36%). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 8.41, P = 0.39). </p> <section id="CD007411-sec-0076"> <h6 class="title"><i>Sensitivity analysis for studies with no treatment as control</i> </h6> <p>Seven studies used 'no treatment' as control group instead of placebo (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). When these studies were removed from the analysis, the association between antioxidant use and increased clinical pregnancy rate remained (Peto OR 1.96, 95% CI 1.36 to 2.83, 996 men, 13 RCTs, 17 intervention arms, P = 0.0003, I<sup>2</sup> = 25%). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 6.43, P = 0.60). </p> </section> <section id="CD007411-sec-0077"> <h6 class="title"><i>Sensitivity analysis for studies rated as high risk of bias</i> </h6> <p>When the seven studies rated with a high risk of bias were removed from the analysis, there remained an association between antioxidants and an increased clinical pregnancy rate (Peto OR 1.78, 95% CI 1.26 to 2.51, 1042 men, 13 RCTs, P = 0.001, I<sup>2</sup> = 8%) (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>). </p> </section> <section id="CD007411-sec-0078"> <h6 class="title"><i>Sensitivity analysis for studies enrolling men with varicocele</i> </h6> <p>When the four studies that enrolled men with varicocele or after varicocelectomy were removed from the analysis, the use of antioxidants remained associated with increased clinical pregnancy rate when compared with placebo or no treatment (Peto OR 1.78, 95% CI 1.34 to 2.38, 1179 men, 15 RCTs, P &lt; 0.0001, I<sup>2</sup> = 23%) (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>). </p> </section> <section id="CD007411-sec-0079"> <h6 class="title"><i>Sensitivity analysis for studies enrolling men in couples undergoing intrauterine insemination</i> (<i>IUI)</i> </h6> <p>Two studies reported on men in couples undergoing IUI (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>). When these studies were removed from the analysis there remained an association between the use of antioxidants and increased clinical pregnancy rate when compared with placebo or no treatment (Peto OR 2.25, 95% CI 1.69 to 3.00, 1245 men, 17 RCTs, P &lt; 0.0001, I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD007411-sec-0080"> <h5 class="title">1.4 Clinical pregnancy; IVF/ICSI</h5> <p>See <a href="./references#CD007411-fig-0016" title="">Analysis 1.4</a>. </p> <p>There were six studies in women undergoing IVF/ICSI which reported on clinical pregnancy rate (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>). The meta‐analysis of these studies showed an increase in clinical pregnancy in those couples undergoing IVF/ICSI, when antioxidant use was compared with placebo or no treatment (Peto OR 1.73, 95% CI 1.15 to 2.61, 452 men, 6 RCTs, P = 0.009, I<sup>2</sup> = 0%). </p> </section> <section id="CD007411-sec-0081"> <h5 class="title">1.5 Adverse events</h5> <p>See <a href="./references#CD007411-fig-0017" title="">Analysis 1.5</a> and <a href="#CD007411-fig-0008">Figure 8</a>. </p> <div class="figure" id="CD007411-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Adverse events." data-id="CD007411-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Adverse events. </p> </div> </div> </div> <p>The adverse events reported in the studies were miscarriage, ectopic pregnancy, stillbirth, gastrointestinal disorders, euphoria, headache, upper respiratory infection, and nasopharyngitis.  </p> <p>1.5.1 Miscarriage. Only six studies reported on miscarriage and the event rate was very low (28 miscarriages from 618 couples) (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>). The analysis of these six studies showed no evidence of increased miscarriage between the use of antioxidants when compared with placebo or no treatment (Peto OR 1.46, 95% CI0.75 to 2.83, 6 RCTs, 664 men, P = 0.27, I<sup>2</sup> = 3%, very low‐certainty evidence). This means that, for subfertile men with a baseline expected miscarriage rate of 5%, the chances of having a miscarriage could lie between 4% and 13% with the use of an antioxidant (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). </p> <p>1.5.2 Ectopic pregnancy. Only two studies (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>) reported on this adverse event and there was no evidence of increase of ectopic pregnancy when antioxidants were compared with placebo or no treatment (Peto OR 1.59, 95% CI 0.16 to 16.01, 2 RCTs, 260 men, P = 0.69, I<sup>2</sup> = 0%). </p> <p>1.5.3 Stillbirth. Only one study (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>) reported on this adverse event and there was no evidence of increase of stillbirth when antioxidants were compared with no treatment (Peto OR 0.14, 95% CI 0.00 to 6.82, 1 RCT, 200 men, P = 0.32, I<sup>2</sup> = not applicable). </p> <p>1.5.4 Gastrointestinal. The analysis of 16 studies showed an association between the use of antioxidants and an increase in gastrointestinal discomfort when compared with placebo or no treatment (Peto OR 2.70, 95% CI 1.46 to 4.99, 1355 men, 16 RCTs, P = 0.002, I<sup>2</sup> = 40%, low‐certainty evidence) (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). However, the event rate was very low, so we could not be sure of these results. Six of these 16 studies reported no events, therefore a funnel plot was not created. </p> <p>1.5.5 Euphoria. Only one study (<a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>) reported on this adverse event and there was no evidence of increased occurrence of euphoria when antioxidants were compared with placebo (Peto OR 1.21, 95% CI 0.16 to 9.01, 1 RCT, 86 men, P = 0.85, I<sup>2</sup> = not applicable). </p> <p>1.5.6 Headache. Only one study (<a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>) reported on this adverse event and there was no evidence of increased occurrence of headache when antioxidants were compared with placebo (Peto OR 2.32, 95% CI 0.95 to 5.67, 1 RCT, 171 men, P = 0.06, I<sup>2</sup> = not applicable). </p> <p>1.5.7 Upper respiratory infection. Only one study (<a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>) reported on this adverse event and there was no evidence of increased occurrence of upper respiratory infection when antioxidants were compared with placebo (Peto OR 1.01, 95% CI 0.25 to 4.17, 1 RCT, 171 men, P = 0.99, I<sup>2</sup> = not applicable). </p> <p>1.5.8 Nasopharyngitis. Only one study (<a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>) reported on this adverse event and there was no evidence of increased occurrence of nasopharyngitis when antioxidants were compared with placebo (Peto OR 0.57, 95% CI 0.17 to 1.92, 1 RCT, 171 men, P = 0.36, I<sup>2</sup> = not applicable). </p> <p>It was unlikely that the adverse events ectopic pregnancy, stillbirth, euphoria, headache, upper respiratory infection, and nasopharyngitis were related to intake of antioxidants especially with the reported extreme low event rate. Therefore, these outcomes were not included in the 'Summary of findings' table. </p> </section> <section id="CD007411-sec-0082"> <h5 class="title">1.6 Sperm DNA fragmentation at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0018" title="">Analysis 1.6</a>, <a href="#CD007411-fig-0009">Figure 9</a>. </p> <div class="figure" id="CD007411-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.6 Sperm DNA fragmentation; type of antioxidant." data-id="CD007411-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.6 Sperm DNA fragmentation; type of antioxidant. </p> </div> </div> </div> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.6.1 Astaxanthin plus vitamin E did not show evidence of decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>) mean difference(MD) 1.40, 95% CI ‐6.64 to 9.44, 72 men, 1 RCT, P = 0.73, I<sup>2</sup> = not applicable). </p> <p>1.6.2 Folic acid did not show evidence of decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD ‐5.80, 95% CI ‐13.40 to 1.80, 38 men, 1 RCT, P = 0.13, I<sup>2</sup> = not applicable).  </p> <p>1.6.3 Folic acid plus zinc did not show evidence of decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD ‐1.20, 95% CI ‐9.36 to 6.96, 39 men, 1 RCT, P = 0.77, I<sup>2</sup> = not applicable). </p> <p>1.6.4 N‐acetylcysteine (NAC) did not show evidence of decreased sperm DNA fragmentation when compared with no treatment (<a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>) (MD 3.90, 95% CI ‐0.42 to 8.22, 35 men, 1 RCT, P = 0.08, I<sup>2</sup> = not applicable). </p> <p>1.6.5 Three studies (six intervention arms) compared polyunsaturated fatty acids (PUFAs) with placebo. <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> did not report SDs, we assumed the outcome to have an SD equal to the highest SD from other studies within this analysis. As heterogeneity was high (51%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0018"> <li> <p><a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a> (two intervention arms) did not show evidence of decreased sperm DNA fragmentation when alpha‐lipoic acid (ALA) was compared with placebo (MD 0.53, 95% CI ‐2.65 to 3.72, 41 men, P = 0.74, I<sup>2</sup> = 20%); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> (three intervention arms) did not show evidence of decreased sperm DNA fragmentation when docosahexaenoic acid (DHA) was compared with placebo (MD ‐1.97, 95% CI ‐10.55 to 6.62, 60 men, P = 0.65, I<sup>2</sup> = 0%); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a> did show evidence of decreased sperm DNA fragmentation when Brudy Plus (DHA plus eicosapentaenoic acid (EPA)) was compared with placebo (MD ‐14.10, 95% CI ‐23.22 to ‐4.98, 36 men, P = 0.002, I<sup>2</sup>= not applicable). </p> </li> </ul> </p> <p>1.6.6 Vitamin C plus vitamin E appeared to be associated with decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>) (MD ‐13.80, 95% CI ‐17.50 to ‐10.10, 64 men, 1 RCT, P &lt; 0.00001, I<sup>2</sup> = not applicable).  </p> <p>1.6.7 Zinc did not show evidence of decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD 1.30, 95% ‐8.62 to 11.22, 42 men, 1 RCT, P = 0.80, I<sup>2</sup> = not applicable).  </p> <p>1.6.8 Five studies (six intervention arms) compared combined antioxidants with placebo or no treatment. As heterogeneity was high (85%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0019"> <li> <p><a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a> (two intervention arms) did show evidence of increased sperm DNA fragmentation when combined antioxidants were compared with no treatment (MD 6.09, 95% CI 3.37 to 8.81, 114 men, P &lt; 0.0001, I<sup>2</sup>= 0%); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did show evidence of decreased sperm DNA fragmentation when combined antioxidants were compared with placebo (MD ‐5.00, 95% CI ‐8.41 to ‐1.59, 80 men, P = 0.004, I<sup>2</sup>= not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> did show evidence of decreased sperm DNA fragmentation when combined antioxidants were compared with placebo (MD ‐3.00, 95% CI ‐5.73 to ‐0.27, 165 men, P = 0.03, I<sup>2</sup>= not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> did not show evidence of decreased sperm DNA fragmentation when combined antioxidants were compared with placebo (MD ‐1.90, 95% CI ‐5.89 to 2.09, 135 men, P = 0.35, I<sup>2</sup>= not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of decreased sperm DNA fragmentation when combined antioxidants were compared with placebo (MD ‐2.90, 95% CI ‐8.10 to 2.30, 75 men, P = 0.27, I<sup>2</sup>= not applicable). </p> </li> </ul> </p> <p>We performed a post‐hoc sensitivity analysis of the combined antioxidants subgroup for studies enrolling men with varicocele. In the literature it is reported that men with varicocele have higher levels of sperm DNA fragmentation. One study in this subgroup reported on men with varicocele (<a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>). When this study was removed from the analysis, heterogeneity was low and there appeared to be an association between the use of combined antioxidants and decreased sperm DNA fragmentation (MD ‐3.31, 95% CI ‐5.08 to ‐1.54, 455 men, 4 RCTs, P = 0.0002, I<sup>2</sup> = 0%).  </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 52.10, P &lt; 0.00001). </p> </section> <section id="CD007411-sec-0083"> <h5 class="title">1.7 Sperm DNA fragmentation at six months; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0019" title="">Analysis 1.7</a>. </p> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.7.1 Three studies compared combined antioxidants with placebo. As heterogeneity was high (74%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0020"> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did show evidence of decreased sperm DNA fragmentation (MD ‐7.10, 95% CI ‐10.79 to ‐3.41, 80 men, P = 0.0002, I<sup>2</sup> = not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> did show evidence of decreased sperm DNA fragmentation (MD ‐4.70, 95% CI ‐7.12 to ‐2.28, 165 men, P = 0.0001, I<sup>2</sup> = not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of decreased sperm DNA fragmentation (MD 2.90, 95% CI ‐3.11 to 8.91, 75 men, P = 0.34, I<sup>2</sup> = not applicable). </p> </li> </ul> </p> <p>1.7.2 Zinc plus folic acid did not show evidence of decreased sperm DNA fragmentation when compared with placebo (<a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>) (MD 3.00, 95% CI 0.02 to 5.98, 853 men, P = 0.05, I<sup>2</sup> = not applicable). </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 17.51, P &lt; 0.0001). </p> <p><b><i>1.8 Data not usable for meta‐analysis</i> </b> </p> <p>See <a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a>. </p> <p>One study reported on DNA fragmentation, but could not be included in the forest plots of the meta‐analysis. <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a> reported the tail length in micrometer measured with the Comet assay instead of a percentage. They reported no statistically significant difference in tail length when folic acid was compared with placebo after 3 months and 6 months.  </p> </section> <section id="CD007411-sec-0084"> <h5 class="title">1.9 Total sperm motility at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0021" title="">Analysis 1.9</a> and <a href="#CD007411-fig-0010">Figure 10</a> </p> <div class="figure" id="CD007411-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.9 Total sperm motility at 3 months or less; type of antioxidant." data-id="CD007411-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.9 Total sperm motility at 3 months or less; type of antioxidant. </p> </div> </div> </div> <p>We analysed this outcome using a fixed‐effect‐model and used subtotals as pooling was not possible. </p> <p>1.9.1 Astaxanthin plus vitamin E did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>) (MD ‐5.20, 95% CI ‐11.56 to 1.16, 72 men, 1 RCT, P = 0.11, I<sup>2</sup> = not applicable). </p> <p>1.9.2 Five studies (seven intervention arms) comparing carnitines with placebo or no treatment did show an increase in total sperm motility (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>) (MD 31.28, 95% CI 31.19 to 31.37, 244 men, 5 RCTs, 7 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 97%). One study (<a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>) did not report standard deviations (SDs); we assumed the outcome to have an SD equal to the highest SD from other studies within this analysis. The heterogeneity was extremely high due to the fact that one study (<a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>) had very small SDs when compared with data in the other studies. However, the authors confirmed, when contacted, that they are indeed SDs and not standard errors (SEs). When these two studies were removed from the analysis, carnitines appeared to be associated with an increase in total sperm motility when compared with placebo or no treatment, with low heterogeneity (MD 11.83, 95% CI 7.78 to 15.87, 128 men, 3 RCTs, 5 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 0%). </p> <p>1.9.3 Carotenoids did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>) (MD 3.50, 95% CI ‐6.95 to 13.95, 36 men, 1 RCT, P = 0.51, I<sup>2</sup> = not applicable). </p> <p>1.9.4 Coenzyme Q10 did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>) (MD 3.61, 95% CI ‐6.13 to 13.35, 47 men, 1 RCT, P = 0.47, I<sup>2</sup> = not applicable). </p> <p>1.9.5 Two studies compared folic acid with placebo and did not show evidence of an increase in total sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD 4.56, 95% CI ‐5.63 to 14.74, 89 men, 2 RCTs, P = 0.38, I<sup>2</sup> = 0%). </p> <p>1.9.6 Magnesium did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>) (MD 14.50, 95% CI ‐6.01 to 35.01, 20 men, 1 RCT, P = 0.17, I<sup>2</sup> = not applicable). </p> <p>1.9.7 N‐acetylcysteine (NAC) did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>) (MD 14.60, 95% CI 0.32 to 28.88, 35 men, P = 0.05, I<sup>2</sup> = not applicable). </p> <p>1.9.8 Three studies (four intervention arms) compared polyunsaturated fatty acids (PUFAs) with placebo and did not show evidence of an increase in total sperm motility (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>) (MD ‐2.40, 95% CI ‐9.89 to 5.09, 105 men, 3 RCTs, 4 intervention arms, P = 0.53, I<sup>2</sup> = 48%). </p> <p>1.9.9 Selenium appeared to be associated with an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>) (MD 14.90, 95% CI 1.14 to 28.66, 34 men, 1 RCT, P = 0.03, I<sup>2</sup> = not applicable). </p> <p>1.9.10 Vitamin C plus vitamin E did not show evidence of an increase in total sperm motility compared with placebo (<a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>) (MD 2.90, 95% CI ‐7.76 to 13.56, 64 men, 1 RCT, P = 0.59, I<sup>2</sup> = not applicable). </p> <p>1.9.11 Vitamin E appeared to be associated with an increase in total sperm motility compared with no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>) (MD 18.90, 95% CI 4.90 to 32.90, 45 men, 1 RCT, P = 0.008, I<sup>2</sup> = not applicable). </p> <p>1.9.12 Three studies compared zinc with placebo or no treatment (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>). As the heterogeneity was high (78%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0021"> <li> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> did not show evidence of an increase in total sperm motility at three months when compared with placebo (MD 4.00, 95% CI ‐12.11 to 20.11, 57 men, P = 0.63); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a> did show an increase in total sperm motility at three months when compared with no treatment (MD 25.00, 95% CI 14.07 to 35.93, 19 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a> did not show evidence of an increase in total sperm motility at 16 weeks when compared with placebo (MD 1.20, 95% CI ‐11.92 to 14.32, 42 men, P = 0.86). </p> </li> </ul> </p> <p>1.9.13 Two studies compared zinc plus folic acid with placebo and did not show evidence of an increase in total sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD 5.26, 95% CI ‐3.64 to 14.16, 93 men, 2 RCTs, P = 0.25, I<sup>2</sup> = 0%). </p> <p>1.9.14 Zinc plus vitamin E appeared to be associated with an increase in total sperm motility compared with no treatment (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>) (MD 26.00, 95% CI 12.85 to 39.15, 20 men, 1 RCT, P = 0.0001, I<sup>2</sup> = not applicable) </p> <p>1.9.15 Zinc plus vitamin E plus vitamin C appeared to be associated with an increase in total sperm motility compared with no treatment (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>) (MD 26.00, 95% CI 12.62 to 39.38, 22 men, 1 RCT, P = 0.0001, I<sup>2</sup> = not applicable). </p> <p>1.9.16 Seven studies (eight intervention arms) compared combined antioxidants with placebo or no treatment (<a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). As heterogeneity was high (88%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0022"> <li> <p><a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a> did not show evidence of increased total sperm motility when compared with placebo (MD ‐6.40, 95% CI ‐15.52 to 2.72, 62 men, P = 0.17); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> did show an increase in total sperm motility when compared with placebo (MD 8.72, 95% CI 4.44 to 13.01, 125 men, P &lt; 0.0001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a> did show an increase in total sperm motility when compared with no treatment (MD 15.20, 95% CI 13.62 to 16.78, 180 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a> did show an increase in total sperm motility when compared with placebo (MD 11.70, 95% CI 0.87 to 22.53, 48 men, P = 0.003); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a> did show an increase in total sperm motility when compared with placebo (MD 20.30, 95% CI 6.77 to 33.83, 30 men, P = 0.003); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> did not show evidence of increased total sperm motility when compared with placebo (MD 0.60, 95% CI ‐4.37 to 5.57, 164 men, P = 0.81); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased total sperm motility when compared with placebo (MD 2.90, 95% CI ‐7.31 to 13.12, 75 men, P = 0.58). </p> </li> </ul> </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 1086.87, P &lt; 0.00001). </p> <p><b><i>1.10 Data not usable for meta‐analysis</i> </b> </p> <p><a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a> </p> <p>Data from two studies could not be used in the forest plot. <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a> reported percentage of WHO class A motile sperm instead of class A plus B, and <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a> reported median differences. Both studies found no difference between intervention and placebo or no treatment for this outcome.  </p> </section> <section id="CD007411-sec-0085"> <h5 class="title">1.11 Total sperm motility at six months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0023" title="">Analysis 1.11</a>. </p> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.11.1 Three studies (five intervention arms) compared carnitines with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>). As the heterogeneity was high (78%), we have not reported the pooled analysis for these studies; individually their results were: </p> <p> <ul id="CD007411-list-0023"> <li> <p><a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a> (three arms) did show an increased total sperm motility at six months when compared with placebo (MD 18.63, 95% CI 12.92 to 24.35, 59 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a> did not show evidence of increased total sperm motility at six months when compared with placebo (MD 1.50, 95% CI‐4.56 to 7.56, 56 men, P = 0.63); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a> did not show evidence of increased total sperm motility at six months when compared with placebo (MD ‐7.70, 95% CI ‐33.24 to 17.84, 21 men, P = 0.55). </p> </li> </ul> </p> <p>1.11.2 Three studies compared coenzyme Q10 with placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). As the heterogeneity was extremely high (99%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0024"> <li> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> did show an increased total sperm motility when compared with placebo (MD 4.50, 95% 0.74 to 8.26, 60 men, P = 0.02); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> did show an increased total sperm motility when compared with placebo (MD 4.50, 95% CI 3.89 to 5.11, 194 men, P &lt; 0.000001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> did show an increased total sperm motility when compared with placebo (MD 10.40, 95% CI 9.77 to 11.03, 225 men, P &lt; 0.000001). </p> </li> </ul> </p> <p>1.11.3 Two studies compared folic acid with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of increased total sperm motility (MD 0.16, 95% CI ‐6.96 to 7.29, 98 men, 2 RCTs, P = 0.96, I<sup>2</sup> = 0). </p> <p>1.11.4 N‐acetylcysteine (NAC) appeared to be associated with an increased total sperm motility when compared with placebo (MD 1.90, 95% CI 1.20 to 2.60, 211 men, P &lt; 0.00001, I<sup>2</sup> = not applicable) (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>). </p> <p>1.11.5 Selenium appeared to be associated with an increased total sperm motility when compared with placebo (MD 3.20, 95% CI 2.50 to 3.90, 211 men, P &lt; 0.00001, I<sup>2</sup> = not applicable) (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>). </p> <p>1.11.6 Selenium plus N‐acetylcysteine appeared to be associated with increased total sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 6.30, 95% CI 5.60 to 7.00, 210 men, P &lt; 0.00001, I<sup>2</sup> = not applicable). </p> <p>1.11.7 Vitamin D plus calcium did not show evidence of increased total sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>) (MD ‐4.00, 95% CI ‐9.57 to 1.57, 260 men, P = 0.16, I<sup>2</sup> = not applicable). </p> <p>1.11.8 Two studies compared vitamin E with placebo or no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>). There appeared to be an association between vitamin E and an increased total sperm motility (MD 11.60, 95% CI 6.18 to 17.02, 132 men, 2 RCTs, P &lt; 0.0001, I<sup>2</sup> = 16%). </p> <p>1.11.9 Two studies compared zinc with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of increased total sperm motility (MD 0.00, 95% CI ‐6.95 to 6.95, 105 men, P = 1.00, I<sup>2</sup> = 0%). </p> <p>1.11.10 Three studies compared zinc plus folic acid to placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of increased total sperm motility (MD 0.24, 95% CI ‐2.54 to 3.02, 956 men, P = 0.87, I<sup>2</sup> = 0%). </p> <p>1.11.11 Four studies compared combined antioxidants with placebo or no treatment (<a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>) and did not show evidence of increased total sperm motility. As the heterogeneity was high (69%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0025"> <li> <p><a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a> did show increased total sperm motility when compared with placebo (MD 4.40, 95% CI 1.49 to 7.31, 104 men, P = 0.003); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> (three arms), did show increased total sperm motility when compared with placebo (MD 12.44, 95% CI 8.29 to 16.59, 125 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> did show increased total sperm motility compared with no treatment (MD 7.60, 95% CI 3.58 to 11.62, 90 men, P = 0.0002); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased total sperm motility compared with placebo (MD ‐0.80, 95% CI ‐9.36 to 7.76, 75 men, P = 0.85). </p> </li> </ul> </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 254.81, P &lt; 0.00001). </p> </section> <section id="CD007411-sec-0086"> <h5 class="title">1.12 Total sperm motility at nine months or more; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0024" title="">Analysis 1.12</a>. </p> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.12.1 One study reported on different types of carnitines. Carnitines appeared to be associated with an increased total sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 8.54, 95% CI 3.01 to 14.07, 59 men, P = 0.002, I<sup>2</sup> = 0%). </p> <p>1.12.2 Three studies reported on coenzyme Q10 (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). As the heterogeneity was extremely high (98%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0026"> <li> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> did not show evidence of increased total sperm motility when compared with placebo (MD ‐2.30, 95% CI ‐5.94 to 1.34, 60 men, P = 0.22); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> did show increased total sperm motility when compared with placebo (MD 1.40, 95% CI 0.79 to 2.01, 194 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> did show increased total sperm motility when compared with placebo (MD 5.40, 95% CI 4.80 to 6.00, 225 men, P &lt; 0.00001). </p> </li> </ul> </p> <p>1.12.3 Vitamin E did not show evidence of increased total sperm motility when compared with no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>) (MD 2.20, 95% CI ‐8.48 to 12.88, 45 men, 1 RCT, P = 0.69, I<sup>2</sup> = not applicable). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 3.42, P = 0.18). </p> </section> <section id="CD007411-sec-0087"> <h5 class="title">1.13 Total sperm motility over time</h5> <p>See <a href="./references#CD007411-fig-0025" title="">Analysis 1.13</a> </p> <p>This analysis was only useful in directly comparing the same studies reporting at the three time points and not in comparing results of meta‐analyses that included different subsets of studies. </p> <p>1.13.1 Total sperm motility at three months or less. We analysed this outcome using a fixed‐effect model (MD 31.17, 95% CI 31.07 to 31.26, 1638 men, 25 RCTs, 36 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 97%) and used subtotals (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). </p> <p>1.13.2 Total sperm motility at six months. We analysed this outcome using a fixed‐effect model (MD 5.77, 95% CI 5.45 to 6.10, 2880 men,17 RCTs, 26 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 94%) and used subtotals (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). </p> <p>1.13.3 Total sperm motility at nine months or more. We analysed this outcome using a fixed‐effect model (MD 3.36, 95% CI 2.94 to 3.78, 583 men, 5 RCTs, 7 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 94%) and used subtotals (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). </p> <p>Two of the studies included in the analysis of the semen parameter outcomes (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>) had consistently reported SDs very much smaller than those reported by most of the other included studies. The review authors considered that these were potentially erroneous, but an attempt to check with the study authors was unsuccessful. One other study (<a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>), also had very small SDs when compared with data in the other studies, but the authors confirmed, when contacted, that they are indeed SDs and not SEs. We tried to manage these analyses in two different ways: firstly we assumed the outcome to have a SD equal to the highest SD from other studies within the same analysis and secondly by treating the data as SEs and converting back to SDs, however heterogeneity remained high in both situations so for the final analyses we reverted to the SDs as reported in the studies. The low SDs may have been due to the strict inclusion and exclusion criteria indicating that the study was homogenous in nature, however we were unable to carry out a sensitivity analysis on these studies as pooling was not possible due to high heterogeneity. </p> </section> <section id="CD007411-sec-0088"> <h5 class="title">1.14 Progressive sperm motility at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0026" title="">Analysis 1.14</a> and <a href="#CD007411-fig-0011">Figure 11</a>. </p> <div class="figure" id="CD007411-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.14 Progressive sperm motility at 3 months or less; type of antioxidant." data-id="CD007411-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.14 Progressive sperm motility at 3 months or less; type of antioxidant. </p> </div> </div> </div> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.14.1 Astaxanthin plus vitamin E did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>) (MD ‐5.10, 95% CI ‐11.46 to 1.26, 72 men, 1 RCT, P = 0.12, I<sup>2</sup> = not applicable). </p> <p>1.14.2 Four studies with carnitines reported an increase in progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>). As the heterogeneity was high (87%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0027"> <li> <p><a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a> (three arms) did show an increase in progressive sperm motility when compared with placebo (MD 13.72, 95% CI 9.08 to 18.35, 59 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> did show an increase in progressive sperm motility when compared with placebo (MD 9.80, 95% CI 5.62 to 13.98, 86 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a> did show an increase in progressive sperm motility when compared with placebo (MD 21.30, 95% CI 20.50 to 22.10, 110 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> did show an increase in progressive sperm motility when compared with placebo (MD 21.00, 95% CI 20.53 to 21.47, 30 men, P &lt; 0.00001). </p> </li> </ul> </p> <p>1.14.3 Carotenoids did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>) (MD ‐0.20, 95% CI ‐7.27 to 6.87, 36 men, 1 RCT, P = 0.96, I<sup>2</sup> = not applicable).  </p> <p>1.14.4 Coenzyme Q10 did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>) (MD 4.60, 95% CI ‐3.54 to 12.74, 47 men, 1 RCT, P = 0.27, I<sup>2</sup> = not applicable). </p> <p>1.14.5 Two studies compared folic acid to placebo and did not show evidence of increased progressive sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>) (MD 5.08, 95% CI ‐4.00 to 14.16, 81 men, 2 RCTs, P = 0.27, I<sup>2</sup> = 18%). </p> <p>1.14.6 N‐acetylcysteine (NAC) did not show evidence of increased progressive sperm motility when compared with no treatment (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>) (MD 3.80, 95% CI ‐1.03 to 8.63, 60 men, 1 RCT, P = 0.12, I<sup>2</sup> = not applicable). </p> <p>1.14.7 Four studies (six intervention arms) compared PUFAs with placebo (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>). <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> did not report SDs; we assumed the outcome to have an SD equal to the highest SD from other studies within this analysis. The heterogeneity was extremely high (95%), which may be due to the relatively small SDs reported in <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a> and <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>. We tried to manage these small SDs by imputing SDs from studies of a similar size and by considering the SDs to be SEs and converting them to SDs. Despite these efforts, heterogeneity remained high, and we reverted the SDs as reported in the studies. We have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0028"> <li> <p><a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD 8.99, 95% CI ‐1.84 to 19.82, 41 men, P = 0.10); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> (three intervention arms) did not show evidence of increased progressive sperm motility when compared with placebo (MD 7.23, 95% CI ‐3.21 to 17.67, 60 men, P = 0.17); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a> did show an increase in progressive sperm motility when compared with placebo (MD 6.40, 95% CI 4.83 to 7.97, 44 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a> did show a decrease in progressive sperm motility when compared with placebo (MD ‐6.60, 95% CI ‐8.57 to ‐4.63, 36 men, P &lt; 0.00001). </p> </li> </ul> </p> <p>1.14.8 Two studies (three intervention arms) compared vitamin C with placebo and did show an increase in progressive sperm motility (<a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>). As the heterogeneity was high (64%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0029"> <li> <p><a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a> did show an increase in progressive sperm motility when compared with placebo (MD 9.60, 95% CI 2.29 to 16.91, 115 men, P = 0.01); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a> did not show evidence of increased progressive sperm motility when vitamin C 200 mg was compared with placebo (MD 2.00, 95% CI ‐24.07 to 28.07, 15 men, P = 0.88); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a> did show an increase in progressive sperm motility when vitamin C 1000 mg was compared with placebo (MD 45.00, 95% CI 15.25 to 74.75, 15 men, P = 0.03). </p> </li> </ul> </p> <p>1.14.9 Vitamin C plus vitamin E did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>) (MD 0.20, 95% CI ‐9.77 to 10.17, 31 men, 1 RCT, P = 0.97, I<sup>2</sup> = not applicable). </p> <p>1.14.10 Vitamin D did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>) (MD ‐0.84, 95% CI ‐7.65 to 5.97, 62 men, 1 RCT, P = 0.81, I<sup>2</sup> = not applicable). </p> <p>1.14.11 Two studies with zinc did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>) (MD 1.14, 95% CI ‐3.37 to 5.64, 157 men, 2 RCTs, P = 0.62, I<sup>2</sup> = 0%). </p> <p>1.14.12 Zinc plus folic acid did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>) (MD 3.80, 95% CI ‐13.66 to 21.26, 54 men, 1 RCT, P = 0.67, I<sup>2</sup> = not applicable). </p> <p>1.14.13 Nine studies (10 intervention arms) compared antioxidants with placebo or no treatment (<a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). As the heterogeneity was very high (91%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0030"> <li> <p><a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD ‐3.30, 95% CI ‐12.08 to 5.48, 62 men, P = 0.46); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a> (two arms) did not show evidence of increased progressive sperm motility when compared with placebo (MD ‐0.42, 95% CI ‐5.53 to 4.69, 57 men, P = 0.87); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD 0.20, 95% CI ‐11.43 to 11.83, 80 men, P = 0.97); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD 1.70, 95% CI ‐4.51 to 7.91, 154 men, P = 0.59); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a> did show an in increase in progressive sperm motility when compared with placebo (MD 10.10, 95% CI 5.41 to 14.79, 83 men, P &lt; 0.0001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD2.80, 95% CI ‐1.41 to 7.01, 165 men, P = 0.19); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a> did show an increase in progressive sperm motility when compared with placebo (MD 15.20, 95% CI 13.62 to 16.78, 180 men, 1 RCT, P &lt; 0.00001, I<sup>2</sup> = not applicable). </p> </li> <li> <p><a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a> did show an increase in progressive sperm motility when compared with placebo (MD 18.00, 95% CI 11.75 to 24.25, 80 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD 0.00, 95% CI ‐12.24 to 12.24, 75 men, P = 1.00). </p> </li> </ul> </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 1258.83, P &lt; 0.00001). </p> </section> <section id="CD007411-sec-0089"> <h5 class="title">1.15 Progressive sperm motility at six months; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0027" title="">Analysis 1.15</a>. </p> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.15.1 Two studies (four intervention arms) compared carnitines with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>) and did show increased progressive sperm motility (MD 11.66, 95% CI 8.68 to 14.64, 145 men, 2 RCTs, 4 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 49%). </p> <p>1.15.2 Coenzyme Q10 appeared to be associated with increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>) (MD 5.00, 95% CI 2.13 to 7.87, 60 men, 1 RCT, P = 0.0006, I<sup>2</sup> = not applicable). </p> <p>1.15.3 Two studies with folic acid did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>) (MD ‐1.77, 95% CI ‐10.21 to 6.67, 81 men, 2 RCTs, P = 0.68, I<sup>2</sup> = 0%). </p> <p>1.15.4 PUFAs appeared to be associated with increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>) (MD 8.80, 95% CI 8.11 to 9.49, 227 men, 1 RCT, P &lt; 0.00001, I<sup>2</sup> = not applicable).  </p> <p>1.15.5 Vitamin D plus calcium did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>) (MD ‐4.00, 95% CI ‐9.59 to 1.59, 260 men, P = 0.16, I<sup>2</sup> = not applicable). </p> <p>1.15.6 Zinc did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>) (MD 2.00, 95% CI ‐13.56 to 17.56, 57 men, 1 RCT, P = 0.80, I<sup>2</sup> = not applicable). </p> <p>1.15.7 Zinc plus folic acid did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>) (MD 2.70, 95% CI ‐14.58 to 19.98, 54 men, 1 RCT, P = 0.76, I<sup>2</sup> = not applicable). </p> <p>1.15.8 Five studies compared antioxidants with placebo or no treatment (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). As heterogeneity was high (65%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0031"> <li> <p><a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a> did not show evidence of increased progressive sperm motility when compared with no treatment (MD 3.90, 95% CI ‐4.10 to 11.90, 60 men, P &lt; 0.34); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did show an increase in progressive sperm motility when compared with placebo (MD 13.20, 95% CI 4.46 to 21.94, 80 men, P =0.003); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD 1.90, 95% CI ‐0.85 to 4.65, 90 men, P = 0.18); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> did show an increase in progressive sperm motility when compared with placebo (MD 6.70, 95% CI 3.36 to 10.04, 180 men, P &lt; 0.0001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased progressive sperm motility when compared with placebo (MD ‐3.40, 95% CI ‐12.89 to 6.09, 75 men, P = 0.48). </p> </li> </ul> </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 54.94, P &lt; 0.00001). </p> <p><b><i>1.16 Data not suitable for meta analysis</i> </b> </p> <p>See <a href="./references#CD007411-fig-0028" title="">Analysis 1.16</a>. </p> <p>One study provided data as percentage improvement and therefore could not be used in the forest plot (<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>). The percentage improvement in the intervention groups was higher compared with placebo (P = 0.01). </p> </section> <section id="CD007411-sec-0090"> <h5 class="title">1.17 Progressive sperm motility at nine months or more; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0029" title="">Analysis 1.17</a>. </p> <p>We analysed this outcome using a fixed‐effect model and used subtotals as pooling was not possible. </p> <p>1.17.1 Carnitines appeared to be associated with an increase in progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>, three intervention arms) (MD 7.77, 95% CI 2.68 to 12.87, 59 men, 1 RCT, 3 intervention arms, P = 0.003, I<sup>2</sup> = 0%). </p> <p>1.17.2 Coenzyme Q10 did not show evidence of increased progressive sperm motility when compared with placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>) (MD ‐0.90, 95% CI ‐2.68 to 0.88, 60 men, 1 RCT, P = 0.32, I<sup>2</sup> = not applicable). </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 9.93, P = 0.002). </p> </section> <section id="CD007411-sec-0091"> <h5 class="title">1.18 Progressive sperm motility over time </h5> <p>See <a href="./references#CD007411-fig-0030" title="">Analysis 1.18</a>. </p> <p>This analysis was only useful in directly comparing the same studies reporting at the three time points and not in comparing results of meta‐analyses that included different subsets of studies. </p> <p>1.18.1 Progressive sperm motility at three months or less. We analysed this outcome using a fixed‐effect model (MD 17.98, 95% CI 17.62 to 18.34, 2054 men, 27 RCTs, 35 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 98%) and used subtotals (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). </p> <p>1.18.2 Progressive sperm motility at six months. We analysed this outcome using a fixed‐effect model (MD 8.05, 95% CI 7.43 to 8.66, 1304 men, 12 RCTs, 16 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 79%) and used subtotals (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). </p> <p>1.18.3 Progressive sperm motility at nine months or more. We analysed this outcome using a fixed‐effect model (MD 0.04, 95% CI ‐1.64 to 1.72, 119 men, 2 RCTs, 4 intervention arms, P = 0.96, I<sup>2</sup> = 72%) and used subtotals (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>). </p> </section> <section id="CD007411-sec-0092"> <h5 class="title">1.19 Sperm concentration at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0031" title="">Analysis 1.19</a> and <a href="#CD007411-fig-0012">Figure 12</a>. </p> <div class="figure" id="CD007411-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.19 Sperm concentration at 3 months or less; type of antioxidant." data-id="CD007411-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.19 Sperm concentration at 3 months or less; type of antioxidant. </p> </div> </div> </div> <p>We analysed this outcome using a fixed‐effect model. We used only subtotals in this analysis. </p> <p>1.19.1 Astaxanthin plus vitamin E did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>) (MD ‐1.00, 95% CI ‐6.79 to 4.79, 72 men, 1 RCT, P = 0.74, I<sup>2</sup> = not applicable). </p> <p>1.19.2 Five studies (7 intervention arms) compared carnitines with placebo or no treatment and showed an increase in sperm concentration (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>). As the heterogeneity was extremely high (95%) we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0032"> <li> <p><a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a> did not show evidence of increased sperm concentration when compared with placebo (MD 7.76, 95% CI ‐0.73 to 16.25, 59 men, P = 0.07, I<sup>2</sup> = 0%); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> did show an increase in sperm concentration when compared with placebo (MD 7.90, 95% CI 4.89 to 10.91, 86 men, P &lt; 0.00001, I<sup>2</sup> = not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a> did not show evidence of increased sperm concentration when compared with no treatment (MD ‐0.90, 95% CI ‐4.80 to 3.00, 48 men, P = 0.65, I<sup>2</sup> = not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a> did show an increase in sperm concentration when compared with placebo (MD 8.50, 95% CI 7.85 to 9.15, 110 men, P &lt; 0.00001, I<sup>2</sup> = not applicable); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> did show an increase in sperm concentration when compared with placebo (MD 29.50, 95% CI 25.39 to 33.61, 30 men, P &lt; 0.00001, I<sup>2</sup> = not applicable). </p> </li> </ul> </p> <p>1.19.3 Carotenoids appeared to be associated with an increase in sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>) (MD 6.30, 95% CI 0.62 to 11.98, 36 men, 1 RCT, P = 0.03, I<sup>2</sup> = not applicable). </p> <p>1.19.4 Coenzyme Q10 did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>) (MD ‐0.10, 95% CI ‐12.37 to 12.17, 47 men, 1 RCT, P = 0.99, I<sup>2</sup> = not applicable). </p> <p>1.19.5 Three studies compared folic acid with placebo and did not show evidence of increased sperm concentration (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>). As the heterogeneity was high (61%) we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0033"> <li> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> did show an increase in sperm concentration when compared with placebo (MD 22.20, 95% CI 3.80 to 40.60, 51 men, P = 0.02); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐9.60, 95% CI ‐39.36 to 20.16, 30 men, P = 0.53). However, in this study there was great baseline imbalance for sperm parameters between the intervention and control group; </p> </li> <li> <p><a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a> did not show evidence of increased sperm concentration when compared with placebo at 16 weeks (MD 0.60, 95% CI ‐8.28 to 9.48, 38 men, P =0.89). </p> </li> </ul> </p> <p>1.19.6 Magnesium did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>) (MD 5.20, 95% CI ‐2.61 to 13.01, 20 men, 1 RCT, P = 0.19, I<sup>2</sup> = not applicable). </p> <p>1.19.7 Two studies compared N‐acetylcysteine (NAC) with placebo or no treatment (<a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>) and did not show evidence of increased sperm concentration (MD 4.59, 95% CI ‐0.27 to 9.46, 95 men, 2 RCTs, P = 0.06, I<sup>2</sup> = 0%). </p> <p>1.19.8 Five studies (eight intervention arms) compared PUFAs with placebo or no treatment (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>) and did show an increase in sperm concentration (MD 3.42, 95% CI 1.69 to 5.15, 209 men, 5 RCTs, 8 intervention arms, P = 0.0001, I<sup>2</sup> = 0%). <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a> reported remarkably small SDs compared with the other included studies. A sensitivity analysis was performed, showing no evidence of increased sperm concentration (MD ‐1.07, 95% CI ‐14.37 to 12.24, 165 men, 4 RCTs, 7 intervention arms, P = 0.88, I<sup>2</sup> = 0%). </p> <p>1.19.9 Selenium did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>) (MD 21.20, 95% CI ‐4.90 to 47.30, 34 men, 1 RCT, P = 0.11, I<sup>2</sup> = not applicable). </p> <p>1.19.10 Vitamin C did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>) (MD 9.70, 95% CI 0.09 to 19.31, 115 men, 1 RCT, P = 0.05, I<sup>2</sup> = not applicable). </p> <p>1.19.11 Two studies compared vitamin C plus vitamin E with placebo (<a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>). As the heterogeneity was high (52%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0034"> <li> <p><a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a> did not show evidence of increased sperm concentration when compared with placebo (MD 7.20, 95% CI ‐4.05 to 18.45, 64 men, P = 0.21); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐4.40, 95% CI ‐15.48 to 6.68, 31 men, P = 0.44). </p> </li> </ul> </p> <p>1.19.12 Vitamin D did not show evidence of increased sperm concentration compared with placebo (<a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>) (MD ‐2.12, 95% CI ‐8.85 to 4.61, 62 men, P = 0.54, I<sup>2</sup> = not applicable). </p> <p>1.19.13 Vitamin E appeared to be associated with an increase in sperm concentration when compared with no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>) (MD 18.90, 95% CI 3.92 to 33.88, 45 men, 1 RCT, P = 0.01, I<sup>2</sup> = not applicable). </p> <p>1.19.14 Three studies compared zinc with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a>). There appeared to be an association between zinc and increased sperm concentration (MD 6.74 95% CI 2.81 to 10.68, 199 men, 3 RCTs, P = 0.0008, I<sup>2</sup> = 41%). </p> <p>1.19.15 Two studies compared folic acid plus zinc with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>). As heterogeneity was high (80%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0035"> <li> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> did show an increase in sperm concentration when compared with placebo (MD 18.00, 95% CI 1.11 to 34.89, 54 men, P = 0.04); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐3.50, 95% CI ‐11.55 to 4.55, 39 men, P = 0.39). </p> </li> </ul> </p> <p>1.19.16 Eleven studies (13 intervention arms) compared combined antioxidants with placebo or no treatment (<a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). As the heterogeneity was very high (86%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0036"> <li> <p><a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐1.10, 95% CI ‐19.48 to 17.28, 62men, P = 0.91); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a> (two arms) did not show evidence of increased sperm concentration when compared with placebo (MD 3.55, 95% CI ‐3.14 to 10.24, 114 men, P = 0.30); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐3.10, 95% CI ‐18.89 to 12.69, 80 men, P = 0.70); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> did show an increase in sperm concentration when compared with placebo (MD 10.69, 95% CI 8.15 to 13.22, 125 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>  did not show evidence of increased sperm concentration when compared with placebo (MD ‐5.60, 95% CI ‐14.50 to 3.30, 154 men, P = 0.22); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a> did show an increase in sperm concentration when compared with placebo (MD 18.40, 95% CI 6.04 to 30.76, 83 men, P &lt; 0.004); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a> did not show evidence of an increased sperm concentration when compared with no treatment (MD ‐0.90, 95% CI ‐1.85 to 0.05, 180 men, P = 0.06); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a> did not show evidence of an increased sperm concentration when compared with placebo (MD ‐4.40, 95% CI ‐16.74 to 7.94, 80 men, P = 0.48); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a> did not show evidence of increased sperm concentration when compared with placebo (MD 6.50, 95% CI ‐16.66 to 29.66, 39 men, P = 0.58); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐7.30, 95% CI ‐20.25 to 5.65, 164 men, P = 0.27); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐11.50, 95% CI ‐33.04 to 10.04, 75 men, P = 0.30). </p> </li> </ul> </p> <p>There was evidence that different antioxidants did not have differing effects (test for subgroup differences: Chi² = 252.54, P &lt; 0.00001). </p> <p><b><i>1.20 Data not usable for meta‐analysis</i> </b> </p> <p>See <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a>. </p> <p>One study (<a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>) provided data as median differences and range and therefore could not be used in the forest plot. This study might indicate some improvement in sperm concentration in the intervention group when measured at three months, however these data were not rigorous and no conclusions could be made. One study (<a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>) provided data as the mean with no SD and did not report the number of patients in whom the outcome was assessed. The P value in <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a> was 0.03, indicating that there may have been an association between L‐carnitine and improved sperm concentration at three months.  </p> </section> <section id="CD007411-sec-0093"> <h5 class="title">1.21 Sperm concentration at six months; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0033" title="">Analysis 1.21</a>. </p> <p>We analysed this outcome using a fixed‐effect model. We used only subtotals in this analysis. </p> <p>1.21.1 Three studies (five intervention arms) compared carnitines with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>). There appeared to be an association between carnitines and increased sperm concentration (MD 7.42, 95% CI 4.97 to 9.87, 201 men, 3 RCTs, 5 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 23%). </p> <p>1.21.2 Three studies compared coenzyme Q10 with placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). As the heterogeneity was extremely high (96%) we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0037"> <li> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐1.50, 95% CI ‐11.39 to 8.39, 60 men, P = 0.77); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> did show an increase in sperm concentration when compared with placebo (MD 5.60, 95% CI 4.38 to 6.82, 194 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> did show an increase in sperm concentration when compared with placebo (MD 11.90, 95% CI 10.72 to 13.08, 225 men, P &lt; 0.00001). </p> </li> </ul> </p> <p>1.21.3 Three studies compared folic acid with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). As the heterogeneity was high (58%) we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0038"> <li> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> did show an increase in sperm concentration when compared with placebo (MD 19.20, 95% CI 12.24 to 26.16, 51 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐22.80, 95% CI ‐60.44 to 14.84, 30 men, P = 0.24). However, in this study there was great baseline imbalance for sperm parameters between the intervention and control group; </p> </li> <li> <p><a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a> did not show evidence of increased sperm concentration when compared with placebo (MD 15.00, 95% CI ‐1.19 to 31.19, 47 men, P = 0.07). </p> </li> </ul> </p> <p>1.21.4 N‐acetylcysteine (NAC) appeared to be associated with an increase in sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 3.30, 95% CI 1.80 to 4.80, 211 men, 1 RCT, P &lt; 0.0001, I<sup>2</sup> = not applicable). </p> <p>1.21.5 PUFAs appeared to be associated with an increase in sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>) (MD 12.50, 95% CI 11.39 to 13.61, 227 men, 1 RCT, P &lt; 0.00001, I<sup>2</sup> = not applicable).  </p> <p>1.21.6 Selenium appeared to be associated with an increase in sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 4.10, 95% CI 2.45 to 5.75, 211 men, 1 RCT, P &lt; 0.00001, I<sup>2</sup> = not applicable). </p> <p>1.21.7 Selenium plus N‐acetylcysteine (NAC) appeared to be associated with an increase in sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 8.60, 95% CI 6.89 to 10.31, 210 men, 1 RCT, P &lt; 0.00001 I<sup>2</sup> = not applicable). </p> <p>1.21.8 Vitamin D plus calcium did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a>) (MD ‐2.50, 95% CI ‐8.18 to 3.18, 269 men, 1 RCT, P = 0.39, I<sup>2</sup> = not applicable). </p> <p>1.21.9 Vitamin E did not show evidence of increased sperm concentration when compared with no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>) (MD 5.90, 95% CI ‐10.83 to 22.63, 45 men, 1 RCT, P = 0.49, I<sup>2</sup> = not applicable). </p> <p>1.21.10 Two studies compared zinc with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of increased sperm concentration (MD 5.51, 95% CI ‐4.00 to 15.01, 105 men, 2 RCTs, P = 0.26, I<sup>2</sup> = 0%). </p> <p>1.21.11 Three studies compared zinc plus folic acid with placebo (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). As heterogeneity was high (84%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0039"> <li> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> did not show evidence of increased sperm concentration when compared with placebo (MD 17.70, 95% CI ‐1.88 to 37.28, 54 men, P = 0.08); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐9.00, 95% CI ‐19.00 to 1.00, 853 men, P = 0.08); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a> did show an increase in sperm concentration when compared with placebo (MD 26.40, 95% CI 6.33 to 46.47, 49 men, P = 0.01). </p> </li> </ul> </p> <p>1.21.12 Six studies (7 intervention arms) compared combined antioxidants to placebo or no treatment (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>). As the heterogeneity was very high (91%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0040"> <li> <p><a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a> did not show evidence of increased sperm concentration when compared with placebo (MD 5.50, 95% CI ‐6.57 to 17.57, 60 men, P = 0.37); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a> did show an increase in sperm concentration when compared with placebo (MD 7.70, 95% CI 2.41 to 12.99, 104 men, P = 0.004); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> did not show evidence of increased sperm concentration when compared with placebo (MD 4.50, 95% CI ‐12.17 to 21.17, 80 men, P = 0.60); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> did show an increase in sperm concentration when compared with placebo (MD 16.48, 95% CI 13.08 to 19.87, 125 men, P &lt; 0.00001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> did show an increase in sperm concentration when compared with placebo (MD 2.00, 95% CI 1.06 to 2.94, 90 men, P &lt; 0.0001); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐2.60, 95% CI ‐25.30 to 20.10, 75 men, P = 0.82). </p> </li> </ul> </p> <p>There was evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 246.11, P &lt; 0.00001). </p> <p><b><i>1.22 Data not usable for meta‐analysis</i> </b> </p> <p><a href="./references#CD007411-fig-0034" title="">Analysis 1.22</a> </p> <p>One study (<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>) provided data as percentage improvement and therefore could not be used in the forest plot. The percentage improvement was higher in the two intervention groups than in the placebo group (P = 0.01).  </p> </section> <section id="CD007411-sec-0094"> <h5 class="title">1.23 Sperm concentration at nine months; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0035" title="">Analysis 1.23</a>. </p> <p>We analysed this outcome using a fixed‐effect model. We used only subtotals in this analysis. </p> <p>1.23.1 Carnitines (three intervention arms) did not show evidence of increased sperm concentration when compared with placebo (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 4.17, 95% CI ‐1.71 to 10.06, 59 men, 1 RCT, 3 intervention arms, P = 0.16, I<sup>2</sup> = not applicable). </p> <p>1.23.2 Three studies compared coenzyme Q10 with placebo (<a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). As the heterogeneity was extremely high (95%), we have not reported the pooled analysis; individually their results were: </p> <p> <ul id="CD007411-list-0041"> <li> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> did not show evidence of increased sperm concentration when compared with placebo (MD ‐5.40, 95% CI ‐15.75 to 4.95, 60 men, P = 0.31); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> did show an increase in sperm concentration when compared with placebo (MD 1.60, 95% CI 0.53 to 2.67, 194 men, P = 0.003); </p> </li> <li> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> did show an increase in sperm concentration when compared with placebo (MD 6.20, 95% CI 5.17 to 7.23, 225 men, P &lt; 0.00001). </p> </li> </ul> </p> <p>1.23.3 Vitamin E did not show evidence of increased sperm concentration when compared with no treatment (<a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>) (MD 11.40, 95% CI ‐2.56 to 25.36, 45 men, 1 RCT, P = 0.11, I<sup>2</sup> = not applicable). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 1.10, P = 0.58). </p> </section> <section id="CD007411-sec-0095"> <h5 class="title">1.24 Sperm concentration over time</h5> <p>See <a href="./references#CD007411-fig-0036" title="">Analysis 1.24</a>. </p> <p>This analysis was only useful in directly comparing the same studies reporting at the three time points and not in comparing results of meta‐analyses that included different subsets of studies. </p> <p>1.24.1 Total sperm concentration at three months or less. We analysed this outcome using a fixed‐effect model (MD 5.49, 95% CI 5.02 to 5.96, 2535 men, 35 RCTs, 47 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 91%) and used subtotals (<a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a>; <a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a>; <a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>; <a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a>; <a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a>; <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a>; <a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a>; <a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a>; <a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a>; <a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>; <a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a>). </p> <p>1.24.2 Total sperm concentration at six months. We analysed this outcome using a fixed‐effect model (MD 7.21, 95% CI 6.73 to 7.70, 2995 men, 19 RCTs, 28 intervention arms, P &lt; 0.00001, I<sup>2</sup> = 92%) and used subtotals (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>). </p> <p>1.24.3 Total sperm concentration at nine months or more. We analysed this outcome using a fixed‐effect model (MD 3.95, 95% CI 3.22 to 4.69, 583 men, 5 RCTs, seven intervention arms, P &lt; 0.00001, I<sup>2</sup> = 86%) and used subtotals (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>; <a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a>; <a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>; <a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a>). </p> </section> </section> <section id="CD007411-sec-0096"> <h4 class="title">2. Head‐to‐head antioxidants (natural conception and undergoing fertility treatment)</h4> <p>The studies included in this comparison did not report on adverse events.</p> <section id="CD007411-sec-0097"> <h5 class="title">2.1 Live birth; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0037" title="">Analysis 2.1</a>. </p> <p>2.1.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased live birth rate when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 1.00, 95% CI 0.13 to 7.92, 30 men, 1 RCT, P = 1.00). </p> <p>2.1.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased live birth rate when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30 men, 1 RCT, P = 0.20). </p> <p>2.1.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased live birth rate when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30 men, 1 RCT, P = 0.20). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 0.79, P = 0.67) </p> </section> <section id="CD007411-sec-0098"> <h5 class="title">2.2 Clinical pregnancy; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0038" title="">Analysis 2.2</a>. </p> <p>2.2.1. L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased clinical pregnancy rate when compared with  L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 1.00, 95% CI 0.13 to 7.92, 30 men, 1 RCT, P = 1.00). </p> <p>2.2.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased clinical pregnancy rate when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30 men,1 RCT, P = 0.20). </p> <p>2.2.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased clinical pregnancy rate when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (Peto OR 0.34, 95% CI 0.06 to 1.79, 30 men,1 RCT, P = 0.20). </p> <p>2.2.4 L‐carnitine versus coenzyme Q10. There was no evidence of the use of L‐carnitine and increased clinical pregnancy rate when compared with coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (Peto OR 1.48, 95% CI 0.54 to 4.05, 156 men, 1 RCT, P = 0.44). </p> <p>2.2.5 L‐carnitine versus L‐carnitine plus coenzyme Q10. There was no evidence of the use of L‐carnitine and increased clinical pregnancy rate when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (Peto OR 0.62, 95% CI 0.27 to 1.46, 156 men, 1 RCT, P = 0.28). </p> <p>2.2.6 Coenzyme Q10 versus L‐carnitine plus coenzyme Q10. There was no evidence of the use of coenzyme Q10 and increased clinical pregnancy rate when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (Peto OR 0.43, 95% CI 0.18 to 1.06, 156 men, 1 RCT, P = 0.07). </p> <p>2.2.7 Vitamin D plus calcium versus vitamin E plus vitamin C. There appeared to be an association between the use of vitamin D plus calcium and increased clinical pregnancy rate when compared with vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>) (Peto OR 5.13, 95% CI 1.21 to 21.79, 86 men, P = 0.03). </p> <p>2.2.8 Combined antioxidants versus L‐carnitine. There was no evidence of the use of combined antioxidants and increased clinical pregnancy rate when compared with L‐carnitine (<a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>) (Peto OR 1.93, 95% CI 0.20 to 19.08, 89 men, P = 0.57). </p> <p>There was no evidence that different antioxidants had differing effects (test for subgroup differences: Chi² = 12.59, P = 0.08). </p> </section> <section id="CD007411-sec-0099"> <h5 class="title">2.3 Sperm DNA fragmentation; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0039" title="">Analysis 2.3</a>. </p> <p>2.3.1 L‐carnitine versus coenzyme Q10. There was no evidence of the use of L‐carnitine and decreased DNA fragmentation when compared with coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD ‐0.80, 95% CI ‐2.22 to 0.62, 125 men, P = 0.27). </p> <p>2.3.2 L‐carnitine versus L‐carnitine plus coenzyme Q10. There was no evidence of the use of L‐carnitine and decreased DNA fragmentation when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 0.40, 95% CI ‐1.14 to 1.94, 125 men, P = 0.61). </p> <p>2.3.3 Coenzyme Q10 verus L‐carnitine plus coenzyme Q10. There was no evidence of the use of coenzyme Q10 and decreased DNA fragmentation when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 1.20, 95% CI ‐0.25 to 2.65, 126 men, P = 0.11). </p> <p>2.3.4 L‐carnitine versus vitamin B1. There was no evidence of the use of L‐carnitine and decreased DNA fragmentation when compared with vitamin B1 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD ‐1.50, 95% CI ‐3.22 to 0.22, 136 men, P = 0.09). </p> <p>2.3.5 Coenzyme Q10 versus vitamin B1. There was no evidence of the use of coenzyme Q10 and decreased DNA fragmentation when compared with vitamin B1 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD ‐0.70, 95% CI ‐2.34 to 0.94, 137 men, P = 0.40). </p> <p>2.3.6 Vitamin B1 versus L‐carnitine plus coenzyme Q10. There appeared to be an association between the use of vitamin B1 and increased DNA fragmentation when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 1.90, 95% CI 0.16 to 3.64, 137 men, P = 0.03). </p> </section> <section id="CD007411-sec-0100"> <h5 class="title">2.4 Total sperm motility at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0040" title="">Analysis 2.4</a>. </p> <p>2.4.1 Coenzyme Q10 200 mg versus coenzyme Q10 400 mg. There was no evidence of the use of coenzyme Q10 200 mg/day and increased sperm motility when compared with coenzyme Q10 400 mg/day (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>) (MD ‐4.86, 95% CI ‐10.60 to 0.88, 65 men, P = 0.10).  </p> <p>2.4.2 Docosahexaenoic acid (DHA) 400 mg versus DHA 800 mg. There was no evidence of the use of DHA 400 g/day and increased sperm motility when compared with DHA 800 mg/day (<a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>) (MD 7.40, 95% CI ‐11.35 to 26.15, 19 men, P = 0.44). </p> <p>2.4.3 DHA versus DHA plus vitamin E. There appeared to be an association between the use of DHA and decreased sperm motility when compared with DHA combined with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐3.77, 95% CI ‐5.42 to ‐2.12, 90 men, P &lt; 0.00001). </p> <p>2.4.4 DHA versus vitamin E. There was no evidence of the use of DHA and increased sperm motility when compared with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐1.60, 95% CI ‐3.30 to 0.10, 90 men, P = 0.07). </p> <p>2.4.5 DHA plus vitamin E versus vitamin E. There appeared to be an association between the use of DHA plus vitamin E and increased sperm motility when compared with vitamin E alone (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD 2.17, 95% CI 0.54 to 3.80, 90 men, P = 0.009).  </p> <p>2.4.6 Ethylcysteine versus vitamin E. There was no evidence of the use of ethyl cysteine and increased sperm motility when compared with vitamin E (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>) (MD ‐1.90, 95% CI ‐41.97 to 38.17, 10 men, P = 0.93). </p> <p>2.4.7 L‐acetyl carnitine plus L carnitine versus vitamin E plus vitamin C. There appeared to be an association between the use of L acetyl carnitine + L carnitine and increased sperm motility when compared with vitamin E + vitamin C (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>) (MD 23.10, 95% CI 20.14 to 26.06, 138 men, P &lt; 0.00001). </p> <p>2.4.8 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 3.40, 95% CI ‐3.73 to 10.53, 30 men, P = 0.35). </p> <p>2.4.9 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 4.80, 95% CI ‐1.76 to 11.36, 30 men, P = 0.15). </p> <p>2.4.10 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 1.40, 95% CI ‐6.42 to 9.22, 30 men, P = 0.73). </p> <p>2.4.11 Selenium versus combined antioxidants. There was no evidence of the use of selenium and increased sperm motility when compared with combined antioxidants (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>) (MD 3.20, 95% CI ‐10.13 to 16.53, 46 men, P = 0.64). </p> <p>2.4.12 Vitamin C 200 mg versus vitamin C 1000 mg. There appeared to be an association between the use of ascorbic acid 200 mg/day and decreased sperm motility when compared with ascorbic acid 1000 mg/day (<a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a>) (MD ‐43.00, 95% CI ‐67.10 to ‐18.90, 20 men, P = 0.0005). </p> <p>2.4.13 Vitamin E plus "compound amino acids" versus vitamin E. There appeared to be an association between the use of vitamin E plus "compound amino acids" and increased sperm motility when compared with vitamin E only (<a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>) (MD 11.90, 95% CI 8.71 to 15.09, 120 men, P &lt; 0.00001). The authors of the study did not define the "compound amino acids" in more detail. </p> <p>2.4.14 Zinc versus folic acid. Two studies compared zinc with folic acid and did not show evidence of an increased sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD ‐3.01, 95% CI ‐11.38 to 5.35, 124 men, P = 0.48, I<sup>2</sup> = 0%). </p> <p>2.4.15 Zinc versus zinc plus folic acid. Two studies compared zinc with zinc plus folic acid and did not show evidence of an increased sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD ‐2.91, 95% CI ‐10.92 to 5.10, 125 men, P = 0.48, I<sup>2</sup> = 0%). </p> <p>2.4.16 Zinc plus folic acid versus folic acid. Two studies compared zinc plus folic acid with folic acid only and did not show evidence of an increased sperm motility (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) (MD 0.24, 95% CI‐6.17 to 6.66, 121 men, P = 0.94, I<sup>2</sup> = 0%). </p> <p>2.4.17 Zinc versus zinc plus vitamin E. There was no evidence of the use of zinc and increased sperm motility when compared with zinc plus vitamin E (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>) (MD ‐1.00, 95% CI ‐15.00 to 13.00, 18 men, P = 0.89). </p> <p>2.4.18 Zinc versus zinc plus vitamin E plus vitamin C. There was no evidence of the use of zinc and increased sperm motility when compared with zinc plus vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>) (MD ‐1.00, 95% CI ‐19.66 to 17.66, 12 men, P = 0.92). </p> <p>2.4.19 Zinc plus vitamin E versus zinc plus vitamin E plus vitamin C. There was no evidence of the use of zinc plus vitamin E and increased sperm motility when compared with zinc plus vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a>) (MD ‐0.00, 95% CI ‐18.97 to 18.97, 18 men, P = 1.00).<br/>  </p> </section> <section id="CD007411-sec-0101"> <h5 class="title">2.5 Total sperm motility at six months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0041" title="">Analysis 2.5</a>. </p> <p>2.5.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 4.10, 95% CI ‐2.70 to 10.90, 30 men, P = 0.24). </p> <p>2.5.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 3.40, 95% CI ‐2.87 to 9.67, 30 men, P = 0.29). </p> <p>2.5.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD ‐0.70, 95% CI ‐7.73 to 6.33, 30 men, P = 0.85). </p> <p>2.5.4 N‐acetylcysteine versus selenium plus NAC. There appeared to be an association between the use of NAC and decreased sperm motility when compared with selenium plus NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD ‐4.40, 95% CI ‐5.14 to ‐3.66, 234 men, P &lt; 0.00001). </p> <p>2.5.5 Selenium versus N‐acetylcysteine (NAC). There appeared to be an association between the use of selenium and increased sperm motility when compared with NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 1.30, 95% CI 0.56 to 2.04, 234 men, P = 0.0006). </p> <p>2.5.6 Selenium versus selenium plus N‐acetylcysteine (NAC). There appeared to be an association between the use of selenium and decreased sperm motility when compared with selenium plus NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD ‐3.10, 95% CI ‐3.85 to ‐2.35, 232 men, P &lt; 0.00001). </p> <p>2.5.7 Zinc versus folic acid. Two studies compared zinc with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of the use of zinc and increased sperm motility when compared with folic acid (MD ‐1.03, 95% CI ‐5.18 to 3.13, 125 men, P = 0.63, I<sup>2</sup> = 0%). </p> <p>2.5.8 Zinc versus zinc plus folic acid. Two studies compared zinc with zinc plus folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of the use of zinc and increased sperm motility when compared with zinc plus folic acid (MD ‐1.69, 95% CI ‐6.95 to 3.58, 127 men, P = 0.53, I<sup>2</sup> = 0%). </p> <p>2.5.9 Zinc plus folic acid versus folic acid. Two studies compared zinc plus folic acid with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of the use of zinc plus folic acid and increased sperm motility when compared with folic acid only (MD 1.03, 95% CI ‐4.23 to 6.29, 126 men, P = 0.70, I<sup>2</sup> = 0%). </p> </section> <section id="CD007411-sec-0102"> <h5 class="title">2.6 Total sperm motility at nine months or more; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0042" title="">Analysis 2.6</a>. </p> <p>2.6.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 3.70, 95% CI ‐1.69 to 9.09, 30 men, P = 0.18). </p> <p>2.6.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 5.30, 95% CI ‐0.73 to 11.33,30 men, P = 0.08). </p> <p>2.6.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 1.60, 95% CI ‐3.29 to 6.49, 30 men, P = 0.52). </p> </section> <section id="CD007411-sec-0103"> <h5 class="title">2.7 Progressive sperm motility at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0043" title="">Analysis 2.7</a>. </p> <p>2.7.1 Coenzyme Q10 200 mg versus coenzyme Q10 400 mg. There was no evidence of the use of coenzyme 200 mg/day and increased progressive sperm motility when compared with coenzyme Q10 400 mg/day (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>) (MD ‐3.52, 95% CI ‐9.71 to 2.67, 65 men, P = 0.26). </p> <p>2.7.2 Docosahexaenoic acid (DHA) versus DHA plus vitamin E. There appeared to be an association between the use of DHA and decreased progressive sperm motility when compared with DHA combined with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐2.22, 95% CI ‐3.50 to 0.94, 90 men, P = 0.0007). </p> <p>2.7.3 DHA versus vitamin E. There was no evidence of the use of DHA and increased progressive sperm motility when compared with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐0.39, 95% CI ‐1.67 to 0.89, 90 men P = 0.55).  </p> <p>2.7.4 DHA plus vitamin E versus vitamin E. There appeared to be an association between the use of DHA plus vitamin E and increased progressive sperm motility when compared with vitamin E alone (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD 1.83, 95% CI 0.68 to 2.98, 90 men, P = 0.002).  </p> <p>2.7.5 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 4.00, 95% CI ‐1.88 to 9.88, 30 men, P = 0.18). </p> <p>2.7.6 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 5.00, 95% CI ‐0.68 to 10.68, 29 men, P = 0.08) </p> <p>2.7.7 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased progressive sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 1.00, 95% CI ‐5.41 to 7.41, 29 men, P = 0.76). </p> <p>2.7.8 L‐carnitine versus vitamin B1. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with vitamin B1 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 1.70, 95% CI ‐1.54 to 4.94, 136 men, P = 0.30).  </p> <p>2.7.9 L‐carnitine versus coenzyme Q10. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 1.30, 95% CI ‐1.70 to 4.30, 125 men, P = 0.40).  </p> <p>2.7.10 L‐carnitine versus L‐carnitine plus coenzyme Q10. There appeared to be an association between the use of L‐carnitine and decreased progressive sperm motility when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD ‐8.20, 95% CI ‐12.31 to ‐4.09, 125 men, P &lt; 0.0001).  </p> <p>2.7.11 Coenzyme Q10 versus L‐carnitine plus coenzyme Q10. There appeared to be an association between the use of coenzyme Q10 and decreased progressive sperm motility when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD ‐9.50, 95% CI ‐13.54 to ‐5.46, 126 men, P &lt; 0.00001).  </p> <p>2.7.12 Coenzyme Q10 versus vitamin B1. There was no evidence of the use of coenzyme Q10 and increased progressive sperm motility when compared with vitamin B1 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD 0.40, 95% CI ‐2.75 to 3.55, 137 men, P = 0.80).  </p> <p>2.7.13 Vitamin B1 versus L‐carnitine plus coenzyme Q10. There appeared to be an association between the use of vitamin B1 and decreased progressive sperm motility when compared with L‐carnitine plus coenzyme Q10 (<a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>) (MD‐9.90, 95% CI ‐14.12 to ‐5.68, 137 men, P &lt; 0.00001).  </p> <p>2.7.14 L‐acetyl carnitine versus L‐carnitine plus vitamin E plus vitamin C. There appeared to be an association between the use of L‐acetyl carnitine and increased progressive sperm motility when compared with L‐carnitine plus vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a>) (MD 13.30, 95% CI 11.21 to 15.39, 138 men, P &lt; 0.00001). </p> <p>2.7.15 L‐carnitine versus vitamin E plus vitamin C. There appeared to be an association between the use of L‐carnitine and increased progressive sperm motility when compared with vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>) (MD 30.50, 95% CI 27.70 to 33.30, 63 men, P &lt; 0.00001). </p> <p>2.7.16 L‐carnitine versus vitamin E. There appeared to be an association between the use of L‐carnitine and increased progressive sperm motility when compared with vitamin E (<a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>) (MD 1.90, 95% CI 1.31 to 2.49, 212 men, P &lt; 0.00001).  </p> <p>2.7.17 L‐carnitine plus vitamin E versus vitamin E. There appeared to be an association between the use of L‐carnitine plus vitamin E and increased progressive sperm motility when compared with vitamin E (<a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>) (MD 14.10, 95% CI 10.11 to 18.09, 113 men, P &lt; 0.00001). </p> <p>2.7.18 Vitamin D plus calcium versus vitamin E plus vitamin C. There appeared to be an association between the use of vitamin D plus calcium and increased progressive sperm motility when compared with vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a>) (MD 6.90, 95% CI 5.38 to 8.42, 86 men, P &lt; 0.000001). </p> <p>2.7.19 Vitamin E plus "compound amino acids" versus vitamin E. There appeared to be an association between the use of vitamin E plus "compound amino acids" and increased progressive sperm motility when compared with vitamin E only (<a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a>) (MD 6.10, 95% CI 3.87 to 8.33, 120 men, P &lt; 0.00001). The authors of the study did not define the "compound amino acids" in more detail. </p> </section> <section id="CD007411-sec-0104"> <h5 class="title">2.8 Progressive sperm motility at six months; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0044" title="">Analysis 2.8</a>. </p> <p>2.8.1 L‐carnitine versus L‐acetyl carnitine. There appeared to be an association between the use of L‐carnitine and increased progressive sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 6.30, 95% CI 0.42 to 12.18, 30 men, P = 0.04). </p> <p>2.8.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of a difference in progressive sperm motility when L‐carnitine was compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 5.70, 95% CI 0.10 to 11.30, 29 men, P = 0.05).  </p> <p>2.8.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of a difference in progressive sperm motility when L‐acetyl carnitine was compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD ‐0.60, 95% CI ‐6.93 to 5.73, 29 men, P = 0.85). </p> <p><b><i>2.9 Progressive motility at six months (data not suitable for meta‐analysis)</i> </b> </p> <p><a href="./references#CD007411-fig-0045" title="">Analysis 2.9</a> </p> <p>One study (<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>) compared coenzyme Q10 versus glutathione and provided data as percentage improvement and therefore could not be used in the forest plot. The authors did not provide a P value of the head‐to‐head comparison. </p> </section> <section id="CD007411-sec-0105"> <h5 class="title">2.10 Progressive sperm motility at nine months or more; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0046" title="">Analysis 2.10</a>. </p> <p>2.10.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 3.80, 95% CI ‐1.50 to 9.10, 30 men, P = 0.16). </p> <p>2.10.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased progressive sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 5.50, 95% CI ‐0.11 to 11.11,29 men, P = 0.05). </p> <p>2.10.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased progressive sperm motility when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 1.70, 95% CI ‐4.17 to 7.57, 29 men, P = 0.57). </p> </section> <section id="CD007411-sec-0106"> <h5 class="title">2.11 Sperm concentration at three months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0047" title="">Analysis 2.11</a>. </p> <p>2.11.1 Coenzyme Q10 200 mg versus coenzyme Q10 400 mg. There was no evidence of the use of the use of coenzyme Q10 200 mg/day and increased sperm concentration when compared with coenzyme Q10 400 mg/day (<a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a>) (MD 0.20, 95% CI ‐3.26 to 3.66, 65 men, P = 0.91). </p> <p>2.11.2 Docosahexaenoic acid (DHA) 400 mg versus DHA 800 mg. There was no evidence of the use of DHA 400 mg/day and increased sperm concentration when compared with DHA 800 mg/day (<a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a>) (MD ‐6.80, 95% CI ‐41.87 to 28.27, 19 men, P = 0.70). </p> <p>2.11.3 DHA versus DHA + vitamin E. There appeared to be an association between the use of DHA and decreased sperm concentration when compared with DHA combined with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐1.45, 95% CI ‐2.47 to ‐0.43, 90 men, P = 0.005). </p> <p>2.11.4 DHA versus vitamin E. There was no evidence of the use of DHA and increased sperm concentration when compared with vitamin E (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD ‐0.24, 95% CI ‐1.26 to 0.78, 90 men, P = 0.64).  </p> <p>2.11.5 DHA plus vitamin E versus vitamin E. There appeared to be an association between the use of DHA plus vitamin E and increased sperm concentration when compared with vitamin E alone (<a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>) (MD 1.21, 95% CI 0.28 to 2.14, 90 men, P = 0.01).  </p> <p>2.11.6 Ethyl cysteine versus vitamin E. There was no evidence of the use of ethyl cysteine and increased sperm concentration when compared with vitamin E (<a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a>) (MD 2.20, 95% CI ‐16.65 to 21.05, 10 men, P = 0.82). </p> <p>2.11.7 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 1.70, 95% CI ‐10.97 to 14.37, 30 men, P = 0.79). </p> <p>2.11.8 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 4.10, 95% CI ‐9.17 to 17.37, 30 men, P = 0.54). </p> <p>2.11.9 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 2.40, 95% CI ‐11.14 to 15.94, 30 men, P = 0.73). </p> <p>2.11.10 L‐carnitine versus vitamin E plus vitamin C. There appeared to be an association between the use of L‐carnitine and increased sperm concentration when compared with vitamin E plus vitamin C (<a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a>) (MD 15.50, 95% CI 12.49 to 18.51, 63 men, P &lt; 0.00001). </p> <p>2.11.11 L‐carnitine versus vitamin E. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with vitamin E (<a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a>) (MD 0.70, 95% CI ‐0.34 to 1.74, 212 men, P = 0.19). </p> <p>2.11.12 L‐carnitine plus vitamin E versus vitamin E. There was no evidence of the use of L‐carnitine plus vitamin E and increased sperm concentration when compared with vitamin E (<a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a>) (MD 1.90, 95% CI ‐10.52 to 14.32, 113 men, P = 0.76). </p> <p>2.11.13 Selenium versus combined antioxidants. There was no evidence of the use of selenium and increased sperm concentration when compared with combined antioxidants (<a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>) (MD 14.70, 95% CI ‐6.51 to 35.91, 46 men, P = 0.17). </p> <p>2.11.14 Zinc versus folic acid. Two studies compared zinc with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) and did not show evidence of the use of zinc and increased sperm concentration when compared with folic acid (MD ‐1.30, 95% CI ‐8.65 to 6.06, 124 men, P = 0.73, I<sup>2</sup> = 0%). </p> <p>2.11.15 Zinc plus folic acid versus folic acid. Two studies compared zinc plus folic acid with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) and did not show evidence of the use of zinc plus folic acid and increased sperm concentration when compared with folic acid only (MD 2.93, 95% CI ‐3.67 to 9.54, 125 men, P = 0.38, I<sup>2</sup> = 0%). </p> <p>2.11.16 Zinc versus zinc plus folic acid. Two studies compared zinc with zinc plus folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a>) and did not show evidence of the use of zinc and increased sperm concentration when compared with zinc plus folic acid (MD ‐4.11, 95% CI ‐9.79 to 1.57, 121 men, P = 0.16, I<sup>2</sup> = 0%). </p> </section> <section id="CD007411-sec-0107"> <h5 class="title">2.12 Sperm concentration at six months or less; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0048" title="">Analysis 2.12</a>. </p> <p>2.12.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 5.90, 95% CI ‐8.92 to 20.72, 30 men, P = 0.44). </p> <p>2.12.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 8.10, 95% CI ‐5.54 to 21.74, 30 men, P = 0.24). </p> <p>2.12.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 2.20, 95% CI ‐10.89 to 15.29, 30 men, P = 0.74). </p> <p>2.12.4 N‐acetylcysteine (NAC) versus selenium plus NAC. There appeared to be an association between the use of NAC and decreased sperm concentration when compared with selenium plus NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD ‐5.30, 95% CI ‐6.86 to ‐3.74, 234 men, P &lt; 0.00001). </p> <p>2.12.5 Selenium versus N‐acetylcysteine (NAC). There was no evidence of the use of selenium and increased sperm concentration when compared with NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD 0.80, 95% CI ‐0.71 to 2.31, 234 men, P = 0.30). </p> <p>2.12.6 Selenium versus selenium plus N‐acetylcysteine (NAC). There appeared to be an association between the use of selenium and decreased sperm concentration when compared with selenium plus NAC (<a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>) (MD ‐4.50, 95% CI ‐6.20 to ‐2.80, 232 men, P &lt; 0.00001). </p> <p>2.12.7 Zinc versus folic acid. Two studies compared zinc with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did show an association between the use of zinc and decreased sperm concentration when compared with folic acid (MD ‐10.10, 95% CI ‐19.12 to ‐1.08, 125 men, P = 0.03, I<sup>2</sup> = 0%). </p> <p>2.12.8 Zinc plus folic acid versus folic acid. Two studies compared zinc plus folic acid with folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of the use of zinc plus folic acid and increased sperm concentration when compared with folic acid only (MD ‐13.58, 95% CI ‐25.99 to ‐1.17, 127 men, P = 0.03, I<sup>2</sup> = 23%). </p> <p>2.12.9 Zinc versus zinc plus folic acid. Two studies compared zinc with zinc plus folic acid (<a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a>; <a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a>) and did not show evidence of the use of zinc and increased sperm concentration when compared with zinc plus folic acid (MD 1.78, 95% CI ‐9.93 to 13.49, 126 men, P = 0.77, I<sup>2</sup> = 0%). </p> <p><b><i>2.13 Sperm concentration at six months (data not suitable for meta‐analysis)</i> </b> </p> <p>One study (<a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>) compared coenzyme Q10 with glutathione and provided data as percentage improvement, and therefore could not be used in the forest plot. The authors did not provide a P value for this head‐to‐head comparison.  </p> </section> <section id="CD007411-sec-0108"> <h5 class="title">2.14 Sperm concentration at nine months or more; type of antioxidant</h5> <p>See <a href="./references#CD007411-fig-0050" title="">Analysis 2.14</a>. </p> <p>Pooling was not possible in this analysis as only one study reported on two subgroups.</p> <p>2.14.1 L‐carnitine versus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 8.20, 95% CI ‐0.07 to 16.47, 30 men, P = 0.05). </p> <p>2.14.2 L‐carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD 6.10, 95% CI ‐3.74 to 15.94, 30 men, P = 0.22). </p> <p>2.14.3 L‐acetyl carnitine versus L‐carnitine plus L‐acetyl carnitine. There was no evidence of the use of L‐acetyl carnitine and increased sperm concentration when compared with L‐carnitine plus L‐acetyl carnitine (<a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a>) (MD ‐2.10, 95% CI ‐10.24 to 6.04, 30 men, P = 0.61). </p> </section> <section id="CD007411-sec-0109"> <h5 class="title">Funnel plot</h5> <p>We assessed publication bias by using a funnel plot. The outcomes live birth and clinical pregnancy included 12 and 20 studies, respectively.  </p> <p>For the outcome of live birth, there was suspected publication bias (<a href="#CD007411-fig-0005">Figure 5</a>). The funnel plot shows a remarkable lack of studies in the left lower section. This could be due to the fact that relatively small studies that do not show an increase of live birth with antioxidants, were not published. For the outcome of clinical pregnancy, there was no clear evidence of publication bias (<a href="#CD007411-fig-0007">Figure 7</a>). We did not have enough studies to look at each of the subgroups for publication bias.   </p> <p>The studies reporting on the primary outcome of live birth did not all have study characteristics in common. They differed in terms of sample size, type and age of studied population, treatment period, and intervention and control. The results of the semen parameters in these studies were similar to those from the other included studies; the great majority did not show a significant improvement in semen parameters.  </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007411-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007411-sec-0110"></div> <section id="CD007411-sec-0111"> <h3 class="title" id="CD007411-sec-0111">Summary of main results</h3> <p>Effectiveness of antioxidants versus placebo or no treatment</p> <p><i>Live birth</i> </p> <p>Evidence of low quality suggests that for subfertile men, the use of antioxidants may be effective in increasing a couple's chances of having a live birth when compared to placebo or no treatment. It was found within the studies that contributed to the analysis of live birth rate, that for subfertile men with a baseline live birth rate of 16%, with the use of an antioxidant this rate could increase to between 17% and 27%. However, there were only 12 studies with a total of 1283 couples reporting on live birth and the certainty of this evidence was considered to be very low (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). The methods were not well explained in three out of 12 of these studies (<a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>), two studies had a significant number of participants who dropped out of the study (<a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>), and <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>, <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>, and <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a> used 'no treatment' as control which introduced a degree of performance bias. When these four high‐risk studies were removed from the analysis, there was no evidence of association between the use of antioxidants and increased live birth. </p> <p>The apparent benefit from antioxidants did not persist when analyses were restricted to placebo‐controlled studies. There was no evidence of increased live birth with the use of antioxidants in studies enrolling men undergoing assisted reproductive techniques (ART) (in vitro fertilisation (IVF)/intracytoplasmic sperm injection(ICSI)). </p> <p><i>Clinical pregnancy</i> </p> <p>The findings of this review also suggest that for subfertile men the use of antioxidants may be effective in increasing a couple's chances of clinical pregnancy rate when compared to placebo or no treatment. It was found that within the studies that contributed to the analysis of clinical pregnancy, the population of subfertile men had a baseline or expected clinical pregnancy rate of 15%,and with the use of antioxidants this would increase to between 20% and 30%. However, there were only 20 studies with a total of 1706 men reporting on clinical pregnancy and the certainty of this evidence was considered to be low (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). The methods were not well explained in six of the 20 studies, with three of these studies having a significant number of participants who dropped out of the study (<a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a>). Furthermore, five of the 25 analyses (one trial had three arms) crossed the line of no effect with wide confidence intervals. </p> <p>The apparent benefit from antioxidants persisted when analyses were restricted to studies at lower risk of bias, placebo‐controlled studies, studies of men not undergoing IUI, studies of men undergoing ART (IVF/ICSI), and studies of men post‐varicocelectomy. </p> <p><i>Adverse events</i> </p> <p>There is no evidence that antioxidants used by the subfertile male lead to an increased miscarriage risk when compared to placebo or no treatment. It was found that within this population of subfertile men with an expected miscarriage rate of 5%, the use of an antioxidant would increase the chances of having a miscarriage to between 4% and 13%. However, there were only six studies with a total of 664 men reporting on miscarriage and the certainty of this evidence was very low (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). The event rate in this analysis was very low with only 39 miscarriages reported in six studies, furthermore there was a high risk of bias within these studies. </p> <p>The use of antioxidants by subfertile men may increase the occurrence of mild gastrointestinal complaints when compared to placebo or no treatment. It was found that within this population of subfertile men with an expected gastrointestinal event rate of 2%, the use of an antioxidant would increase the chances of having gastrointestinal complaints to between 2% and 7%. However, there were only 16 studies with a total of 1355 men reporting on gastrointestinal complaints and the certainty of this evidence was low (<a href="./full#CD007411-tbl-0001">summary of findings Table 1</a>). The event rate in this analysis was low with only 46 events reported; furthermore there was a high risk of bias within these studies. </p> <p>There was no evidence that the risk of other adverse events, such as stillbirth and ectopic pregnancy, differed between antioxidant or control group. </p> <p><i>Sperm DNA fragmentation</i> </p> <p>Thirteen studies (1813 men) reported on DNA fragmentation with suitable data for meta‐analysis. Pooled analysis of these 13 studies was not possible due to high heterogeneity. Pooling of the results from the subgroups was not possible either because of heterogenic data. One study reported substantially higher DNA fragmentation rates (&gt; 80%) compared to other included studies, which could be explained by enrolment of participants post‐varicocelectomy (<a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a>). </p> <p><i>Sperm parameters</i> </p> <p>The pooled results for total sperm motility, progressive sperm motility and concentration at three, six and nine months were unreliable as heterogeneity was extremely high in each analysis. Studies could be pooled in some antioxidant subgroups, with differing results per type of antioxidant and duration of treatment. </p> <p><i>Effectiveness of antioxidants versus antioxidants (head‐to‐head)</i> </p> <p>In the head‐to‐head studies only four studies reported on live birth and/or clinical pregnancy; one study with different types of carnitines in multiple arms (versus placebo), one study comparing L‐carnitine with coenzyme Q10, and a combination of these two, one study comparing vitamin D plus calcium with vitamin E plus vitamin C, and one study comparing combined antioxidants with L‐carnitine (versus no treatment). Only vitamin D plus calcium showed an association. However, due to the small study size no direct conclusions can be drawn. The head‐to‐head studies did not report adverse events. </p> </section> <section id="CD007411-sec-0112"> <h3 class="title" id="CD007411-sec-0112">Overall completeness and applicability of evidence</h3> <p>Of the 90 studies included in this review, only 14 reported on the primary outcome of live birth, and only 22 reported on clinical pregnancy rate. Live birth and clinical pregnancy rate are the outcomes of most interest to subfertile couples and until these are robustly reported by all subfertility studies we will not be able to draw clear conclusions for the use of antioxidants for subfertile men. We believe that the lower baseline rate for clinical pregnancy than the baseline rate for live birth could be due to the difference in included populations. In the clinical pregnancy analysis (20 studies) there were four studies including men with varicocele; those studies did not report live birth and were therefore not included in the live birth rate analysis (12 studies). Adverse events such as miscarriage, ectopic pregnancy, stillbirth, gastrointestinal side effects, euphoria, headache, upper respiratory infection, and nasopharyngitis appear to be poorly reported, and the evidence is of very low certainty. The high heterogeneity may be an artefact caused by some studies reporting very small and potentially erroneous standard deviations (SDs). This undermines the credibility of the data. </p> <p>Three of the trials included in the analysis of the semen parameter outcomes (<a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>; <a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a>; <a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a>) had consistently reported SDs very much smaller than those reported by most of the other included trials. The review authors considered that these were potentially erroneous, but an attempt to check with the study authors was unsuccessful. One other trial (<a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a>), also had very small SDs when compared to data in the other trials, but the authors confirmed, when contacted, that they are indeed SDs and not standard errors (SEs). We tried to manage these analyses in two different ways: firstly by imputing SDs from studies of a similar size and secondly by treating the data as SEs and converting back to SDs, however heterogeneity remained high in both situations so for the final analyses we reverted to the SDs as reported in the studies. The low SDs may have been due to the strict inclusion and exclusion criteria indicating that the trial was homogenous in nature, however we were unable to carry out a sensitivity analysis on these trials as pooling was not possible due to high heterogeneity. For the analysis of sperm concentration at three months, the heterogeneity was low despite the small SDs reported in <a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a>. After sensitivity analysis the heterogeneity remained low, however this resulted in a confidence interval crossing the line of no effect. </p> <p>Eighteen of the 90 included trials were very small in size (randomising less than 50 men), 39 of 90 included trials were small in size (randomising between 50 and 100 men) and only 33 of 90 included trials included more than 100 men. The estimates of the intervention effect tend to be more beneficial in smaller studies. Smaller studies also may not be as rigorous as the larger studies in their methodology (<a href="./references#CD007411-bbs2-0234" title="HigginsJP , GreenS , editors.Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> <p>We tried to assess which type of antioxidant might have a beneficial effect on the outcomes of interest in this review, however only three studies at the most could be pooled in any antioxidant subgrouping. Eighteen studies (<a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a>; <a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a>; <a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a>; <a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a>; <a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a>; <a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a>; <a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a>; <a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a>; <a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a>; <a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a>; <a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a>; <a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a>; <a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a>; <a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a>) used combined antioxidants versus placebo or no treatment and were used in the meta‐analysis. Ten of these studies reported on clinical pregnancy rate, showing an association between the use of combined antioxidants and increased clinical pregnancy rate. Only five of these studies reported on live births, showing no evidence of an increased live birth with the use of combined antioxidants. When the analysis of clinical pregnancy rate was restricted to these five studies reporting live birth, there was no evidence of increased clinical pregnancy rate with the use of combined antioxidants. </p> <p>The head‐to‐head comparison does not provide constructive information as we could not pool direct comparisons. Subgrouping of antioxidants could be performed in 11 comparisons, each comparison pooling two studies. These were all studies comparing zinc with folic acid or a combination of the two. </p> <p>There were 29 studies that contained data that were unusable in the analysis, with either some or all of their data (<a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a>; <a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a>; <a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a>; <a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a>; <a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a>; <a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a>; <a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a>; <a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a>; <a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a>; <a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a>; <a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a>; <a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a>; <a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a>; <a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a>; <a href="./references#CD007411-bbs2-0050" title="Lu XL , LiuJJ , LiJT , YangQA , ZhangJM .Melatonin therapy adds extra benefit to varicecelectomy in terms of sperm parameters, hormonal profile and total antioxidant capacity: A placebo-controlled, double-blind trial. Andrologia2018;50(6):e13033. ">Lu 2018</a>; <a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a>; <a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a>; <a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a>; <a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a>; <a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a>; <a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a>; <a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a>; <a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a>; <a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a>; <a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a>; <a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a>; <a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a>; <a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a>; <a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a>). The reasons for this were baseline imbalance, no report of the number of patients in whom outcome was assessed, and presentation of percentages or mean differences (<a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a>; <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a>; <a href="./references#CD007411-fig-0028" title="">Analysis 1.16</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a>; <a href="./references#CD007411-fig-0034" title="">Analysis 1.22</a>). Attempts were made to contact these authors regarding the data. There was no clear evidence of publication bias. </p> </section> <section id="CD007411-sec-0113"> <h3 class="title" id="CD007411-sec-0113">Quality of the evidence</h3> <p>The evidence was graded as low to very low certainty. The main limitation was that out of the 67 included studies in the meta‐analysis only 20 studies reported clinical pregnancy, and of those 12 reported on live birth. Other limitations included poor reporting of study methods, imprecision, the number of small studies, reporting bias, and lack of data about adverse events. Publication bias was suspected for the outcome of live birth. </p> <p><a href="#CD007411-fig-0003">Figure 3</a> shows the review authors' judgements about the risk of bias of the studies included in this review. All included studies were described as randomised, however only just over 50% gave information on how the randomisation was achieved. Allocation concealment was described in only 36% of the studies. Blinding was better described with over 57% of the studies being double‐blinded or occasionally single‐blinded; 7% of studies stated that there was no blinding, and 20% of included studies used no treatment as a control. Dropout rates were high in some studies and dropout rates tended to be higher in the control groups, which created a potential for differential follow‐up with better reporting of clinical pregnancies in the intervention groups. Reporting bias was unclear in 68% of studies. </p> </section> <section id="CD007411-sec-0114"> <h3 class="title" id="CD007411-sec-0114">Potential biases in the review process</h3> <p>There may have been some potential for bias in the review process, as there were some changes in previous updates of the review compared to the protocol. These included additions and deletions to exclusion criteria such as the removal of pentoxifylline, and adding the new outcome progressive sperm motility. Some bias in the review process may have arisen due to the inclusion of studies that have had a dropout of participants of &gt; 20%, with subsequent imbalances in the number of participants between the treatment and control groups. </p> </section> <section id="CD007411-sec-0115"> <h3 class="title" id="CD007411-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>The results of our review are in agreement with those of other published systematic reviews. Two other reviews described the effects of L‐carnitine and L‐acetylcarnitine on subfertile men. The systematic review and meta‐analysis by Zhou and colleagues (<a href="./references#CD007411-bbs2-0296" title="ZhouX , LiuF , ZhaiS .Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review. Asia Pacific Journal of Clinical Nutrition2007;16 Suppl 1:383-90. [MEDLINE: 17392136]">Zhou 2007</a>) compared L‐carnitine and L‐acetylcarnitine therapy versus placebo treatment and found improvements in pregnancy rate and total sperm motility. <a href="./references#CD007411-bbs2-0294" title="ZhangX , CuiY , DongL , SunM , ZhangY .The efficacy of combined l-carnitine and l-acetyl carnitine in men with idiopathic oligoasthenoteratozoospermia: a systematic review and meta-analysis. Andrologia2020;52(2):e13470.">Zhang 2020</a> also found improved total sperm motility, progressive sperm motility, and pregnancy rates with the use of L‐carnitine and L‐acetyl carnitine. Our review was unable to pool the results of the carnitine studies due to inconsistencies between the studies and excluded biochemical and undefined pregnancy from the meta‐analysis. The descriptive review by Patel and Sigman (<a href="./references#CD007411-bbs2-0269" title="PatelSR , SigmanM .Antioxidant therapy in male infertility. Urologic Clinics of North America.2008;35(2):319-30. [MEDLINE: 18423251]">Patel 2008</a>) discusses the improvement in pregnancy rates with oral intake of antioxidants, however Patel states that randomised controlled trials (RCTs) have not shown an effect on sperm motility and that there is a need for more RCTs in men with oxidative stress. Furthermore, <a href="./references#CD007411-bbs2-0223" title="GargH , KumarR .An update on the role of medical treatment including antioxidant therapy in varicocele. Asian Journal of Andrology2016;18(2):222-8.">Garg 2016</a> discusses in a review the effect of antioxidants in men with varicocele. They conclude that antioxidant therapy is a potential option as primary treatment or adjunct after surgical repair of varicocele. <a href="./references#CD007411-bbs2-0287" title="WangJ , WangT , DingW , WuJ , WuG , WangY , et al.Efficacy of antioxidant therapy on sperm quality measurements after varicocelectomy: A systematic review and meta-analysis. Andrologia2019;51(10):e13396.">Wang 2019</a> discussed antioxidant therapy in men with varicocele as well, and found no evidence of increased pregnancy rate. </p> <p>Agarwal and colleagues discussed in both an overview of the literature (<a href="./references#CD007411-bbs2-0177" title="AgarwalA , NallellaKP , AllamaneniS , SaidTM .Role of antioxidants in treatment of male infertility: an overview of the literature. Reproductive Biomedicine Online2004;8(6):616-27.">Agarwal 2004</a>) and systematic review (<a href="./references#CD007411-bbs2-0256" title="MajzoubA , AgarwalA .Systematic review of antioxidant types and doses in male infertility: benefits on semen parameters, advanced sperm function, assisted reproduction and live-birth rate. Arab Journal of Urology 2 January 2018;16(1):113-24.">Majzoub 2018</a>), the effectiveness of antioxidants. In the 2004 overview Agarwal notes that vitamin E and a combination of vitamin E with other antioxidants such as N‐acetylcysteine, vitamin A and fatty acids appear to improve pregnancy rates in men with asthenozoospermia. This is in agreement with our review. However, their conclusion that carnitines also appear to have an effect on pregnancy rates could not be confirmed. In the systematic review <a href="./references#CD007411-bbs2-0256" title="MajzoubA , AgarwalA .Systematic review of antioxidant types and doses in male infertility: benefits on semen parameters, advanced sperm function, assisted reproduction and live-birth rate. Arab Journal of Urology 2 January 2018;16(1):113-24.">Majzoub 2018</a> included 29 studies, of which there were 19 RCTs and 10 prospective studies. In 26 studies they found a significant positive effect on basic semen parameters, advanced sperm function tests, ART outcomes or live birth rate. Specifically, a positive effect was seen on live birth rate and fertilisation rate when using vitamin E, vitamin C, carnitines, coenzyme Q10 and zinc. A difference between differing antioxidants was not seen in our review. </p> <p>Another review (<a href="./references#CD007411-bbs2-0275" title="RossC , MorrissA , KhairyM , KhalafY , BraudeP , CoomarasamyA , et al.A systematic review of the effect of oral antioxidants on male infertility. Reproductive Biomedicine Online2010;20(6):711-23. [PMID: 20378409]">Ross 2010</a>) showed improvement in pregnancy rate and sperm quality after antioxidant therapy. This is in agreement with our review, although we are uncertain of the sperm parameter outcomes due to the extreme heterogeneity. A systematic review (<a href="./references#CD007411-bbs2-0248" title="LafuenteR , Gonzalez-ComadranM , SolaI , LopezG , BrassescoM , CarrerasR , et al.Coenzyme Q10 and male infertility: a meta-analysis. Journal of Assisted Reproduction and Genetics.2013;30(9):1147-56.">Lafuente 2013</a>) looking at the effect of coenzyme Q10 and male subfertility found an association between this antioxidant and improved pregnancy rate, sperm concentration and motility. We did agree on the effect of coenzyme Q10 on sperm motility and concentration at six months, however we could not draw clear conclusions due to the heterogeneity in these analyses. A more recent systematic review with meta‐analysis studied the effectiveness of folate and folate plus zinc on sperm parameters in subfertile men (<a href="./references#CD007411-bbs2-0241" title="IraniM , AmirianM , SadeghiR , LezJL , Latifnejad RoudsariR .The effect of folate and folate plus zinc supplementation on endocrine parameters and sperm characteristics in sub-fertile men: a systematic review and meta-analysis. Urology Journal2017;14(5):4069-78.">Irani 2017</a>). They concluded that folate alone was only effective on sperm concentration, and folate plus zinc only on sperm concentration and morphology. Both interventions did not have any effect on sperm motility. This effect of zinc plus folate or folate alone could be confirmed with our review. The review by Zhou and colleagues (<a href="./references#CD007411-bbs2-0297" title="ZhouZ , CuiY , ZhangX , ZhangY .The role of N-acetyl-cysteine (NAC) orally daily on the sperm parameters and serum hormones in idiopathic infertile men: a systematic review and meta-analysis of randomised controlled trials. Andrologia2021;53(2):e13953. [DOI: 10.1111/and.13953]">Zhou 2021</a>) focused on N‐acetyl‐cysteine (NAC) and men with idiopathic infertility and found an increased sperm concentration and total motility after use of NAC. We found a similar effect in the six months comparisons, however due to inclusion of other studies, we found no evidence of increased sperm parameters in the other comparisons including NAC. </p> <p>A review on nutritional and medical therapies (<a href="./references#CD007411-bbs2-0264" title="OmarMI , PalRP , KellyBD , BruinsHM , YuanY , DiemerT , et al.Benefits of empiric nutritional and medical therapy for semen parameters and pregnancy and live birth rates in couples with idiopathic infertility: a systematic review and meta-analysis. European Urology2019;75(4):615-25.">Omar 2019</a>) and male infertility reports no improvement of pregnancy rates following treatment with L‐carnitine or L‐carnitine combined with L‐acetyl‐carnitine, which is in line with our review. </p> <p>It should be noted that some of these reviews are relatively outdated, given the newly published studies in the past decade.<br/>The above‐mentioned systematic reviews mainly reported on overall pregnancy rates, whereas this updated Cochrane Review reported specifically on clinical pregnancy rates (as confirmed by the identification of a gestational sac on ultrasound) so fewer studies were available for analysis. </p> <p>A Cochrane Review of antioxidants for female subfertility has been published (<a href="./references#CD007411-bbs2-0279" title="Showell MG , Mackenzie-ProctorR , JordanV , Hart RJ .Antioxidants for female subfertility. Cochrane Database of Systematic Reviews2020;2020(8):CD007807.">Showell 2020</a>) showing that there is limited evidence for a beneficial effect of antioxidants for subfertile women. Furthermore, a recent systematic review and meta‐analysis looking at the effect of micronutrient supplementation, in both male and females, on IVF outcomes showed a positive influence on clinical outcomes in terms of pregnancy rate and/or live birth rate (<a href="./references#CD007411-bbs2-0247" title="Kofi ArhinS , ZhaoY , LuXS , ChetryM , LuJQ .Effect of micronutrient supplementation on IVF outcomes: a systematic review of the literature. Reproductive BioMedicine Online2017;35(6):715-22.">Kofi Arhin 2017</a>). However, only five RCTs could be included, with significant heterogeneity among the interventions and study designs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007411-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD007411-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological risk of bias summary: review authors' judgements about each methodological bias item for each included study." data-id="CD007411-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological risk of bias summary: review authors' judgements about each methodological bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Methodological risk of bias graph: review authors' judgements about each methodological bias item presented as percentages across all included studies." data-id="CD007411-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological risk of bias graph: review authors' judgements about each methodological bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant." data-id="CD007411-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant." data-id="CD007411-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.1 Live birth; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.3 Clinical pregnancy; type of antioxidant." data-id="CD007411-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.3 Clinical pregnancy; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical pregnancy; type of antioxidant." data-id="CD007411-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Clinical pregnancy; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Adverse events." data-id="CD007411-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.5 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.6 Sperm DNA fragmentation; type of antioxidant." data-id="CD007411-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.6 Sperm DNA fragmentation; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.9 Total sperm motility at 3 months or less; type of antioxidant." data-id="CD007411-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.9 Total sperm motility at 3 months or less; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.14 Progressive sperm motility at 3 months or less; type of antioxidant." data-id="CD007411-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.14 Progressive sperm motility at 3 months or less; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.19 Sperm concentration at 3 months or less; type of antioxidant." data-id="CD007411-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antioxidant(s) versus placebo or no treatment, outcome: 1.19 Sperm concentration at 3 months or less; type of antioxidant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 1: Live birth; type of antioxidant" data-id="CD007411-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 1: Live birth; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 2: Live birth; IVF/ICSI" data-id="CD007411-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 2: Live birth; IVF/ICSI </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 3: Clinical pregnancy; type of antioxidant" data-id="CD007411-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 3: Clinical pregnancy; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 4: Clinical pregnancy; IVF/ICSI" data-id="CD007411-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 4: Clinical pregnancy; IVF/ICSI </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 5: Adverse events" data-id="CD007411-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 6: Sperm DNA fragmentation at 3 months or less; type of antioxidant" data-id="CD007411-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 6: Sperm DNA fragmentation at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 7: Sperm DNA fragmentation at 6 months; type of antioxidant" data-id="CD007411-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 7: Sperm DNA fragmentation at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0020"> <p> <div class="table" id="CD007411-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Sperm DNA fragmentation (data not suitable for meta‐analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P‐value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Folic acid</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Boonyarangkul 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Folic acid</b> </p> <p>DNA tail length, COMET assay</p> <p>3 month:</p> <p>Mean = 4.04 (n = 15)</p> <p>SE = 0.94</p> <p>6 month:</p> <p>Mean = 6.01</p> <p>SE = 1.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>DNA tail length, COMET assay</p> <p>3 month<b>:</b> </p> <p>Mean = 10.08 (n = 15)</p> <p>SE = 3.39</p> <p>6 month:</p> <p>Mean = 8.69</p> <p>SE = 4.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 8: Sperm DNA fragmentation (data not suitable for meta‐analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 9: Total sperm motility at 3 months or less; type of antioxidant" data-id="CD007411-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 9: Total sperm motility at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0022"> <p> <div class="table" id="CD007411-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Total sperm motility at 3 months or less (data not suitable for meta analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessopoulou 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> <p>Median difference = 7 (n = 15)</p> <p>Min/max difference = ‐27 ‐ 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>Median difference = 7 (n = 15)</p> <p>Min/max difference = ‐33 ‐ 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Combined antioxidants</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Galatioto 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N‐acetylcysteine (NAC) 600 mg + vitamins‐minerals</b> </p> <p>% of motile sperm (Class A WHO) = 58% (n = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No treatment</b> </p> <p>% of motile sperm (Class A WHO) = 51% (n = 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.847</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 10: Total sperm motility at 3 months or less (data not suitable for meta analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 11: Total sperm motility at 6 months; type of antioxidant" data-id="CD007411-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 11: Total sperm motility at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 12: Total sperm motility at 9 months or more; type of antioxidant" data-id="CD007411-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 12: Total sperm motility at 9 months or more; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 13: Total sperm motility over time" data-id="CD007411-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 13: Total sperm motility over time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 14: Progressive sperm motility at 3 months or less; type of antioxidant" data-id="CD007411-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 14: Progressive sperm motility at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 15: Progressive sperm motility at 6 months; type of antioxidant" data-id="CD007411-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 15: Progressive sperm motility at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0028"> <p> <div class="table" id="CD007411-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Progressive sperm motility at 6 months (data not suitable for meta analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Coenzyme Q10</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coenzyme Q10 200 mg</b> </p> <p>% improvement = 36 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>% improvement = 4 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Glutathione</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glutathione 250 mg</b> </p> <p>% improvement = 38 (n = 51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>% improvement = 4 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 16: Progressive sperm motility at 6 months (data not suitable for meta analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 17: Progressive sperm motility at 9 months or more; type of antioxidant" data-id="CD007411-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 17: Progressive sperm motility at 9 months or more; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 18: Progressive sperm motility over time" data-id="CD007411-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 18: Progressive sperm motility over time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 19: Sperm concentration at 3 months or less; type of antioxidant" data-id="CD007411-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 19: Sperm concentration at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0032"> <p> <div class="table" id="CD007411-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Sperm concentration at 3 months or less (data not suitable for meta analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Carnitines</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Lenzi 2003</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>L‐carnitine</b> </p> <p>Mean = 9 (1st phase data) (n = 43)</p> <p>No SD given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>Mean = 5.3 (n = 43)</p> <p>No SD given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kessopoulou 1995</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> <p>Median difference = ‐15 (n = 15)</p> <p>Min/max difference = ‐58 ‐ 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>Median difference = 0 (n = 15)</p> <p>Min/max difference = ‐37 ‐ 160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 20: Sperm concentration at 3 months or less (data not suitable for meta analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 21: Sperm concentration at 6 months; type of antioxidant" data-id="CD007411-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 21: Sperm concentration at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0034"> <p> <div class="table" id="CD007411-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Sperm concentration at 6 months (data not suitable for meta analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Glutathione</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Glutathione 250 mg</b> </p> <p>% improvement = 26 (n = 51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>% improvement = 2 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Coenzyme Q10</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coenzyme Q10 200 mg</b> </p> <p>% improvement = 24 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> <p>% improvement = 2 (n = 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 22: Sperm concentration at 6 months (data not suitable for meta analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0034">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 23: Sperm concentration at 9 months or more; type of antioxidant" data-id="CD007411-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 23: Sperm concentration at 9 months or more; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 24: Sperm concentration over time" data-id="CD007411-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Antioxidant(s) versus placebo or no treatment, Outcome 24: Sperm concentration over time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 1: Live birth; type of antioxidant" data-id="CD007411-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 1: Live birth; type of antioxidant</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 2: Clinical pregnancy; type of antioxidant" data-id="CD007411-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 2: Clinical pregnancy; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 3: Sperm DNA fragmentation; type of antioxidant" data-id="CD007411-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 3: Sperm DNA fragmentation; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 4: Total sperm motility at 3 months or less; type of antioxidant" data-id="CD007411-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 4: Total sperm motility at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 5: Total sperm motility at 6 months; type of antioxidant" data-id="CD007411-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 5: Total sperm motility at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 6: Total sperm motility at 9 months or more; type of antioxidant" data-id="CD007411-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 6: Total sperm motility at 9 months or more; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 7: Progessive sperm motility at 3 months or less; type of antioxidant" data-id="CD007411-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 7: Progessive sperm motility at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 8: Progressive sperm motility at 6 months; type of antioxidant" data-id="CD007411-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 8: Progressive sperm motility at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0045"> <p> <div class="table" id="CD007411-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Progressive motility at 6 months (data not suitable for meta‐analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Coenzyme Q10 (n=50</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glutathione (n=51)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% improvement = 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% improvement = 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 9: Progressive motility at 6 months (data not suitable for meta‐analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 10: Progressive sperm motility at 9 months; type of antioxidant" data-id="CD007411-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 10: Progressive sperm motility at 9 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 11: Sperm concentration at 3 months or less; type of antioxidant" data-id="CD007411-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 11: Sperm concentration at 3 months or less; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 12: Sperm concentration at 6 months; type of antioxidant" data-id="CD007411-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 12: Sperm concentration at 6 months; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007411-fig-0049"> <p> <div class="table" id="CD007411-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Sperm concentration at 6 months (data not suitable for meta‐analysis)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Coenzyme Q10 (n=50)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Glutathione (n=51)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Saeed Alkumait 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% improvement = 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% improvement = 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not provided</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 13: Sperm concentration at 6 months (data not suitable for meta‐analysis) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0049">Navigate to figure in review</a></div> </div> <div class="figure" id="CD007411-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/urn:x-wiley:14651858:media:CD007411:CD007411-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Head‐to‐head antioxidant(s), Outcome 14: Sperm concentration at 9 months or more; type of antioxidant" data-id="CD007411-fig-0050" src="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_t/tCD007411-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Head‐to‐head antioxidant(s), Outcome 14: Sperm concentration at 9 months or more; type of antioxidant </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/media/CDSR/CD007411/image_n/nCD007411-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007411-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants compared to placebo or no treatment for patients with male subfertility</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antioxidants compared to placebo or no treatment for patients with male subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with male subfertility<br/><b>Setting: clinic</b> <br/><b>Intervention:</b> antioxidants<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with antioxidants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth rate per couple randomised</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(171 to 269)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.43</p> <p>(1.07 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1283</p> <p>(12 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy rate per couple randomised</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>146 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1000</p> <p>(199 to 297)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.89</p> <p>(1.45 to 2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1706</p> <p>(20 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events ‐ Miscarriage</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 1000</p> <p>(36 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.46</p> <p>(0.75 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>664</p> <p>(6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ Gastrointestinal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> <p>(22 to 71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.70</p> <p>(1.46 to 4.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1355</p> <p>(16 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Peto Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for serious risk of bias: lack of blinding and incomplete accounting of patients and outcome events </p> <p><sup>2</sup> Downgraded one level for suspected publication bias based on the funnel plot </p> <p><sup>3</sup> Downgraded one level for serious imprecision: less than 400 events </p> <p><sup>4</sup> Downgraded one level for serious imprecision: crossing the line of no effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antioxidants compared to placebo or no treatment for patients with male subfertility</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007411-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data for undefined or biochemical pregnancy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Undefined or biochemical pregnancy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="bottom"> <p><b>Antioxidant</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="bottom"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Peto OR [CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="bottom"> <p><i>Antioxidant(s) versus placebo or no treatment</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Combined antioxidants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.17 [0.16 to 413.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 [0.88 to 8.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 [0.32 to 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 [0.17 to 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Arginine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.82 [0.11 to 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Carnitines</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0.74 [0.04 to 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>8.57 [0.82 to 89.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.37 [1.61 to 43.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7.20 [0.95 to 54.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>7.50 [2.01 to 27.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Coenzyme Q10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>Vitamin C + Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.26 to 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Head‐to‐head antioxidant(s)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>L‐acetyl carnitine + L‐carnitine vs Vitamin E + Vitamin C</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.72 [0.81 to 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>L‐carnitine + Vitamin E vs Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.01 [2.49 to 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vitamin E + amino acids vs Vitamin E</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52 [0.41 to 15.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data for undefined or biochemical pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007411-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes and conclusions from all included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design, population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes described in methods section</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes reported on in results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>In meta‐analysis Y or N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conclusions</b> </p> <p>+ = positive effect</p> <p>‐ = negative or no effect</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0001" title="AbbasiB , MolaviN , TavalaeeM , AbbasiH , Nasr-EsfahaniMH .Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reproductive BioMedicine Online2020;41(6):1084-91. ">Abbasi 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men post‐varicocelectomy</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALA improved sperm motility compared to baseline. No significant difference in sperm parameters between ALA and placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>ALA does not improve semen quality compared to placebo after varicocelectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0002" title="AkiyamaM .In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen. Japanese Journal of Urology1999;90(3):421-8. ">Akiyama 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, head‐to‐head</p> <p>Infertile men, high ROS levels</p> <p>N = 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethylcystein did not improve sperm density and motility but "sperm function" increased and ROS levels decreased, compared to vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Ethylcysteine shown to be effective for improvement of sperm parameters when compared to vitamin E </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0003" title="AlahmarAT .The impact of two doses of coenzyme Q10 on semen parameters and antioxidant status in men with idiopathic oligoasthenoteratozoospermia. Clinical and Experimental Reproductive Medicine2019;46(3):112-8. [DOI: https://doi.org/10.5653/cerm.2019.00136]">Alahmar 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CoQ10 200 and 400 mg improved sperm concentration and motility, greater improvement with 400 mg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>CoQ10 improves sperm parameters, greater improvement with a 400 mg dose compared to 200 mg </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0004" title="AlahmarAT , SenguptaP .Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biological Trace Element Research2020;199(4):1246-52. ">Alahmar 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ number of drop‐outs unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CoQ10 and selenium each improved sperm concentration and motility, greater improvement with CoQ10 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>CoQ10 and selenium improve sperm parameters, greater improvement with CoQ10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0005" title="AminiL , MohammadbeigiR , VafaM , HaghaniH , Vahedian-AzimiA , KarimiL , et al.Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: A randomized controlled trial. Complementary Therapies in Medicine2020;53:102529. ">Amini 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D did not improve sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Vitamin D does not improve sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0006" title="Ardestani ZadehA , ArabD , Kia NS , HeshmatiS , AmirkhaliliSN .The role of vitamin e - selenium - folic acid supplementation in improving sperm parameters after varicocelectomy: a randomized clinical trial. Urology journal2019;16(5):495-500. ">Ardestani 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men post‐varicocelectomy</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co‐administration of folic acid, selenium and vitamin E improved sperm concentration and motility </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>A combination of folic acid + selenium + vitamin E improves sperm parameters after varicocelectomy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0007" title="AttallahD , El NasharIH , MahmoudR , ShaabanOM , SalmanSA .N-acytelcysteine prior to intrauterine insemination in couples with isolated athenozospermia: a randomized controlled trial. Fertility and Sterility2013;100(3 Suppl):S462. ">Attallah 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Idiopathic asthenozospermia, IUI</p> <p>N = 30</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, chemical and clinical pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, chemical and clinical pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NAC increased sperm concentration and motility.</p> <p>Clinical pregnancy was not significantly different between the groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>NAC improves semen quality and improves pregnancy rates prior to IUI, no improvement of pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0008" title="AzizollahiG , AzizollahiS , BabaeiH , KianinejadM , BaneshiMR , Nematollahi-mahaniSN .Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. Journal of Assisted Reproduction and Genetics2013;30(4):593-9. AzizollahiG , AzizollahiS , BabaeiH , KianinejadMA , BaneshiMR , Nematollahi-MahaniSN .Effects of zinc sulfate and folic acid coadministration on sperm parameters, protamine content and acrosomal integrity of varicocelectomized patients. Iranian Journal of Reproductive Medicine2013;1:37. AzizollahiS , AzizollahiG , NematollahiSN , BabaeiH , RastegariA , MaghsudiS .The effect of folic acid administration on protamine deficiency, acrosomal activity and semen parameters in varicocelectomized patients. Human Reproduction2011;26 Suppl 1 Abstract no: P-57:i340. AzizollahiS , Nematollahi-MahaniSN , AzizollahiG , BaneshiMR , SafariZ .The effect of folic acid and zinc sulfate on endocrine parameters and seminal antioxidant level, after variocelectomy. Iranian Journal of Reproductive Medicine2013;1:36. ">Azizollahi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm trial</p> <p>Men post‐varicocelectomy</p> <p>N = 160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild improvement in sperm parameters with the use of antioxidants zinc, folic acid or both </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Co‐administration of zinc and folic acid improved sperm parameters and increased varicocelectomy outcomes, only zinc an improvement in pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0009" title="BahmyariR , AriafarA , SayadiM , HossieniS , AzimaS .The effect of daily intake of selenium, vitamin e and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. International Journal of Fertility &amp; Sterility2021;15(1):8-14. ">Bahmyari 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic OAT</p> <p>N = 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No improvement of sperm parameters with the use of selenium, folic acid and vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Co‐administration of selenium, folic acid and vitamin E were not effective to improve sperm parameters </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0010" title="BalerciaG , RegoliF , ArmeniT , KoverechA , ManteroF , BoscaroM .Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertility and Sterility2005;84(3):662-71. ">Balercia 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in motility in LAC group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Long‐term carnitine is effective in increasing sperm motility. No evidence of increased live birth or clinical pregnancy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0011" title="BalerciaG , BuldreghiniE , VigniniA , TianoL , PaggiF , AmorosoS , et al.Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertility and Sterility2009;91(5):1785-92. ">Balercia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile and unexplained</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Co enzyme Q10 increased sperm motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Q10 is effective in improving sperm kinetic features in asthenospermia. No evidence of increased live birth or clinical pregnancy. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0012" title="BarekatF , TavalaeeM , DeemehMR , BahreinianM , AzadiL , AbbasiH , et al.A Preliminary Study: N-acetyl-L-cysteine Improves Semen Quality following Varicocelectomy. International Journal of Fertility &amp; Sterility2016;10(1):120-6. ">Barekat 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Subfertile men with varicocele</p> <p>N = 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical spontaneous pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters significantly improved after surgery compared to before surgery in both the NAC and control groups. NAC might have an additional value by improving sperm motility post‐varicocelectomy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The results of this study revealed that NAC improved chromatin integrity and pregnancy rate when administered as adjunct therapy post‐varicocelectomy </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0013" title="BiagiottiG , CavalliniG , ModeniniF , VitaliG , MagliC , FerrarettiA .Prostaglanadins pulsed down-regulation enhances carnitine therapy performance in severe idiopathic oligoasthenospermia. Human Reproduction2003;18 Suppl 1:202. ">Biagiotti 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Severe idiopathic oligoasthenospermia</p> <p>N = 42</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A significant improvement in morphology concentration, motility in the carnitine group</p> <p>No side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Quality of semen is positively associated with fertilisation and implantation rates in assisted reproduction </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0014" title="Blomberg JensenM , Gerner LawaetzJ , AnderssonA , PetersenJH , NordkapL , BangAK , et al.Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men. Human Reproduction2016;31(8):1875-85. Blomberg JensenM , LawaetzJG , PetersenJH , JuulA , JorgensenN .Effects of vitamin D supplementation on semen quality, reproductive hormones, and live birth rate: a randomized clinical trial. Journal of Clinical Endocrinology &amp; Metabolism2018;103(3):870-81. ">Blomberg Jensen 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with impaired semen quality</p> <p>N = 307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, reproductive hormones, live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, reproductive hormones, live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters, concentration provided as median + IQR and converted to mean + SD </p> <p>Y ‐ live birth rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D was not associated with changes in semen parameters, although spontaneous pregnancies tended to be higher in couples in which the man was in the treatment group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Vitamin D did not improve semen quality. The positive impact of vitamin D supplementation on live birth rate and serum inhibin B in oligozoospermic and vitamin D–deficient men may be of clinical importance and warrant verification by others. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0015" title="BoonyarangkulA , VinayanuvattikhunN , ChiamchanyaC , VisutakulP .Comparative study of the effects of tamoxifen citrate and folate on semen quality of the infertile male with semen abnormality. Journal of the Medical Association of Thailand2015;98(11):1057-63. ">Boonyarangkul 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, tamoxifen excluded</p> <p>Men with abnormal semen analysis</p> <p>N = 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA damage (Comet assay)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA tail length</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Folate alone significantly decreased DNA tail length at 3‐months. Sperm motility was significantly increased after 3‐months Folate alone. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Our study indicated that folate in combination with Tamoxifen citrate could improve sperm quality including semen parameters and sperm DNA integrity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0016" title="BusettoG , VirmaniA , Del GiudiceF , MicicS , AgarwalA , De BerardinisE .Varicocele and oligoasthenoteratozoo-spermia: Evaluation of antioxidant supplementation effect on pregnancy rate and sperm quality. Fertility and Sterility2017;108 (3 Supplement 1):e133. BusettoG , VirmaniMA , AntoniniG , RagonesiG , De BerardinisE , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligoasthenoteratozoospermia, with and without varicocele: a DBPC study. Fertility and Sterility2016;106 (Supplement 3):e46. BusettoGM , AgarwalA , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , et al.Effect of metabolic and antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double-blind placebo-controlled study. Andrologia2018;50(3):Epub. BusettoGM , VirmaniA , AntoniniG , RagonesiG , Del GiudiceF , AgarwalA , et al.Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: a double blind place controlled (DBPC) study. Human Reproduction2017;32 (Supplement 1):i142-3. ">Busetto 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT, 50% included with varicocele</p> <p>N = 104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm concentration, total sperm count, progressive and total motility were significantly increased in supplemented (Proxeed Plus) patients. Increased pregnancy rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Supplementation with metabolic and antioxidant compounds could be efficacious when included in strategies to improve fertility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0017" title="CavalliniG , FerrarettiAP , GianaroliL , BiagiottiG , VitaliG .Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocoele associated oligoasthenospermia [see comment]. Journal of Andrology2004;25(5):761-70. CavalliniG , FerrarettiAP , GianaroliL , MagliMC , BiagiottiG , VitaliG .Cinnoxicam + carnitines for idiopathic dyspermia. The 20th Annual Meeting of the European Society of Human Reproduction and Embryology. Human Reproduction2004. ">Cavallini 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Idiopathic OAT men with varicocele</p> <p>N = 325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median +IQR converted to mean + SD)</p> <p>N ‐ pregnancy rate, unclear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in sperm parameters for carnitines when compared to placebo.</p> <p>Carnitine groups had a significantly higher pregnancy rate than placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The antioxidant plus anti‐inflammatory group was more effective in improving sperm parameters and pregnancy than those of carnitines alone or placebo however carnitines alone were more effective than placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0018" title="Cheng JB , ZhuJ , NiF , JiangH .L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Zhonghua nan ke xue [National journal of andrology]2018;24(1):33‐8. ">Cheng 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, head‐to‐head</p> <p>Idiopathic OAT</p> <p>N = 312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y/N ‐ sperm parameters, results not available for all groups and parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm parameters and DNA fragmentation in the L‐carnitine plus CoQ10 group compared to placebo. </p> <p>Combination and L‐carnitine groups had remarkably higher pregnancy rate than placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combination of LC and CoQ10 improve semen parameters and outcome of clinical pregnancy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0019" title="ConquerJA , MartinJB , TummonI , WatsonL , TekpeteyF .Effect of DHA supplementation on DHA status and sperm motility in asthenozoospermic males. Lipids2000;35(2):149-54. ">Conquer 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Asthenozoospermic men</p> <p>N = 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHA showed no effect on sperm motility or concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>DHA supplementation increased DHA levels in the sperm but not motility or concentration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0020" title="CyrusA , KabirA , GoodarziD , MoghimiM .The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. International Brazilian Journal of Urology2015;41(2):230-8. ">Cyrus 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with varicocele</p> <p>N = 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin C was not effective on sperm count but improved sperm motility and morphology significantly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Ascorbic acid can play a role as adjuvant treatment after varicocelectomy in infertile men </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0021" title="DawsonEB , HarrisWA , PowellLC .Relationship between ascorbic acid and male fertility. World Review of Nutrition and Dietetics1990;62:1-26. ">Dawson 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with sperm agglutination</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>(SEs converted to SDs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The group receiving 1000 mg of AA showed more improvement in parameters than the 200mg group and the placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin C can improve sperm parameters, especially dosage of 1000 mg.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0022" title="DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. [Chinese]. Zhonghua nan ke xue = National Journal of Andrology2014;20(12):1082-5. DengXL , LiYM , YangXY , HuangJR , GuoSL , SongLM .Efficacy and safety of vitamin D in the treatment of idiopathic oligoasthenozoospermia. Zhong Hua Nan Ke Xue2014;20(12):1082-5. ">Deng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Men with idiopathic oligoasthenozoospermia</p> <p>N = 86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse reactions, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse reactions, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin D is a safe option for the treatment of idiopathic oligoasthenozoospermia and can effectively improve the semen quality especially the progressive sperm motility </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin D can improve forward movement sperm number and percentage, improve the woman's clinical pregnancy rate, and is well tolerated </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0023" title="DimitriadisF , TsambalasS , TsounapiP , KawamuraH , VlachopoulouE , HaliasosN , et al.Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU International2010;106(8):1181-5. ">Dimitriadis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment, vardenafil/sildenafil arms excluded</p> <p>Men with oligoasthenospermia</p> <p>N = 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An improvement in sperm concentration with carnitine versus no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Enhancement of Leydig cell secretory function may increase sperm concentration and motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0024" title="EnerK , AldemirM , IsikE , OkuluE , OzcanMF , UgurluM , et al.The impact of vitamin E supplementation on semen parameters and pregnancy rates after varicocelectomy: a randomised controlled study. Andrologia2016;48(7):829-34. ">Ener 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men with varicocele</p> <p>N = 56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, unknown if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The administration of vitamin E increased all of the parameters; however not statistically significant </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Vitamin E supplementation does not improve the sperm parameters after varicocelectomy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0025" title="EslamianG , AmirjannatiN , SadeghiMR , RashidkhaniB , PahlavanS , HooshangiA , et al.The effects of combined supplementation of docosahexaenoic acid and vitamin E on fatty acid changes in sperm membrane in asthenozoospermic men. Iranian Journal of Nutrition Sciences &amp; Food Technology2013;8(1):23-37. HekmatdoostA .The effects of administration of combined docosahexaenoic acid and vitamin E supplements on spermatogram and seminal plasma oxidative stress in infertile men with asthenozoospermia. www.clinicaltrials.gov. [ClinicalTrials.gov: NCT01846325]">Eslamian 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Asthenoszoospermic men</p> <p>N = 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, sperm membrane and serum fatty acids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data not usable, no continuous data but categories from 'significantly improvement' to 'worsened' </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters improved with DHA + vitamin E supplementation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm parameters improve with DHA + vitamin E supplementation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0026" title="EslamianG , AmirjannatiN , NooriN , Sadeghi MR , HekmatdoostA .Effects of coadministration of DHA and vitamin e on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. American Journal of Clinical Nutrition2020;112(3):707-19. ">Eslamian 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Asthenozoospermic men</p> <p>N = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only imputed data provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of sperm concentration in the DHA + vitamin E group compared to groups treated with DHA+placebo, vitamin E+placebo and placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combined DHA and vitamin E improve sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0027" title="ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infertile men. Human Reproduction2016;31 (Supplement 1):i137-8. ExpositoA , Perez-SanzJ , CrisolL , AspichuetaF , QuevedoS , Diaz-NunezM , et al.A prospective double-blind randomized placebo-controlled study of the effect of vitamin E on semen parameters in infetile men. Human Reproduction2016;31 (Supp1):i137-i138 Abstract no: P-018. ">Exposito 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Normozoospermic, oligozoospermic and asthenozoospermic men</p> <p>N = 113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ pregnancy rate</p> <p>Both not included because data included normospermic men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50% of oligozoospermic men improved sperm concentration and sperm count to normozoospermic levels. This trend was also observed in asthenozoospermic men, but nog significantly </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E treatment by oral administration improves semen parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0028" title="GalatiotoGP , GravinaGL , AngelozziG , SacchettiA , InnominatoPF , PaceG , et al.May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele?World Journal of Urology2008;26(1):97-102. ">Galatioto 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with persistent oligospermia after embolisation of varicocele</p> <p>N = 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only medians given</p> <p>N ‐ pregnancy, unclear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant difference in sperm count in combined antioxidant group but not in motility.</p> <p>One pregnancy in the NAC group</p> <p>No significant adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>NAC does not improve pregnancy rate, no significant adverse events, but do significantly increase sperm count </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0029" title="GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .[Adjuvant antioxidant therapy in varicocele infertility]. Urologiia (Moscow, Russia)2017;(2 (supplement)):64-72. GamidovSI , OvchinnikovRI , PopovaAY , AvakyanAY , SukhikhGT .Adjuvant antioxidant therapy in varicocele infertility. [Russian]. Urologiia2017;2:64-72. OvchinnikovR , GamidovS , PopovaA .Efficacy of adjuvant antioxidant therapy after microsurgical varicocelectomy in infertile men. Andrology2018;6:63‐. ">Gamidov 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Men with varicocele</p> <p>N = 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+SD)</p> <p>Y ‐ DNA fragmentation (median+IQR converted to mean+ SD)</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SpermActine (SA) resulted in a 22.3% decrease in the level of sperm DNA fragmentation at 3 months. SA + vitamin complex resulted in a 27% increase in the sperm concentration at 3 months. There were no side effects of pharmacotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant therapy leads to an improvement in the basic sperm parameters (sperm concentration and motility) and a decrease in the level of sperm DNA fragmentation in the short term. There were no side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0030" title="Gamidov SI , Ovchinnikov RI , PopovaAY .Double-blind, randomized placebo-controlled study of efficiency and safety of complex acetyl-L-carnitine, L-carnitine fumarate and alpha-lipoic acid (Spermactin Forte) for treatment of male infertility. Urologiia2019;4:62-8. ">Gamidov 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with high oxidative stress and DNA fragmentation</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spermactin Forte significantly improvement sperm motility and decreased oxidative stress. There were more pregnancies in the intervention group (13 versus 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The use of the SpermActin Forte antioxidant improves sperm analysis in most patients. SpermActin Forte is an effective and safe method of treating male infertility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0031" title="Gonzalez-RavinaC , Aguirre-LipperheideM , PintoF , Martin-LozanoD , Fernandez-SanchezM , BlascoV , et al.Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reproductive Biology2018;18(3):282-8. ">Gonzalez‐Ravina 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, outcomes provided as change + SD <a href="./references#CD007411-fig-0027" title="">Analysis 1.15</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a> </p> <p>N ‐ DNA fragmentation, outcomes provided as change + SD <a href="./references#CD007411-fig-0020" title="">Analysis 1.8</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of progressive sperm motility in the DHA 1g and 2g groups after 1 month and in the DHA 0.5 group after 3 months. Greater effect in asthenozoospermic men </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>DHA (0.5, 1 and 2g) had beneficial effects on sperm function without producing any adverse effects, obtaining more immediate results with higher doses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0032" title="GopinathPM , KalraB , SaxenaA , MalikS , KochharK , KalraS , et al.Fixed dose combination therapy of antioxidants in treatment of idiopathic oligoasthenozoospermia: Results of a randomized, double-blind, placebo-controlled clinical trial. International Journal of Infertility and Fetal Medicine2013;4(1):6-13. ">Gopinath 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Idiopathic OAT men</p> <p>N = 138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined antioxidant significantly improved sperm count and total motility in both treatment arms (1 vs 2 tablets). Mild adverse events were reported, no severe. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Exogenous administration of fixed dose combination of antioxidants is safe and effective therapy in improving the male subfertility regarding sperm parameters. Only mild adverse events when using combined antioxidants </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0033" title="GoswamiSK , YasminS , ChakrabortyP , ChattopadhyayR , GhoshS , GoswamiM , et al.Role of dietary antioxidant supplementation in treatment of idiopathic male infertility: promising evidence from a sub-continental study. Fertility and Sterility2015;1):e288. ">Goswami 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Arm treated with diet enriched in antioxidants not used</p> <p>Men with idiopathic infertility and high ROS</p> <p>N = 175</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, not reported in results</p> <p>N ‐ DNA fragmentation, no results reported besides p‐value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in DNA fragmentation between the study groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>No conclusions on antioxidants versus placebo. A diet rich in antioxidants and lifestyle modifications can bring almost the same effect as antioxidant supplements </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0034" title="GrecoE , IacobelliM , RienziL , UbaldiF , FerreroS , TesarikJ .Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. Journal of Andrology2005;26(3):349-53. ">Greco 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile males with high DNA fragmentation</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in concentration or motility however DNA fragmentation was significantly reduced in the vitamin C + E when compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>A short oral treatment of Vitamin C + E can reduce DNA fragmentation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0035" title="HaghighianHK , HaidariF , Mohammadi-AslJ , DadfarM .Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertility &amp; Sterility2015;104(2):318-24. ">Haghighian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic asthenozoospermia</p> <p>N = 48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, reported "none", however not clear which side effects they aimed for </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters were significantly higher in ALA group. No side effects due to the oral administration of ALA were observed in any participants. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0036" title="HajeM , NaoomK .Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. International Journal of Infertility and Fetal Medicine2015;6(1):20-4. ">Haje 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, tamoxifen arms excluded</p> <p>Infertile men with idiopathic OAT</p> <p>N = 128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, range of treatment 3 ‐ 6 months and not divided</p> <p>N ‐ pregnancy rate, unclear if pregnancy and no numbers but percentage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine did not improve sperm count or motility. Only tamoxifen or tamoxifen + L‐carnitine improved pregnancy rate, not significantly. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Administration of tamoxifen or L‐carnitine can improve sperm parameters and ICSI outcomes. Combining those result in maximum therapeutic effect </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0037" title="Huang WJ , LuXL , LiJT , Zhang JM .Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology2020;8(1):110-6. ">Huang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Oligozoospermic men</p> <p>N = 769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, evaluation of MTHFR polymorphism, DNA fragmentation, pregnancy rate, live birth </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, evaluation of MTHFR polymorphism, DNA fragmentation, pregnancy rate, live birth </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmentation</p> <p>N ‐ pregnancy, clinical</p> <p>N ‐ live births</p> <p>All outcomes reported for MTHFR polymorphism groups only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Folic acid significantly increased sperm parameters, decreased oxidative stress and DNA fragmentation and lead to a higher pregnancy and live birth rate in the MTHFR 677 TT group. Effect not seen in other MTHFR groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Folic acid has a beneficial effect on oligozoospermia with MTHFR 677 TT genotype in terms of sperm parameters, DNA fragmentation and pregnancy outcomes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0038" title="JosephT , MascarenhasM , KaruppusamiR , KarthikeyanM , KunjummenAT , Kamath MohanS .Antioxidant pretreatment for male partner before ART for male factor subfertility: a randomized controlled trial. Human Reproduction )pen2020;2020(4):hoaa050. ">Joseph 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men scheduled for ART</p> <p>N = 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+SD)</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in clinical pregnancies or live births when combined vitamin C + vitamin E + zinc were compared to no treatment. No improvement of sperm parameters </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No difference in clinical pregnancy and live births. No improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0039" title="KessopoulouE , PowersHJ , SharmaKK , PearsonMJ , RussellJM , CookeID , et al.A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertility and Sterility1995;64(4):825-31. ">Kessopoulou 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Male infertility</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse effects, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only medians given <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a>; <a href="./references#CD007411-fig-0032" title="">Analysis 1.20</a> </p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences in sperm outcomes were seen between the groups. 1 pregnancy in the vitamin E group and nil in the placebo (first phase data) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>No difference in semen parameters. There is evidence of increased live birth and clinical pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0040" title="KizilayF , AltayB .Evaluation of the effects of antioxidant treatment on sperm parameters and pregnancy rates in infertile patients after varicocelectomy: a randomized controlled trial. International Journal of Impotence Research2019;31(6):424-31. ">Kizilay 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Varicocele patients with oligozoospermia</p> <p>N = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm parameters and higher clinical pregnancy rate in combined antioxidant group compared to no treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant treatment provides an important contribution<br/>to varicocelectomy outcomes and improves pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0041" title="KopetsR , KuibidaI , ChernyavskaI , CherepanynV , MazoR , FedevychV , et al.Dietary supplementation with a novel l-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: A randomized clinical study. Andrology2020;8(5):1184-93. ">Kopets 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic infertility</p> <p>N = 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The percentage of normal spermiograms was significantly higher in the combined antioxidant group. Higher spontaneous pregnancy rate in antioxidant group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Combined l‐carnitine/l‐acetyl‐carnitine, l‐arginine,<br/>glutathione, CoQ10, zinc, folic acid, cyanocobalamin, and selenium improves sperm quality and increases pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0042" title="KorshunovM , KorshunovaE , DarenkovS .Does antioxidant therapy (AT) may improve fresh-TESA/ICSI cycle outcome in patients with obstructive azoospermia (OA)? In: European Urology, Supplements. Vol. 17. 2018:e1105. ">Korshunov 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Obstructive azoospermia, TESA/ICSI candidates</p> <p>N = 46</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy, live births</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy, live birth, embryo quality, early pregnancy loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> <p>N ‐ adverse events, miscarriage. No data provided by authors.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical pregnancy and live birth rate were 62,5% vs 59,1% and 54,1% vs 40,9% in the antioxidant and no treatment group, respectively. Higher early pregnancy loss rate in control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Antioxidant therapy may have a positive effect for patients with obstructive azoospermia. It might improve ART outcome and decrease pregnancy loss </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0043" title="Kumalic SI , Klun IV , Bokal EV , PinterB .Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiology and Oncology2020;55(1):97-105. ">Kumalic 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events, after contact with author: clinical pregnancy rate and live births after ICSI </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>Y ‐ adverse events</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live births</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical differences in sperm parameters between astaxanthin + vitamin E group and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>The oral intake of astaxanthin did not affect any semen parameters in patients with OAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0044" title="KumamotoY , MarutaH , IshigamiJ , KamidonoS , OrikasaS , KimuraM , et al.Clinical efficacy of mecobalamin in the treatment of oligozoospermia--results of double-blind comparative clinical study. Hinyokika Kiyo. Acta Urologica Japonica1988;34:1109-32. ">Kumamoto 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with abnormal sperm count or motility</p> <p>N = 396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only scales given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference in sperm outcomes in vitamin B 12 groups or placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement in sperm parameters after use of vitamin B12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0045" title="LenziA , LombardoF , SgroP , SalaconeP , CaponecchiaL , DonderoF , et al.Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial [see comment]. Fertility and Sterility2003;79(2):292-300. ">Lenzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Infertile men with OAT</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition of pregnancy given see <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The patient groups showed no differences in sperm outcomes between therapy (carnitine) and placebo groups. </p> <p>Six pregnancies in the carnitine group and nil in the placebo (first phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>The pregnancies obtained during the carnitine therapy period could suggest that carnitines may also lead to improvement in sperm function and fertilisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0046" title="LenziA , SgroP , SalaconeP , PaoliD , GilioB , LombardoF , et al.A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia [see comment]. Fertility and Sterility2004;81(6):1578-84. ">Lenzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with OAT</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition of pregnancy given <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Four participants taking carnitine induced a pregnancy in their partner and nil in the placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>No evidence of improved sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0047" title="LiZ , ChenGW , ShangXJ , BaiWJ , HanYF , ChenB , et al.A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Zhong Hua Nan Ke Xue2005;11(10):761-4. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with OAT</p> <p>N = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, no definition given <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine and acetyl carnitine more effective than vitamin E + vitamin C for pregnancy, sperm parameters and no evidence of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine and acetyl carnitine more effective than vitamin E + vitamin C for pregnancy, sperm parameters and no evidence of adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0048" title="LiZ , GuR , LiuY , XiangZ , CaoX , HanY , et al.Curative effect of L-carnitine supplementation in the treatment of male infertility. Academic Journal of Shanghai Second Medical University2005;25(3):292-4. ">Li 2005a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with OAT</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statistical significance for carnitines over vitamin E + C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sperm parameters for carnitines compared to vitamin E + C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0049" title="LombardoF , GandiniL , AgarwalA , SgroP , DonderoF , LenziA .A prospective double blind placebo controlled cross over trial of carnitine therapy in selected cases of male infertility. Fertility and Sterility2002;78 Suppl 1:68-9. ">Lombardo 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over</p> <p>Infertile men with OAT</p> <p>N = 100</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters (concentration, motility) carnitines versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0051" title="MartinezAM , Sordia-HernandezLH , MoralesJA , MerinoM , VidalO , Garcia GarzaMR , et al.A randomized clinical study assessing the effects of the antioxidants, resveratrol or SC1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pacific Journal of Reproduction2015;4(2):106-11. ">Martinez 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, SG1002 arm excluded</p> <p>Men with idiopathic OAT</p> <p>N = 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SDs given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Resveratrol treatment did not significantly affect any of the parameters.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Resveratrol treatment did not significantly affect any of the parameters. SG1002 may reverse oligoasthenozoospermia. It seems to be more potent antioxidant than resveratrol </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0052" title="Martinez-SotoJC , DomingoJC , CardobillaLP , PellicerA , LanderasJ .Effect of dietary DHA supplementation on sperm DNA integrity. Fertility and Sterility September 2010;94(4):S235-6. ">Martinez‐Soto 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 50</p> <p>Conference abstract + manuscript from author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences were found in traditional sperm parameters or lipid composition of the sperm membrane after DHA treatment, only reduction in the percentage of spermatozoa with DNA damage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Positive effect only on DNA fragmentation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0053" title="MehniNM , KetabchiAA , HosseiniE .Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iranian Journal of Reproductive Medicine2014;12(12):817-24. ">Mehni 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo, pentoxifylline arms excluded</p> <p>Infertile men with OAT</p> <p>N = 235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine only improved sperm motility, combined with pentoxifylline it improves all sperm parameters. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Positive effect only on sperm motility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0054" title="MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Assessment of sperm motility in oligoasthenospermic men, treated with metabolic and essential nutrients, in a randomized, double blind, placebo study. Human Reproduction2016;31 (Supplement 1):i151-2. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study in oligoasthenospermic men treated with metabolic and essential nutrients showed that progressive sperm motility was correlated to seminal carnitine levels. Andrology2016;4 (Supplement 2):56. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .DBPC study showed significant correlation of DNA fragmetation index (DFI) and seminal carnitine with progressive sperm motility in oligospermic men treated with metabolic and essential nutrients. Fertility and Sterility2017;108 (3 Supplement 1):e307-8. MicicS , LalicN , BojanicN , DjordjevicD , VirmaniA , AgarwalA .Oligoastenospermic men treated with proxeed plus showed correlation between sperm motility and seminal carnitine. Fertility and Sterility2016;106 (Supplement 3):e298-9. MicicS , LalicN , DjordjevicD , Bogavac-StanojevicN , VirmaniA , AgarwalA .Seminal carnitine and DNA fragmentation index (DFI) impact progressive sperm motility in oligoasthenospermic men treated with metabolic and essential nutrients, with moderate accuracy. Human Reproduction2017;32 (Supplement 1):i132. MicicS , LalicN , DjordjevicD , BojanicN , Bogavac-StanojevicN , BusettoGM , et al.Double-blind, randomised, placebo-controlled trial on the effect of L-carnitine and L-acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia. Andrologia2019;51(6):e13267. ">Micic 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with OAT</p> <p>N = 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>(median+IQR converted to mean + SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proxeed Plus significantly improved sperm volume, motility and DNA fragmentation compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Beneficial effects of carnitine<br/>derivatives (Proxeed plus) on progressive motility, vitality and sperm DNA fragmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0055" title="MorganteG , ScolaroV , TostiC , Di SabatinoA , PiomboniP , De LeoV .Treatment with carnitine, acetyl carnitine, L-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia. Minerva Urologica e Nefrologica2010;62(3):213-8. ">Morgante 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Infertile men with idiopathic asthenospermia</p> <p>N = 180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm motility.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Improvement of sexual satisfaction</p> <p>Significant improvement in sperm motility</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0056" title="NadjarzadehA , ShidfarF , AmirjannatiN , VafaMR , MotevalianSA , GohariMR , et al.Coenzyme Q10 improves seminal oxidative defense but does not affect on seman in idiopathic oligoasthenoteratozoospermia: a randomized double- blind placebo controlled trial. Journal of Endocrinological Investigation2011;34:e224-8. ">Nadjarzadeh 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with Idiopathic OAT</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant changes in semen parameters of CoQ10 group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>CoQ10 further evidence suggesting that supplementation is associated with alleviating oxidative stress, although it does not show any significant effects on sperm concentration, motility and morphology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0057" title="NouriM , AmaniR , Nasr-EsfahaniM , TarrahiMJ .The effects of lycopene supplement on the spermatogram and seminal oxidative stress in infertile men: A randomized, double-blind, placebo-controlled clinical trial. Phytotherapy Research2019;33(12):3203-11. ">Nouri 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with history of infertility</p> <p>N = 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm concentration with lycopene compared to placebo. Increase of total motility in lycopene group compared to baseline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Lycopene improves sperm parameters and oxidative stress biomarkers in infertile men</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0058" title="NozhaCF , LeilaAK , ZouhirS , HanenG , KhledZ , TarekR .Oxidative stress and male infertility: comparative study of combined vitamin E/selenium treatment versus vitamin B. Human Reproduction2001;17(Abstract book 1):111-2. ">Nozha 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Men with OAT</p> <p>N = unclear, 20?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E + selenium significantly improves sperm motility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E + selenium associated with improved sperm motility when compared with vitamin B </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0059" title="OmuAE , DashtiH , Al-OthmanS .Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. European Journal of Obstetrics, Gynecology, and Reproductive Biology1998;79(2):179-84. ">Omu 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with asthenozoopermia</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters,</p> <p>pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only % increase or decrease, not usable</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm quality by zinc therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Zinc has a role in improving sperm parameters. Significant increase in pregnancy, not live birth </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0060" title="OmuAE , Al-AzemiMK , KehindeEO , AnimJT , OriowoMA , MathewTC .Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Medical Principles and Practice2008;17(2):108-16. ">Omu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment</p> <p>Men with asthenozoospermia</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zinc therapy alone, in combination with vitamin E or with vitamin E+C were associated with comparably improved sperm parameters and less sperm DNA fragmentation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Zinc therapy reduces asthenozoospermia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0061" title="PeivandiS , AbasaliK , NargesM .Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. Journal of Reproduction and Infertility2010;10(4):331. ">Peivandi 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Infertile men</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not defined as clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvements in mean sperm concentration and progressive sperm motility upon two months of L‐carnitine intake but no significant changes were found in sperm volume or morphology. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm outcomes and biochemical pregnancies. L‐carnitine intake effectively improved the mean sperm count and progressive sperm motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0062" title="PopovaAY , OvchinnikovRI , GamidovSI .Antioxidant therapy improves the results of -test in infertile men during a preparation for assisted reproductive technology (IVF/ICSI). Urologiia2019;1:90-6. ">Popova 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men planning ART treatment</p> <p>N = 80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change in sperm motility. A pregnancy rate in the combined antioxidants (Androdoz) group was 45% compared to 25% in the control group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>Androdoz contributes to an increase in positive outcomes of ART program. "Androdoz improves the main criteria of sperm analysis and functional tests (HBA‐test)". </p> <p>This is based on the improvement of morphology</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0063" title="PourmandG , MovahedinM , DehghaniS , MehrsaiA , AhmadiA , PourhoseinM , et al.Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Urology2014;84(4):821-5. PourmandGH , MovahedinM , DehghanS , MehrsaiA , AhmadiA , PourhoseinM .Does L-carnitine therapy add any extra benefit to standard inguinal varicocelectomy in terms of deoxyribonucleic acid damage or sperm quality factor indices: a randomized study. Iranian Journal of Reproductive Medicine.2015;(4 suppl. 1):67. ">Pourmand 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, no treatment</p> <p>Men with male factor infertility and varicocele</p> <p>N = 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SD given<br/>N ‐ DNA fragmentation, no SD given </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference between the two groups (varicocelectomy with L‐carnitine or with no adjuvant therapy). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Addition of 750 mg of L‐carnitine orally daily to standard inguinal varicocelectomy does not add any extra benefit in terms of improvement in semen analysis parameters or<br/>DNA damage </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0064" title="PovedaC , RodriguezR , ChuEE , AparicioLE , GonzalesIG , MorenoCJ .A placebo-controlled double-blind randomized trial of the effect of oral supplementation with spermotrend, maca extract (lepidium meyenii) or L-carnitine in semen parameters of infertile men. Fertility and Sterility2013;100(3 Suppl):S440. ">Poveda 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 60</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L‐carnitine significantly improves sperm concentration, Spermotrend and Maca improve sperm motility. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Sperm concentration with L‐carnitine and motility with combined antioxidant Spermotrend</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0065" title="PryorJP , BlandyJP , EvansP , Chaput de SaintongeDM , UsherwoodM .Controlled clinical trial of arginine for infertile men with oligozoospermia. British Journal of Urology1978;50:47-50. ">Pryor 1978</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐over, placebo</p> <p>Men with severe oligozoospermia</p> <p>N = 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, bar graph of % patients showing an increase in motility and density </p> <p>N ‐ pregnancy rate, not clear if clinical. Included in biochemical analysis <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arginine was no more effective than placebo for sperm parameters and biochemical pregnancy rates </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>There was no difference in the conception rates of the wives or changes in the quality of the semen during each period of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0066" title="RaiganiM , SadeghiMR , AkhondiMA , Amir JannatiN , Soleimani BadiaM .Impacts of MTHFR polymorphism on the effects of folic acid and zinc sulfate supplementations in OAT men. Iranian Journal of Reproductive Medicine2010;1):46. RaiganiM , YaghmaeiB , AmirjanntiN , LakpourN , AkhondiMM , ZeraatiH , et al.The micronutrient supplements, zinc sulphate and folic acid, did not ameliorate sperm functional parameters in oligoasthenoteratozoospermic men. Andrologia2014;46(9):956-62. ">Raigani 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with proven male factor infertility</p> <p>N = 83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters ( median+IQR converted to mean+ SD)</p> <p>Y ‐ DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm concentration, DNA fragmentation not significantly improved in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Zinc sulphate and folic acid supplementation did not ameliorate sperm quality in infertile men with severely compromised sperm parameters, OAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0067" title="RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Human Reproduction1999;14(4):1028-33. RolfC , CooperTG , YeungCH , NieschlagE .Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study [see comment]. Human Reproduction1999;14(4):1028-33. ">Rolf 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenospermia</p> <p>N = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rates, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not stated as clinical pregnancy</p> <p>N ‐ adverse events, not clear which side effects aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events or pregnancies in either group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Overall no difference vitamin E + C versus placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0068" title="Saeed AlkumaitMH , Abdul-Aziz MM , NimaMH .The effect of glutathione versus co-enzyme q10 on male infertility original study. Medico Legal Update2020;20(1):409‐14. ">Saeed Alkumait 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Infertile men</p> <p>N = 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, data provided as percentage improvement, <a href="./references#CD007411-fig-0028" title="">Analysis 1.16</a>; <a href="./references#CD007411-fig-0034" title="">Analysis 1.22</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significantly higher percentage improvement of progressive sperm motility and concentration with glutathione or CoQ10 compared to placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Both glutathione and CoQ10 are effective treatment options for improving sperm motility, morphology and concentration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0069" title="SafarinejadMR , SafarinejadS .Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. Journal of Urology2009;181(2):741-51. ">Safarinejad 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not specified which adverse events aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All semen parameters significantly improved with selenium and N‐acetyl‐cysteine treatment. Administering selenium plus N‐acetyl‐cysteine resulted in additive beneficial effects. Zero adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Supplemental selenium and N‐acetyl‐cysteine improve semen quality. Zero adverse events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0070" title="SafarinejadME .Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. Journal of Urology2009;182(1):237-48. ">Safarinejad 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not specified which adverse events aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement in sperm density and motility after coenzyme Q10 therapy. Zero adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Coenzyme Q10 supplementation resulted in a statistically significant improvement in certain sperm parameters. Zero adverse events </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0071" title="SafarinejadMR .Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia2011;43(1):38-47. ">Safarinejad 2011b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic OAT</p> <p>N = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ adverse events, not clear how many patients had gastrointestinal upsets in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant improvement of sperm concentration and progressive motility after omega‐3 fatty acids therapy. Significantly more adverse events (gastrointestinal and pruritus) in the omega‐3 group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>These findings suggest a protective effect of omega‐3 fatty acid intake in idiopathic infertile men. More adverse events in omega‐3 group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0072" title="SafarinejadMR , ShafieiN , SafarinejadS .Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. Journal of Urology2012;188(2):526-31. ">Safarinejad 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men</p> <p>N = 228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters improved significantly after coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Coenzyme Q10 was significantly effective in men with unexplained oligoasthenoteratozoospermia for improving sperm density, sperm motility and sperm morphology </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0073" title="SchistermanEF , ClemonsT , PetersonCM , JohnstoneE , HammoudAO , LambD , et al.A randomized trial to evaluate the effects of folic acid and zinc supplementation on male fertility and livebirth: design and baseline characteristics. American Journal of Epidemiology2020;189(1):8‐26. SchistermanEF , SjaardaLA , ClemonsT , Carrell D, PerkinsNJ , JohnstoneE , et al.Effect of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: a randomized clinical trial. JAMA2020;323(1):35‐48. SchistermanEF , SjaardaLA , ClemonsT , CarrellDT , PerkinsNJ , JohnstoneE , et al.Effects of folic acid and zinc supplementation in men on semen quality and live birth among couples undergoing infertility treatment: findings from the fazst randomized trial. Fertility and Sterility2019;112(3):e2‐. ">Schisterman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Male partner of couples planning infertility treatment. Data from subfertile men used.</p> <p>N = 2370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live births, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live births, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>N ‐ pregnancy, clinical;</p> <p>N ‐ live births</p> <p>N ‐ adverse events</p> <p>Data not provided for male factor infertility subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in sperm parameters between folic acid + zinc and placebo. No results on clinical outcomes in male factor subgroup </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Folic acid and zinc did not significantly improve semen quality. The findings also were similar when restricted to men with known male factor infertility or poor semen quality at baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0074" title="ScottR , MacPhersonA , YatesRW , HussainB , DixonJ .The effect of oral selenium supplementation on human sperm motility. British Journal of Urology1998;82(1):76-80. ">Scott 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Men with subfertility and low sperm motility</p> <p>N = 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not usable due to pooling of data in the two intervention groups <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm motility increased in both selenium‐treated groups, only significant if both treatment groups were combined. Sperm density unaffected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>±</p> <p>Selenium supplementation in subfertile men with low selenium status can improve sperm motility and the chance of successful conception. However, not all patients responded; 56% showed a positive response to treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0075" title="SharifzadehF , NorouziS , AshrafiM , AminimoghaddamS , KoohpayezadehJ .Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. Journal of Obstetrics, Gynecology and Cancer Research2016;1(2):e7242. [2476-5848]">Sharifzadeh 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Idiopathic subfertile men</p> <p>N = 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y‐ sperm parameters</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in concentration in zinc group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Normal sperm percentage and total sperm concentration increased after zinc sulphate treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0076" title="PryorJL , StacyL , GlassS , CampagnoneJ , SigmanM .Randomized double blind placebo controlled trial of carnitine for the treatment of idiopathic asthenospermia. Fertility and Sterility2003;80 Suppl 3:48. SigmanM , GlassS , CampagnoneJ , PryorJL .Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility2006;85(5):1409-14. ">Sigman 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with low sperm motility</p> <p>N = 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, biochemical <a href="#CD007411-tbl-0002">Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant or clinically significant increase in motility or total motile sperm counts between baseline, 12 weeks, or 24 weeks in the carnitine or placebo arms. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Carnitine supplementation demonstrated no clinically or statistically significant effect on sperm motility or total motile sperm counts. No difference in pregnancy rate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0077" title="SivkovAV , OshchepkovVN , EvdokimovVV , KeshishevNG , SkabkoOV .Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility. [Russian]. Urologii2011;5:27-33. ">Sivkov 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with chronic prostatitis and infertility</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no SD given <a href="./references#CD007411-fig-0022" title="">Analysis 1.10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One‐month course of therapy produced no side effects, had a positive effect on low fertility of ejaculate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Selenium + zinc improve</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0078" title="SofikitisN , DimitriadisF , SkourosS , StavrouS , SeminisG , GiannakisI , et al.Effects of avanafil on semen quality and sperm cytoskeleton in oligoasthenospermic infertile men: a randomized controlled trial. Journal of Sexual Medicine2016;2:S164-5. ">Sofikitis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, no treatment, Avanafil excluded</p> <p>Oligoasthenospermic infertile men</p> <p>N = 39</p> <p>Abstract only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, no data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in L‐carnitine group regarding sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No direct conclusion made about L‐carnitine. From result section concluded: no impact on sperm parameters after use of L‐carnitine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0079" title="BanksN , SunF , KrawetzSA , CowardRM , MassonP , SmihJF , et al.Male vitamin D status and male factor infertility. Fertility and Sterility2020;114(3):e63‐4. SteinerAZ , HansenKR , BarnhartKT , Cedars M\\\\\\\\\\\\i, LegroRS , DiamondMP , et al.The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility2020;113(3):552. ">Steiner 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with one abnormal semen parameter</p> <p>N = 171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, clinical pregnancy, live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>(data shared by authors after requested via e‐mail)</p> <p>Y ‐ pregnancy, clinical</p> <p>Y ‐ live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in sperm motility, DNA fragmentation, pregnancy rate and live birth rate between combined antioxidants and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement in semen parameters in infertile males. This study suggests that combination antioxidants does not improve pregnancy or live birth rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0080" title="StenqvistA , OleszczukK , LeijonhufvudI , GiwercmanA .Impact of antioxidant treatment on DNA fragmentation index: a double-blind placebo-controlled randomized trial. Andrology2018;6(6):811-6. ">Stenqvist 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with DNA fragmentation ≥ 25%</p> <p>N = 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ DNA fragmentation</p> <p>N ‐ pregnancy rate, biochemical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference between the antioxidant and placebo group was seen for semen parameters including DNA fragmentation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Six months treatment with combined antioxidants had no effect on sperm parameters including DNA fragmentation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0081" title="SuleimanSA , AliME , ZakiZM , el-MalikEM , NasrMA .Lipid peroxidation and human sperm motility: protective role of vitamin E. Journal of Andrology1996;17(5):530-7. ">Suleiman 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Asthenospermic men</p> <p>N = 110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, live birth, miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> <p>Y ‐ adverse events: miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E significantly decreased the MDA concentration in spermatozoa and improved sperm motility. Significant increase pregnancy/live birth rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Vitamin E increases sperm motility, pregnancy rate and live birth rate compared to placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0082" title="SunLL , WanXX , ZhangY , ZhangYH , ZhaoWJ , WangD , et al.L-carnitine improves sperm acrosin activity in male infertility patients. Zhonghua nan ke xue [National journal of andrology]2018;24(12):1064‐1068. ">Sun 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Infertile men with low acrosin activity</p> <p>N = 232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of progressive sperm otility in men treated with L‐carnitine compared to vitamin E </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine can effectively elevate sperm acrosin activity in male infertility patients, particularly in those with asthenozoospermia </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0083" title="TremellenK , FroilandD , MiariG , ThompsonJ .A randomised control trial examining the effect of an antioxidant on sperm function pregnancy outcome during IVF treatment. The Fertility Society of Australia 25th Annual scientific meeting. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2006;46 Suppl 2:A.2. TremellenK , MiariG , FroilandD , ThompsonJ .A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2007;47:216-21. ">Tremellen 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Male factor infertility</p> <p>N = 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pregnancy rate, adverse events, live birth provided by author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ live birth</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antioxidant group recorded a statistically significant improvement in viable pregnancy rate. Side‐effects on the Menevit antioxidant were rare (8%) and mild in nature. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Menevit antioxidant appears to be a useful ancillary treatment that significantly improves pregnancy rates in couples undergoing IVF‐ICSI treatment. Side‐effects on the Menevit antioxidant were rare (8%) and mild in nature. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0084" title="TsounapiP , HondaM , DimitriadisF , KoukosS , HikitaK , ZachariouA , et al.Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia2018;50(8):e13071. ">Tsounapi 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, head‐to‐head</p> <p>Profertil + avanafil and avafanil only groups not used</p> <p>Idiopathic OAT</p> <p>N = 217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmentation</p> <p>Not reported in how many patients sperm outcomes were assessed</p> <p>Y ‐ pregnancy rate, clinical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significantly higher total and progressive sperm motility in Profertil group compared to L‐carnitine and no treatment. No difference in pregnancy rate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Profertil or Profertil combined with avanafil or or avanafil alone improves sperm membrane permeability with an improvement in sperm motility </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0085" title="VinogradovIV , GamidovSI , Gabliya MY , ZhukovOB , OvchinnikovRI , MalininaOY , et al.Docosahexaenoic acid in the treatment of idiopathic male infertility. Urologiia2019;1:78-83. ">Vinogradov 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Infertile men with at least one abnormal sperm parameter</p> <p>N = 109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, DNA fragmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters</p> <p>N ‐ DNA fragmenation</p> <p>Only results after cryotolerance test provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical differences between results after Brudy plus (combined antioxidant) and placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+/‐</p> <p>No conclusions on outcomes of interest.</p> <p>Brudy Plus increases cryotolerance, promotes the normal formation of the genetic material and reduces the frequency of ultrastructural sperm disorders. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0086" title="WangYX , YangSW , QuCB , HuoHX , LiW , LiJD , et al.L-carnitine: safe and effective for asthenozoospermia. Zhonghua nan ke xue - National Journal of Andrology2010;16(5):420-2. ">Wang 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head</p> <p>Infertile men with asthenozoospermia</p> <p>N = 135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, not clear if clinical <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>N ‐ adverse events, zero found, however not clear which they aimed for</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase in L‐carnitine + vitamin E group for sperm motility, no difference for sperm density and morphology. Pregnancy rate significantly higher in L‐carnitine + vitamin E group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>L‐carnitine (+vitamin E) significantly improves sperm motility and pregnancy rate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0087" title="EbischIM , PierikFH , De JongFH , ThomasCM , Steegers-TheunissenRP .Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men?International Journal of Andrology2006;29(2):339-45. WongWY , MerkusHM , ThomasCM , MenkveldR , ZielhuisGA , Steegers-TheunissenRP .Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility2002;77(3):491-8. ">Wong 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multiple arm, placebo</p> <p>Fertile and subfertile men</p> <p>N = 103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters (median+IQR converted to mean+ SD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Subfertile men demonstrated a significant 74% increase in total normal sperm count and a minor increase of 4% abnormal spermatozoa </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Total normal sperm count increases after combined zinc sulphate and folic acid treatment in both subfertile and fertile men </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0088" title="ZalataA , ChristopheA , HorrbinD , DhoogeW , ComhaireF .Protection of sperm function and DNA by essential fatty acids and antioxidants dietary supplementation. Fertility and Sterility1998;70:287. ZalataA , ChristopheA , HorrobinD , DhoogeW , ComhaireF .Effect of essential fatty acids and antioxidants dietary supplementation on the oxidative DNA damage of the human spermatozoa. In: ESHRE 14th annual meeting. Goteborg, 1998:270-1. ">Zalata 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Head‐to‐head, pilot</p> <p>Men attending andrology clinic</p> <p>N = 22</p> <p>Conference abstract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N ‐ sperm parameters, only before and after median data given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in sperm parameters after treatment (acetyl‐cysteine or DHA). DNA damage measured by 8‐OHdG (fmol/ug) was significantly decreased after supplementation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>No improvement of sperm parameters</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0089" title="ZavaczkiZ , SzollosiJ , KissS , KoloszarS , FejesI , KovacsL , et al.Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnesium Research2003;16(2):131-6. ">Zavaczki 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, placebo</p> <p>Men with idiopathic infertility</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, clinical pregnancy, adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>Y ‐ pregnancy rate, clinical</p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant changes in sperm characteristics were detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> <p>Magnesium neither leads to a significant improvement of sperm variables nor does it increase the pregnancy rates </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007411-bbs2-0090" title="Zhou QS , ZengFC , ZhangZX , ZhouB , SunZY .Compound amino acid combined with vitamin E for idiopathic asthenospermia. Zhonghua nan ke xue [National journal of andrology]2016;22(4):343‐6. ">Zhou 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parallel, head‐to‐head</p> <p>Idiopathic asthenozoospermia</p> <p>N = 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sperm parameters, pregnancy rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y ‐ sperm parameters</p> <p>N ‐ pregnancy rate, definition unclear <a href="#CD007411-tbl-0002">Table 1</a> </p> <p>Y ‐ adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant increase of total and progressive sperm motility in vitamin E and vitamin E + compound amino acids group. Greater increase in compound amino acids group. 5.7% pregnancy in combined group, 2% in vitamin E group. No adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> <p>Compound amino acid combined with vitamin E can safely and effectively improve sperm motility in idiopathic asthenospermia patients. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>DHA:</b> docosahexaenoic acid; <b>IUI:</b> intrauterine insemination; <b>NAC:</b> N‐acetylcysteine; <b>OAT:</b> oligoasthenoteratozoospermia; <b>ROS:</b> reactive oxygen species </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes and conclusions from all included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/full#CD007411-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007411-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidant(s) versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Live birth; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.07, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Astaxanthin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.34, 7.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.24, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.53, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Vitamin D + Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.59, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.51 [2.36, 30.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [1.02, 13.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.86, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Live birth; IVF/ICSI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.01, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical pregnancy; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.45, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Astaxanthin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.35, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.30, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.53, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Magnesium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.73 [0.17, 445.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.71, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.7 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.71 [1.98, 22.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.8 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.43 [1.39, 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.9 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [0.15, 99.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.10 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.22, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Clinical pregnancy; IVF/ICSI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.15, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Miscarriage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.75, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Ectopic pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.16, 16.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Stillbirth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Gastrointestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.46, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Euphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.16, 9.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.95, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.7 Upper respiratory infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.25, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.8 Nasofaryngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Sperm DNA fragmentation at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Astaxanthin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐6.64, 9.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐13.40, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Folic acid + Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐9.36, 6.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [‐0.42, 8.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐4.00, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.6 Vitamin C + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.80 [‐17.50, ‐10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.7 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐8.62, 11.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.8 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐2.00, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Sperm DNA fragmentation at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.57 [‐6.49, ‐2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.02, 5.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Sperm DNA fragmentation (data not suitable for meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Total sperm motility at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Astaxanthin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐11.56, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>31.28 [31.19, 31.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Carotenoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐6.95, 13.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [‐6.13, 13.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.5 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [‐5.63, 14.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.6 Magnesium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.50 [‐6.01, 35.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.7 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.60 [0.32, 28.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.8 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐9.89, 5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.9 Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.90 [1.14, 28.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.10 Vitamin C + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐7.76, 13.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.11 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.90 [4.90, 32.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.12 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.85 [5.40, 20.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.13 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.26 [‐3.64, 14.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.14 Zinc + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.00 [12.85, 39.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.15 Zinc + Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.00 [12.62, 39.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.16 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.71 [11.33, 14.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Total sperm motility at 3 months or less (data not suitable for meta analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Total sperm motility at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.09 [5.99, 14.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.28 [6.85, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐6.96, 7.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.20, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.5 Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [2.50, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.6 Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [5.60, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.7 Vitamin D + Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐9.57, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.8 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.60 [6.18, 17.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.9 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐6.95, 6.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.10 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐2.54, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.11 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.76 [4.77, 8.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Total sperm motility at 9 months or more; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.54 [3.01, 14.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [2.91, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐8.48, 12.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Total sperm motility over time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Total sperm motility at 3 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>31.17 [31.07, 31.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Total sperm motility at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.77 [5.45, 6.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Total sperm motility at 9 months or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [2.94, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Progressive sperm motility at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Astaxanthin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐11.46, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.92 [20.52, 21.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 Carotenoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐7.27, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [‐3.54, 12.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.5 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.08 [‐4.00, 14.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.6 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐1.03, 8.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.7 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.32, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.8 Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.95 [4.10, 17.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.9 Vitamin C + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐9.77, 10.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.10 Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐7.65, 5.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.11 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [‐3.37, 5.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.12 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐13.66, 21.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.13 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.16 [9.91, 12.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Progressive sperm motility at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.66 [8.68, 14.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [2.13, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.77 [‐10.21, 6.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.4 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [8.11, 9.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.5 Vitamin D + Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐9.59, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.6 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐13.56, 17.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.7 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐14.58, 19.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.8 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.01 [2.05, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Progressive sperm motility at 6 months (data not suitable for meta analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Glutathione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Progressive sperm motility at 9 months or more; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.77 [2.68, 12.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.68, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Progressive sperm motility over time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Progressive sperm motility at 3 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.98 [17.62, 18.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Progressive sperm motility at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.05 [7.43, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Progressive sperm motility at 9 months or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐1.64, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Sperm concentration at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Astaxathin + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐6.79, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.71 [8.09, 9.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.3 Carotenoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [0.62, 11.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.4 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐12.37, 12.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.5 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.72 [‐4.01, 11.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.6 Magnesium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [‐2.61, 13.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.7 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [‐0.27, 9.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.8 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [1.69, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.9 Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.20 [‐4.90, 47.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.10 Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.70 [0.09, 19.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.11 Vitamin C + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [‐6.58, 9.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.12 Vitamin D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐8.85, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.13 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.90 [3.92, 33.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.14 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.74 [2.81, 10.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.15 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐6.79, 7.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.16 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐0.33, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Sperm concentration at 3 months or less (data not suitable for meta analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Sperm concentration at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.42 [4.97, 9.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [7.95, 9.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.3 Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.39 [11.09, 23.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.4 N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [1.80, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.5 PUFAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.50 [11.39, 13.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.6 Selenium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [2.45, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.7 Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.60 [6.89, 10.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.8 Vitamin D + Calcium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐8.18, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.9 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.90 [‐10.83, 22.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.10 Zinc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.51 [‐4.00, 15.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.11 Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [‐6.70, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.12 Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>534</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [2.28, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Sperm concentration at 6 months (data not suitable for meta analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Glutathione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Sperm concentration at 9 months or more; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 Carnitines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.17 [‐1.71, 10.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [3.19, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.3 Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.40 [‐2.56, 25.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Sperm concentration over time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Sperm concentration at 3 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.49 [5.02, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 Sperm concentration 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.21 [6.73, 7.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.3 Sperm concentration at 9 months or more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.95 [3.22, 4.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antioxidant(s) versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007411-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Head‐to‐head antioxidant(s)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Live birth; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.13, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Clinical pregnancy; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.13, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 L‐carnitine vs Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.54, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 L‐carnitine vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.27, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Coenzyme Q10 vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.18, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Vitamin D + Calcium vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [1.21, 21.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.8 Combined antioxidants vs L‐carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.20, 19.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Sperm DNA fragmentation; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 L‐carnitine vs Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.22, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 L‐carnitine vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐1.14, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Coenzyme Q10 vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐0.25, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 L‐carnitine vs Vitamin B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.22, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Coenzyme Q10 vs Vitamin B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.34, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.6 Vitamin B1 vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.16, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Total sperm motility at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Coenzyme Q10 200 mg vs Coenzyme Q10 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.86 [‐10.60, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Docosahexaenoic acid (DHA) 400 mg vs Docosahexaenoic acid 800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.40 [‐11.35, 26.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 DHA vs DHA + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.77 [‐5.42, ‐2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 DHA versus Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐3.30, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.5 DHA + Vitamin E vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.54, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.6 Ethylcysteine vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐41.97, 38.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.7 L‐acetyl carnitine + L‐carnitine vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.10 [20.14, 26.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.8 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [‐3.73, 10.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.9 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.80 [‐1.76, 11.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.10 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐6.42, 9.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.11 Selenium vs combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [‐10.13, 16.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.12 Vitamin C 200mg vs Vitamin C 1000mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.00 [‐67.10, ‐18.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.13 Vitamin E + 'Compound amino acids' vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.90 [8.71, 15.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.14 Zinc vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.01 [‐11.38, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.15 Zinc vs Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.91 [‐10.92, 5.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.16 Zinc + Folic acid vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐6.17, 6.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.17 Zinc vs Zinc + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐15.00, 13.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.18 Zinc vs Zinc + Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐19.66, 17.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.19 Zinc + Vitamin E vs Zinc + Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐18.97, 18.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Total sperm motility at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [‐2.70, 10.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [‐2.87, 9.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐7.73, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 N‐acetylcysteine (NAC) vs Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.40 [‐5.14, ‐3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 Selenium vs N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.56, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.6 Selenium vs Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐3.85, ‐2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.7 Zinc vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐5.18, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.8 Zinc vs Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.69 [‐6.95, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.9 Zinc + Folic acid vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [‐4.23, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Total sperm motility at 9 months or more; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐1.69, 9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.30 [‐0.73, 11.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐3.29, 6.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Progessive sperm motility at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Coenzyme Q10 200 mg vs Coenzyme Q10 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.52 [‐9.71, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Docosahexaenoic acid (DHA) vs DHA + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐3.50, ‐0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 DHA vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.67, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 DHA + Vitamin E vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.68, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.5 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [‐1.88, 9.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.6 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [‐0.68, 10.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.7 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐5.41, 7.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.8 L‐carnitine vs Vitamin B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.54, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.9 L‐carnitine vs Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐1.70, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.10 L‐carnitine vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.20 [‐12.31, ‐4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.11 Coenzyme Q10 vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.50 [‐13.54, ‐5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.12 Coenzyme Q10 vs Vitamin B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐2.75, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.13 Vitamin B1 vs L‐carnitine + Coenzyme Q10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.90 [‐14.12, ‐5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.14 L‐acetyl carnitine + L‐carnitine vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.30 [11.21, 15.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.15 L‐carnitine vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.50 [27.70, 33.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.16 L‐carnitine vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.31, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.17 L‐carnitine + Vitamin E vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.10 [10.11, 18.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.18 Vitamin D + Calcium vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.90 [5.38, 8.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.19 Vitamin E + 'Compound amino acids' vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [3.87, 8.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Progressive sperm motility at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [0.42, 12.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [0.10, 11.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐6.93, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Progressive motility at 6 months (data not suitable for meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Progressive sperm motility at 9 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐1.50, 9.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [‐0.11, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐4.17, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Sperm concentration at 3 months or less; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Coenzyme Q10 200 mg vs Coenzyme Q10 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐3.26, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Docosahexaenoic acid (DHA) 400 mg vs Docosahexaenoic acid (DHA) 800 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐41.87, 28.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 DHA vs DHA + Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.45 [‐2.47, ‐0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.4 DHA vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐1.26, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.5 DHA + Vitamin E vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.28, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.6 Ethylcysteine vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐16.65, 21.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.7 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐10.97, 14.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.8 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [‐9.17, 17.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.9 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐11.14, 15.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.10 L‐carnitine vs Vitamin E + Vitamin C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.50 [12.49, 18.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.11 L‐carnitine vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.34, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.12 L‐carnitine + Vitamin E vs Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [‐10.52, 14.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.13 Selenium vs Combined antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.70 [‐6.51, 35.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.14 Zinc vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐8.65, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.15 Zinc vs Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [‐3.67, 9.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.16 Zinc + Folic acid vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.11 [‐9.79, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Sperm concentration at 6 months; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.90 [‐8.92, 20.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.10 [‐5.54, 21.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐10.89, 15.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.4 N‐acetylcysteine (NAC) vs Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.30 [‐6.86, ‐3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.5 Selenium vs N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.71, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.6 Selenium vs Selenium + N‐acetylcysteine (NAC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.50 [‐6.20, ‐2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.7 Zinc vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.10 [‐19.12, ‐1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.8 Zinc vs Zinc + Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.58 [‐25.99, ‐1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.9 Zinc + Folic acid vs Folic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [‐9.93, 13.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Sperm concentration at 6 months (data not suitable for meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Sperm concentration at 9 months or more; type of antioxidant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 L‐carnitine vs L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.20 [‐0.07, 16.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 L‐carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐3.74, 15.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 L‐acetyl carnitine vs L‐carnitine + L‐acetyl carnitine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐10.24, 6.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Head‐to‐head antioxidant(s)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007411.pub5/references#CD007411-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007411.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007411-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007411-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007411-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007411-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007411-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD007411-note-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD007411-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD007411-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007411-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD007411-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007411-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007411\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007411\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007411\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007411\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007411\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007411.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007411.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007411.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007411.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007411.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715483211"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007411.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715483215"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007411.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d88294ea99374',t:'MTc0MDcxNTQ4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 